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Summary 
The aim of the present thesis was the in vivo investigation of the topical bioavailability of a 
model glucocorticosteroid, triamcinolone acetonide (TACA), using tape stripping. The layer by 
layer removal of the stratum corneum by tape stripping enables the quantification of drug 
amounts penetrated into the stratum corneum over time. This dermatopharmacokinetic (DPK) 
approach has been subject of fervent discussions in the past years, and concern about 
adequacy and reproducibility of the technique has been expressed. Yet, the successful 
performance of reliable and reproducible tape stripping investigations highly depends on the 
use of a standardized methodology and suitable analytical methods. This thesis proposed a 
standardized tape stripping protocol in combination with carefully validated analytical methods 
(Project I). After a proof of concept, the set of methods was applied in an in vivo investigation of 
the influence of different factors on topical bioavailability. Both pharmacokinetic and 
pharmacodynamic aspects ultimately determining the successful therapy outcome were 
investigated: the effect of dose and application frequency (Project II), the effect of occlusion 
(Project III), and the efficacy of a low-dose TACA formulation (Project IV). Concomitantly, the 
corticosteroid accumulation within the stratum corneum (reservoir development) was monitored, 
since a reservoir can considerably affect the therapy outcome and is particularly advantageous 
to prevent systemic side effects.  
In Project I, the tape stripping technique was standardized and an HPLC method for TACA 
quantification on tapes after extraction was validated. The standardized tape stripping protocol 
included the use of a template (ensured the removal of stratum corneum samples from the 
same skin site) and a hand roller (ensured a constant pressure on the tape before stripping), 
and, most importantly, the removal of the entire stratum corneum of one skin site to cope with 
inter- and intra-individual differences in stratum corneum thickness. The HPLC method for 
TACA quantification was successfully validated and proved to have suitable specificity, linearity, 
accuracy, precision, and robustness in the working range. The combination of 1) standardized 
tape stripping as sampling method, 2) UV/VIS-spectroscopy for quantification of corneocytes 
(previously validated), and 3) the new validated HPLC method for quantification of TACA was 
then applied in a proof of concept with 6 healthy volunteers. TACA was applied on their forearm 
skin in either an acetonic solution or an ethanolic gel, and stratum corneum samples were 
removed by tape stripping after 0.5 h, 3 h, and 24 h. A clear vehicle effect on the TACA 
penetration could be observed. Whereas TACA deeply penetrated into the stratum corneum 
after application of the acetonic solution, the penetration after application of the ethanolic gel 
was only superficial (development of a skin surface reservoir). The method set proved to be 
suitable for the investigation of the TACA penetration into stratum corneum and was applied in a 
pharmacokinetic clinical trial with healthy volunteers (Projects II and III). 
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In Project II, the effect of dose and application frequency on the in vivo penetration of TACA 
into stratum corneum was investigated in 15 healthy volunteers. Dose and application frequency 
of topical corticosteroids are recurrently debated topics. Multiple-daily applications are common, 
although a superior efficacy compared to once-daily applications is not unequivocally proven. In 
the dose experiment, higher TACA amounts were quantified within the stratum corneum after 
application of a high dose (300 µg/cm2 vs. 100 µg/cm2; acetonic solution). However, this 
difference was only significant immediately after application, and no difference was recorded at 
4 h and 24 h. The application frequency experiment showed slightly higher TACA amounts 
within the stratum corneum after multiple application (3x100 µg/cm2) than after single 
application of the total dose (1x300 µg/cm2). As a result of multiple applications, the skin was 
periodically reloaded with new drug, thus achieving temporary higher amounts within the 
stratum corneum and redissolving potential TACA crystals. The still well quantifiable TACA 
amount retained within the stratum corneum at 24 h was rather due to the slow diffusion through 
the stratum corneum barrier than to a classical reservoir formation. The performance of a mass 
balance showed that a high TACA dose could result in faster stratum corneum permeation and 
higher systemic exposure, unwelcome in topical therapy. Thus, a low dose applied once daily 
may be preferable to higher doses. 
In Project III, the effects of occlusion before (pre-occlusion) and after (post-occlusion) TACA 
application (100 µg/cm2; acetonic solution) were investigated on the forearms of 10 healthy 
volunteers. Occlusion is known to enhance skin hydration and can induce the formation of a 
stratum corneum reservoir. Moreover, occlusion is clinically used to improve the efficacy of 
topical corticosteroids in severe forms of skin diseases. Pre-occlusion showed no effect on the 
TACA penetration into stratum corneum. In contrast, post-occlusion enhanced the TACA 
penetration by a factor of 2, favoring the development of a 24 h-lasting reservoir. 
The efficacy of low-dose TACA in the treatment of atopic dermatitis was proved in Project IV, a 
double-blind, vehicle-controlled, randomized pharmacodynamic explorative study with half-side 
comparison in 14 patients. Low-dose TACA was added to a marketed skin care cream 
(Lichtena®) in a concentration which was 40 times lower than typical therapeutical corticosteroid 
concentrations (25 vs. 1000 µg/g). Twice-daily application of the low-dose TACA formulation 
reduced the severity of the lesions (assessed by SCORAD) already after 1 week. In contrast, 
the cream base alone had no significant influence on the severity of atopic dermatitis measured 
for 1 month. These findings indicate that some corticosteroids may already be effective at much 
lower concentrations than usually used therapeutically, and that marketed corticosteroid 
formulations may contain a much higher concentration than necessary. 
The investigations described in this thesis show how tape stripping, correctly performed, asserts 
itself as a valuable technique for topical bioavailability assessment. The DPK approach can be 
applied for the investigation of topical bioavailability of other compounds as well, provided that 
specific analytical methods for their quantification are developed and validated. Re-
implementation of the DPK approach on regulatory level could be considered.  
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Aim of the thesis 
The aim of this thesis was to investigate in vivo the topical bioavailability of a model 
glucocorticosteroid, triamcinolone acetonide (TACA), using tape stripping. The layer by layer 
removal of the stratum corneum by tape stripping enables the quantification of drug amounts 
penetrated into the stratum corneum over time. This DPK approach has been subject of fervent 
discussions in the past years, and concern about adequacy and reproducibility of the technique 
has led to the withdrawal of the corresponding FDA draft guidance “Topical dermatological drug 
products NDAs and ANDAs – In vivo bioavailability, bioequivalence, in vitro release, and 
associated studies” [1]. Currently, no technique is advised at regulatory level for the specific 
assessment of topical bioavailability.  
Since the successful performance of reliable and reproducible tape stripping investigations 
highly depends on the techniques used, this thesis proposes a standardized tape stripping 
protocol in combination with carefully validated analytical methods (UV/VIS-spectroscopy, 
HPLC) to possibly rehabilitate the tape stripping technique (Project I). After proof of concept 
with 6 healthy volunteers, the set of methods was applied to investigate in vivo different factors 
which influence percutaneous penetration and which thus, ultimately, influence the successful 
outcome of a topical therapy. The therapeutical class of corticosteroids was chosen because it 
is still the gold standard for the therapy of several dermatological affections. Among the wide 
palette of corticosteroids, TACA as a commonly used and moderately potent steroid was 
chosen as model. Both pharmacokinetic and pharmacodynamic aspects were investigated. 
The effect of the following pharmacokinetic parameters on the TACA penetration into stratum 
corneum was assessed in a clinical trial with 25 healthy volunteers: dose, application frequency, 
and occlusion. Dose and application frequency (Project II) of topical corticosteroids are 
recurrently debated topics. Multiple-daily applications are common, although a superior efficacy 
compared to once-daily applications is not unequivocally proven. Occlusion (Project III) is 
known to enhance the percutaneous penetration of many but not all drugs. Moreover, occlusion 
can induce the formation of a drug reservoir within the stratum corneum. A skin reservoir is 
desired in topical therapy, since the drug should remain for a long time at the site of action, 
exerting a local and not a systemic action. Finally, the efficacy of a low-dose TACA formulation 
was assessed in a pharmacodynamic clinical trial with 14 patients suffering from atopic 
dermatitis (Project IV). 
This thesis is structured into a theoretical and an experimental section. The theoretical section 
gives an overview of: anatomy and physiology of the skin (Chapter 1); principles of 
percutaneous absorption and topical bioavailability (Chapter 2); techniques for the assessment 
of topical bioavailability and regulatory requirements (Chapter 3); skin reservoir (Chapter 4); and 
topical corticosteroids (Chapter 5). In this last chapter, both pharmacodynamic and 
pharmacokinetic aspects of dose, application frequency, and occlusion are reviewed. The 
experimental section describes the validation of the methodology (Project I) and the results of 
the in vivo investigations (Projects II-IV), submitted for publication in different scientific journals. 
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1. Human skin 
1.1. Skin anatomy and physiology 
The human skin (integumentum commune) is the barrier between the organism’s internal 
environment and its surroundings. With an area of 1.5-1.8 m2, it is our biggest organ. The 
following vital functions are ensured by the skin: mechanical and chemical protection, protection 
against UV radiation and micro-organisms, thermoregulation, and sensory perception. 
Anatomically, the skin can be divided into subcutis and cutis (Fig.1-1). The subcutis (tela 
subcutanea) is formed of small lobes of fat (panniculus adiposus) separated by septa of 
connective tissue. The fat is responsible for thermo-insulation, and the connective tissue 
incorporates lymph and blood vessels reaching into the dermis. The cutis is divided into dermis 
(corium) and epidermis, which are firmly bound together in the dermo-epidermal junction by 
hemidesmosomes on the epidermal side and by anchoring collagen fibrils on the dermal 
side [2]. 
 
 
 
 
 
 
 
 
 
 
Fig.1-1: Schematic representation of the 
different skin layers (from [2]). 
The dermis is about 1-3 mm thick, and consists of cells (fibroblasts, inflammatory cells) and 
fibers (collagen, elastic, reticular) embedded in an amorphous matrix consisting of 
mucopolysaccharides produced by the fibroblasts. Also present in the dermis are: blood and 
lymph vessels, free nerves endings for the perception of temperature, itching and pain, 
encapsulated nerve endings such as the Vater-Pacini corpuscles (sensitive to pressure and 
vibration) and the Meissner’s corpuscles (sensitive to touch), nerves for the vegetative 
innervation, and muscles (M. arrector pili, mimetic muscles). Skin appendages (hair, sebaceous 
glands, sweat glands, nails) originate in the dermis or in the upper subcutis (sweat glands). 
Cutis 
Subcutis 
Sweat gland 
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Structurally, the dermis comprises the deeper situated, thicker stratum reticulare (few cells 
except fibroblasts, many fibers) and the stratum papillare (many cells, capillaries, nerves), 
located just below the epidermis [2].  
The epidermis is the outermost skin layer and is a vessel-free, nerve-free, stratified, squamous 
epithelium with a water content of 70%. It is nourished by the underlying capillary loops of the 
stratum papillare. The thickness of the epidermis varies depending on the anatomical region, 
with mean values of 77 µm at the forearm [3], minimal values of 30 µm at the eye lid and 
maximal values of 1.6 mm at the plantar region. Two kinds of cells make up the epidermis. First, 
the keratinocytes (90%), which are responsible for keratin production and are kept together by 
desmosomes. Second, the dendritic cells (10%): melanocytes (pigment cells), Langerhans cells 
(immunocompetent cells), and Merkel’s cells (responsible for the perception). The following 
layers characterize the epidermis: the stratum basale (basal layer) with one cell layer, the 
stratum spinosum (prickle cell layer) with 2-5 cell layers, the stratum granulosum (granular 
layer) with 1-3 cell layers, the stratum lucidum (in palmar and plantar skin only), and the stratum 
corneum (corneal layer) with 10-20 cell layers. In a cycle of about 1 month, new keratinocytes 
originate in the stratum basale, differentiate in the stratum spinosum, produce keratohyalin-
containing granules and lipid/enzymes-containing lamellar bodies (Odland bodies), which are 
then exocyted in the stratum granulosum and are finally transformed into the stratum 
corneum [2].  
Within the stratum corneum, the keratinocytes undergo complete keratinization, forming the 
nucleus-devoid, flattened, hexagonal corneocytes of about 0.5-3 µm thickness and 30-40 µm 
width [4]. The bottom part of the stratum corneum (stratum compactum) is very firmly bound 
together by corneo(desmo)somes and intercellular lipids and has an important protective 
function. The top part is looser in its structure (stratum disjunctum) and undergoes 
desquamation by enzymatic digestion of the corneo(desmo)somes [5]. The thickness of the 
stratum corneum depends, like the thickness of epidermis and dermis, on the anatomical 
region. Mean values of 15 µm (16 ± 4 cell layers) were recorded at the flexor forearm and 
maximal values of 1 mm (86 ± 36 cell layers) at the heel [3, 6-8] . 
1. Human skin 
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1.2. Stratum corneum, the skin barrier 
The stratum corneum consists of 15% water, 70% proteins, and 15% lipids. According to the 
brick-and-mortar model [9, 10], two compartments can be discerned: keratinous, lipid-devoid 
corneocytes as bricks and intercellular, continuous lamellar bilayers of lipids as mortar. The 
corneocytes are built out of an insoluble protein complex consisting of highly organized keratin 
macrofibrils, and they contain natural moisturizing factors (NMF), low-molecular-weight, water-
soluble compounds responsible for water retention. The NMF are mainly derived from the 
protein filaggrin and are composed of amino acids (40%), pyrrolidon carboxylic acid (12%), 
lactic acid (12%), and urea (7%) [11]. Each corneocyte is encapsulated in an insoluble tough 
protein shell of 10 nm thickness, the cornified cell envelope, which is covalently bound to an 
outer lipid envelope consisting of a layer of long-chain ceramides [12]. The free intercellular 
lipid bilayers of the stratum corneum have a unique composition compared to other epithelial 
lipid bilayers and consist of ceramides (50%), cholesterol (25%), and fatty acids (10-20%, highly 
enriched in linoleic acid). No phospholipids are present in healthy stratum corneum, and more 
than one third of the lipids have chain lengths longer than 22 carbons (vs. 16-18 carbons in 
other mammalian cell membranes) [13]. Most lipids of the lamellar bilayer are derived from the 
Odland bodies, extruded as phospholipids, sphingolipids, and plasma membrane constituents at 
the interface stratum granulosum / stratum corneum and then enzymatically cleaved [14].  
It was not until the 1940’s that the stratum corneum clearly emerged as the specific site of the 
skin barrier for both endogenous and exogenous compounds [15, 16]. In the 70’s, the 
intercellular lipids were recognized as the primary site of the barrier [17]. The qualitative and 
quantitative organization of the intercellular lipid lamellae is determinant for the barrier function. 
Several models such as the domain-mosaic [18], the sandwich [19], and the single-gel-phase 
model [20] have been proposed to explain their molecular organization [21]. An appropriate 
moisturization level of the stratum corneum, regulated by the presence of NMF, is also 
important for the maintenance of an effective skin barrier [11]. 
The stratum corneum is very resistant to physical (mechanical, thermic, actinic) and chemical 
(acids, to a lesser extent bases) damage. The barrier is more sensitive to organic solvents 
which can extract the intercellular lipids and to detergents which can damage the cell 
membrane [22]. 
Lipophilic compounds usually pass more easily through the lipophilic stratum corneum barrier 
than hydrophilic compounds. However, the passage through the hydrophilic (epi)dermis may 
then become the rate limiting step for a lipophilic compound. Furthermore, hydrophilic 
substances may penetrate the barrier also by follicular pathways [23]. The topic of 
percutaneous penetration is extensively discussed in chapter 2. 
1. Human skin 
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1.3. Skin metabolism 
The maturation process of the stratum corneum requires the involvement of different enzymes, 
for example for the formation of the cornified envelope (e.g., C kinase, acid phosphatase) and 
intercellular lipid lamellae (e.g., β-glucocerebrosidase, phospholipase A2, sphyngomyelinase, 
cholesterol sulfatase) as well as for the corneodesmosome hydrolysis during desquamation 
(e.g., trypsine, chymotrypsine-like serine proteases) [24]. These enzymes have been detected 
even in the upper layers of the stratum corneum, and their activity shows a high pH-
dependence [25]. 
The presence of a wide spectrum of enzymes outlines the highly metabolic activity of the skin, 
which comprises both phase-1 and phase-2 metabolism. Among the phase-1 enzymes, 
reductases, esterases, oxidases (e.g., cytochrome P-450 monooxygenases), and hydrolases 
(e.g., proteases) have been localized within the skin. Among the phase-2 enzymes, different 
transferases needed for conjugation to glucuronic acid, sulphur, glutathione, and glycine have 
been detected. The skin activity of the CYP 450 enzymes can be as high as 1-5% of the liver 
activity and the one of the transferases even 10% [26, 27].  
Most of the metabolizing enzymes are located in epidermis, sebaceous glands, and hair 
follicles. The resident skin microflora (e.g., Staphylococcus epidermidis) can exert additional 
metabolic activity. Staphylococcus aureus, for example, is responsible for the metabolization of 
the steroid ester betamethasone 17-valerate to betamethasone in psoriatic and eczematous 
skin [28]. 
Cutaneous metabolism has been observed for different xenobiotics such as corticosteroids, β-
blockers, nitrates, theophylline, polycyclic aromatic hydrocarbons, and pesticides [26-28]. The 
metabolism of xenobiotics can lead to the inactivation of the compound and/or to the formation 
of toxic metabolites (irritant, allergenic, or even carcinogenic). Yet, the metabolic activity of the 
skin can also be profitably commercialized, for example with the design of inactive compounds 
undergoing metabolic transformation in the skin to form the active drug (prodrug concept). 
This can be useful for parent drugs displaying inappropriate lipophilicity, high toxicity, or 
chemical instability. An esterification of glucocorticosteroids (e.g., 17-monoester, 21-monoester, 
or 17,21-diester) leads to a higher lipophilicity and consequently to an enhanced penetration 
rate and a prolonged dermal retention. By contrast, the antedrug concept is defined by the 
design of locally highly potent drugs undergoing rapid metabolic deactivation as soon as the 
systemic circulation is reached (also known as “soft drugs”). Systemic side effects are 
minimized and the safety profile is improved. A single compound can consist of a combination 
of both concepts (pro-antedrugs) [29]. Prednicarbate (prednisolone-17-ethylcarbonate-21-
propionate), for example, is cleaved within the skin to the pharmacologically active prednisolone 
17-ester and further metabolized to the less active prednisolone in the systemic circulation.  
2. Percutaneous absorption and topical bioavailability 
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2. Percutaneous absorption and topical bioavailability 
2.1. Definitions 
The EMEA (European Agency for the Evaluation of Medicinal Products) defines the term 
bioavailability as the “rate and extent to which the active substance or active moiety is 
absorbed from a pharmaceutical form and becomes available at the site of action” [30]. The 
“absence of a significant difference in the rate and extent to which the active ingredient or active 
moiety in pharmaceutical equivalents or pharmaceutical alternatives1 becomes available at the 
site of drug action when administered at the same molar dose under similar conditions in an 
appropriate designed study” is termed bioequivalence [31].  
Topical dermatological drug products belong to the class of locally acting drug products [32]. In 
this case, the site of pharmacological action is the skin. Stratum corneum and skin surface are 
considered to be the compartments of invasion, whereas the blood system represents the 
compartment of excretion [33]. Therefore, two different types of bioavailability have to be 
distinguished for topical application. The topical bioavailability reflects the rate and extent to 
which the active moiety becomes available at the site of action, i.e. the skin. The systemic 
bioavailability, instead, may not properly reflect the cutaneous bioavailability for medications 
intended to treat local skin disorders but becomes important for the toxicological evaluation of 
the body burden and for transdermal therapeutic systems (TTSs) [34]. 
Percutaneous absorption is the uptake of a compound into the 
systemic circulation after topical application and describes the 
movement through the various layers of the skin with respect to 
both rate and extent (Fig. 2-1). The percutaneous absorption 
process can be divided into the following 3 steps [35]. 
Penetration is the entry of a substance into a particular layer. 
Permeation is the passage through one layer into another 
layer. Absorption is the uptake of a substance into the 
vascular system (blood and/or lymph vessel), which acts as the 
central compartment, and reflects the systemic bioavailability. 
 
 
Fig. 2-1: Different compartments that 
a compound has to pass through 
during percutaneous absorption.
                                                     
1
 Drug products are pharmaceutical equivalents if they contain the same amount of the same active substance(s) in 
the same dosage forms that meet the same or comparable standards and pharmaceutical alternatives if they contain 
the same active moiety but differ in chemical form (salt, ester, etc) or in dosage form or strength [30]. 
Skin Surface 
Stratum Corneum 
Epidermis 
Dermis 
Blood / Lymph 
2. Percutaneous absorption and topical bioavailability 
Carolina Pellanda  Page 14 of 186 University of Basel, 2006 
2.2. Routes of penetration into the skin 
There are 3 potential routes of penetration from the skin surface into the epidermis (Fig. 2-2) 
[36]: 1) the intercellular route, 2) the transcellular route, and 3) the transappendageal route 
through either the eccrine (sweat) glands or the hair follicles with their associated sebaceous 
glands. 
 
 
 
 
Fig. 2-2: The 3 possible routes of penetration into the stratum corneum: 1) intercellular, 2) transcellular, 
3) transappendageal route. The stratum corneum is depicted according to the brick-and-mortar model [9, 10]: 
the corneocytes represent the bricks, the intercellular lipids represent the mortar. 
Under normal circumstances, the predominant is the intercellular route, which consists of a 
tortuous route along the cornified envelope-armored corneocytes through the structured 
intercellular lipid bilayers [37, 38]. The tortuous diffusional path length has been estimated to be 
as long as 300-500 µm [39, 40] in contrast to a mean stratum corneum thickness of just 20 µm. 
The transport process involves sequential diffusion and partitioning between the polar head 
group regions and the long alkyl chains of the lipids [41]. The transcellular route is possible for 
small hydrophilic substances like water [38]. Waibler observed an in vivo intracellular 
distribution of hydrophilic dyes (patent blue, sodium fluoresceine) applied in water, and a 
prevalent intercellular distribution of the lipophilic dye curcumin applied in liquid paraffin [42]. 
The transappendageal route was, in the past, considered to play a subordinate role during 
percutaneous penetration, since the skin surface of the appendages yields only a maximal of 
0.1% of the total skin surface2. The contribution of the appendages was regarded as an initial 
“shunt” diffusion, whereas the main “bulk” diffusion took place through the stratum corneum 
[33]. Yet, the transappendageal route can be relevant for polar steroids showing a low diffusion 
through the stratum corneum [44, 45] as well as for lipophilic compounds [43]. A higher impact 
of the transappendageal route on percutaneous absorption has to be expected on the forehead, 
where the follicle density is very high (292 follicles/cm2 vs. 14-22 /cm2 in other skin regions) [46]. 
                                                     
2
 De facto, the actual area for potential transfollicular absorption is much higher than the mere skin surface area 
because the hair follicle is an invagination of the epidermis extending deep into the dermis [43] 
transcellular intercellular transappendageal 
Skin appendage 
1 2 3 Intercellular lipids 
Corneocyte 
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2.3. Mathematical models 
2.3.1. Fick’s laws of diffusion 
After application of a topical formulation, the active compound has to be released from the 
vehicle, partition between vehicle and stratum corneum, and diffuse through (and partition 
between) the different layers of the skin before it can exert its pharmacological action, finally 
being “excreted” into the systemic circulation (Fig. 2-3). Diffusion is a passive kinetic process 
taking place along a concentration gradient from a region of higher concentration to a region of 
lower concentration. The diffusion through the skin can be described by Fick’s first law: 
Adt
dm
dx
dcDJ 1⋅=−=  (Equation 1) 
where J is the steady state flux of the compound mass (m) through the stratum corneum per 
unit area (A) and unit time (t) (µg/cm2s), D is the diffusion coefficient of the compound in the 
stratum corneum (cm2/s), c is the drug concentration, and x is the position [47]. The solution of 
the equation with the appropriate boundary conditions gives: 
ckc
h
DKJ p ∆⋅=∆⋅=  (Equation 2) 
where K is the partition coefficient of the compound between vehicle and stratum corneum, h is 
the diffusional pathlength (cm), kp is the permeability coefficient, and ∆c (= cappl - crec) is the 
concentration difference (µg/cm2) across the stratum corneum between applied concentration 
(cappl) and concentration below the stratum corneum (in vivo) or in the receptor phase (in vitro, 
crec) [36, 48]. Under normal circumstances, the applied concentration (cappl) is much larger than 
the concentration in deeper skin layers, and ∆c can be replaced with cappl. The real diffusional 
pathlength (h) is the tortuous pathway along the intercellular lipids, which is longer than the 
mere stratum corneum thickness. However, the stratum corneum thickness is mostly used, 
since it is easily measurable.  
If the steady state is not attained, the diffusional flux can be explained by Fick’s second law, 
which describes the concentration change over time at a definite position x within the 
membrane [47]: 
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Different solutions of this equation with appropriate boundary conditions have been 
proposed [49-51].  
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Fig. 2-3: Schematic depiction of percutaneous absorption (modified from [52]). 
2.3.2. Solubility 
The concentration difference of the compound across the skin or the membrane (concentration 
gradient ∆c) is the driving force for diffusion. A balance has to be found between good solubility 
within the vehicle and good release from the vehicle [48]. The maximal stable concentration is 
achieved at saturation solubility (thermodynamic activity or leaving potential = 1) [48]. Particles 
suspended within the vehicle do not directly contribute to the concentration gradient but 
constitute a reservoir maintaining saturation conditions in the vehicle for a prolonged time.  
2.3.3. Partition coefficient (K) 
The partition coefficient is a thermodynamic, time-independent factor and displays the relative 
preference of a compound to stay either within the vehicle or within the membrane. The degree 
of partitioning is dependent on the relative solubility (affinity) of the compound in both vehicle 
and membrane. A hostile vehicle environment, and thus a higher affinity to the membrane, 
favors partitioning [48]. 
2.3.4. Diffusion coefficient (D)  
The degree of diffusion within a specific medium (vehicle, membrane) is described by the 
diffusion coefficient. The diffusion coefficient depends on: the physicochemical properties of 
both the diffusing compound (size, radius) and the diffusional medium (viscosity), temperature, 
and pressure. The Einstein diffusion equation points out the dependency on these 
factors [47]: 
Stratum corneum 
(lipophilic)
Viable epidermis
(hydrophilic)
Dermis
(hydrophilic)
Liberation
Diffusion (slow)
Partitioning (reversible)
Diffusion (fast)
Partitioning (reversible)
Partitioning (reversible)
Blood circulation
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2.3.5. Permeability coefficient (kp)  
The permeability coefficient is a heterogeneous rate constant characteristic for a membrane and 
a compound and is expressed as depth of diffusion per unit time (cm/h): 
h
DKk p
⋅
=  (Equation 5) 
This constant can be calculated from experimental results by dividing the flux J with the 
concentration difference ∆c (see Equation 2), whereas it is more difficult to calculate the terms K 
and D separately [41]. 
 
Permeability is influenced to a greater extent by variation of the partition coefficient than by 
variation of the diffusion coefficient. This can be observed in the analysis of a homologous 
series (e.g., of n-alkanols), where partition coefficient and permeability coefficient increase with 
increasing chain length, whereas the diffusion coefficient remains more or less constant (Table 
2-1) [35].  
Table 2-1: Average permeability data for n-alkanols. The diffusion coefficients were calculated from Equation 2 
using 40 µm for stratum corneum thickness (data from [35]). 
Alkanol Partition Coefficient K 
(vehicle/stratum corneum) 
Diffusion Coefficient D 
[cm2/s] 
Permeability Coefficient kp 
[cm/h] 
Methanol 0.6 0.9 x 10-9 0.5 x 10-3  
Ethanol 0.9 1.0 x 10-9 0.8 x 10-3  
Propanol 1.1 1.2 x 10-9 1.2 x 10-3  
Butanol 2.5 1.1 x 10-9 2.5 x 10-3  
Pentanol 5.0 1.4 x 10-9 6.1 x 10-3  
Hexanol 10 1.4 x 10-9 13.0 x 10-3  
Heptanol 30 1.2 x 10-9 32.1 x 10-3  
Octanol Not available 1.1 x 10-9 50.4 x 10-3  
Nonanol Not available Not available 61.2 x 10-3  
Decanol Not available Not available 79.2 x 10-3  
 
 
R = universal gas constant = kB . NA = 8.314472 J/mol K 
kB = Boltzmann constant = R/NA = 1.3806505 . 10-23 J/K 
NA = Avogadro’s number = 6.0221415 . 1023 /mol 
η = viscosity of the medium (vehicle, membrane) 
r = radius of the compound particle 
T = absolute temperature 
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2.4. Factors affecting percutaneous absorption 
2.4.1. Overview 
Factors affecting percutaneous absorption and topical bioavailability of topically applied 
compounds are: 
- the physicochemical characteristics of the compound 
- the physicochemical characteristics of the vehicle 
- the application conditions 
- the skin conditions. 
 
2.4.2. Physicochemical characteristics of the compound 
Molecular weight (size), degree of ionization (charge), and lipophilicity are important factors 
determining the partition and diffusion coefficients [35, 53]. The molecular weight is inversely 
proportional to percutaneous absorption and seems to particularly influence the diffusion 
coefficient. Molecules larger than 500 Daltons have usually more difficulty to pass through the 
healthy stratum corneum [54]. It is a common presumption that only non-ionized compounds are 
able to diffuse through the lipophilic intercellular regions of the stratum corneum. Yet, ionized 
compounds have been reported to permeate through human skin through the intracellular and 
transappendageal pathway, albeit at a slower rate [35]. Moreover, the formation of ion pairs 
between compound ions and ions present in the skin can lead to neutral compounds [41]. As 
most drugs are either weak acids or weak bases, the pH of aqueous vehicles determines the 
ionization state (compare chapter 2.4.3) [48, 55]. 
The best percutaneous absorption would be achieved by an amphiphilic compound showing 
both high solubility in the lipophilic stratum corneum (maximal input into the stratum corneum) 
and high aqueous solubility in the hydrophilic viable epidermis (maximal output into deeper 
layers). In general, compounds with a log Koctanol/water of about 1-3 have optimum partition 
behavior [56]. High penetration into the stratum corneum but limited penetration into the viable 
epidermis (observed for very lipophilic compounds) may induce a reservoir into the stratum 
corneum (see chapter 4). The same can occur for compounds with small diffusivity in the 
stratum corneum and for compounds binding to specific tissue components [35]. 
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2.4.3. Physicochemical characteristics of the vehicle 
The vehicle can both influence drug release as well as alter the stratum corneum structure. 
Drug release is affected by the viscosity of the vehicle (alteration of diffusion coefficient) and by 
the solubility of the compound in the vehicle. Alteration of the stratum corneum structure 
includes extraction of intercellular skin lipids and occlusive effects. The pH of the vehicle, the 
state of the compound in the vehicle (dissolved, suspended), the concentration of the 
compound, and the presence of cosolvents (e.g., propylene glycol), penetration enhancers 
(e.g., urea, DMSO3), and surfactants are all factors influencing percutaneous absorption. 
Among the penetration enhancers, two types can be distinguished: those influencing diffusion 
(e.g., Azone®4, oleic acid, surfactants) and those influencing partitioning (most solvents, e.g., 
propylene glycol) [41].  
After application of a topical formulation to the skin, the vehicle undergoes important structural 
changes also known as “metamorphosis of the vehicle”. The partitioning between vehicle and 
stratum corneum, and thus the penetration into stratum corneum, is different for each 
component of the formulation. In addition, evaporation of the different ingredients is possible. 
After application of a compound in a volatile vehicle (e.g., ethanol, acetone), the rapid 
evaporation of the vehicle subsequently increases the concentration and the saturation degree 
of the compound, thus altering the driving force of diffusion (enhanced thermodynamic activity). 
The maximum drug penetration into the skin is known to take place when the drug is in a 
saturated state [57]. In some cases, supersaturation can occur and thus further enhance 
percutaneous penetration [58].  
After complete evaporation of the solvent, the remnant drug precipitates onto the skin as 
”solvent deposited solid”. In this case, percutaneous penetration becomes a dissolution rate 
limited process [59, 60]. Percutaneous absorption following application in a volatile vehicle is 
quite different than percutaneous absorption from non-volatile vehicles and is not a steady-state 
process [61]. Akther et al. observed, after application of flurbiprofen and ibuprofen in acetone, 
an initially low percutaneous penetration which then increased as soon as evaporation of the 
vehicle took place [60]. Different mathematical models of percutaneous absorption kinetics after 
application of finite vehicle volumes and solvent deposited solids have been proposed [49]. 
                                                     
3
 DMSO is dimethyl sulfoxide. 
4
 Azone® is 1-dodecylaza cycloheptan-2-one. 
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2.4.4. Application conditions  
Dosing technique, dose, and application under occlusion are the most important application 
conditions affecting percutaneous absorption. 
Two main dosing techniques are known - the infinite and the finite. The infinite dose technique 
concerns the application of an amount of material much higher than is expected to penetrate 
into the skin. The surplus of material forms a surface reservoir which appears to be “infinite”. 
The steady-state flux after application of an infinite dose follows Fick’s first law of diffusion 
(described in chapter 2.3.1). The finite dose technique is more closely related to clinical 
settings. A definite, low amount of material is applied. With time, the amount of material on the 
skin surface is depleted and the flux into the skin decreases. No steady-state flux can be 
observed. In this case, the diffusion has to be explained with an appropriate solution of Fick’s 
second law (chapter 2.3.1), and several models have been proposed [62-64]. A special case at 
the boundary between finite and infinite dosing is observed after finite application of poorly 
absorbed compounds (e.g., corticosteroids). In this case, the amount recovered on the skin 
surface after penetration is usually high (ca. 60-95% of the dose applied) and forms a not 
completely depleted (i.e. infinite) surface reservoir. Table 2-2 outlines the different dosing 
techniques [65]. 
Table 2-2: Dosing techniques for topical drug application (modified from [65]). 
Dosing technique Loading Estimated bioavailability Comment 
Infinite dose high  
(> 10 mg/cm2) 
< 5% (typically 1-2%) Mostly for experimental settings 
Finite/Infinite dose clinical use  
(0.5-5 mg/cm2) 
< 5% (typically 1-2%) Poorly absorbed molecules in clinical 
situations (e.g., corticosteroids) 
Finite dose clinical use  
(0.5-5 mg/cm2) 
> 10% (typically 25-50%) Well absorbed molecules in clinical 
situations (e.g., nitroglycerin) 
After application of a single dose, the following parameters have been shown to influence 
percutaneous absorption: concentration of the dose, applied film thickness, area on which the 
dose is applied, and duration of the application. The effect of concentration on the percutaneous 
absorption of topical corticosteroids is explained in detail in chapter 5.2. Other effects have 
been reviewed by Surber and Davis [65].  
Occlusion is defined as the external insulation of the skin with a water evaporation limiting 
barrier [66] and can be performed either by covering the skin with an impermeable wrap (e.g., 
plastic film, tape or wound wrap, gloves, impermeable textiles, diapers) or by applying topical 
vehicles containing fats or oils (e.g., petrolatum or paraffin). Because of the inhibition of the 
transepidermal water loss (TEWL) from the skin surface by occlusion, the normal water content 
of the stratum corneum (10-20%) can be increased by up to 50%. Even short-time occlusion 
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(e.g., 30 min) results in a overhydration of the skin [67, 68]. Water has been shown to 
accumulate either within the corneocytes, inducing their swelling5 [69], or within the intercellular 
lipids, forming intercellular water pools [70]. Moreover, occlusion has an effect on: skin surface 
temperature (increase from 32°C to 37°C), blood flo w, composition of epidermal lipids, DNA 
synthesis, epidermal morphology and turnover, composition of the microbial skin flora, pH, and 
activity of sweat glands and Langerhans cells. In general, the barrier function of the stratum 
corneum is reduced by occlusion [67, 71]. The increased stratum corneum hydration and 
increased temperature can positively alter the partitioning of applied compounds between 
vehicle, stratum corneum, and viable epidermis, thus enhancing percutaneous absorption in a 
simple manner. After occlusion, the hydrated stratum corneum and the viable epidermis 
appears more similar (facilitated partitioning), with a greater effect for lipophilic compounds [72, 
73]. The specific effect of occlusion on the penetration of topically applied compounds with a 
focus on corticosteroids is described in chapter 5.4. 
                                                     
5
 The swelling of the corneocytes is more pronounced in the thickness: 25-30% increase in thickness and 3-5% increase 
in length have been observed after occlusion [69]. 
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2.4.5. Skin conditions 
The main skin conditions affecting percutaneous absorption are: the anatomic site, the 
temperature, the blood flow, and the health state. Minor factors are: age, skin type, race, 
gender, and the circadian rhythm of the barrier function. 
Percutaneous absorption in man varies depending on the anatomic site (reviewed in Wester 
and Maibach [74]). Experiments with hydrocortisone resulted in the following rank order of 
penetration: scrotum > forehead > scalp > back > forearm > palm > plantar skin [75]. There are 
3 main theories which attempt to explain the regional differences in percutaneous absorption: 
first, the variation of stratum corneum thickness and especially the lipid composition [76]; 
second, the different distribution of skin appendages acting as shunts; third, the differences in 
cutaneous blood flow [23]. Increased blood flow and skin hydration can be caused by an 
increased skin temperature and occlusion. A higher skin temperature increases the compound 
solubility and diffusion within vehicle and stratum corneum, thus enhancing percutaneous 
absorption [65].  
Physical (weather, sunlight, occlusion), chemical (solvents, detergents, acids, alkalis), and 
pathological factors (mechanical damage, skin diseases) all influence the state of the skin. 
Many skin disorders (e.g., atopic dermatitis, psoriasis, ichthyosis, xerosis) are characterized by 
an imbalance of the lipid composition and structure, especially of the stratum corneum 
ceramides. In addition, a diminished water-binding property, a lack of NMF, an incomplete 
maturation of the cornified envelope, and a defective corneocyte cohesion and desquamation 
have been reported [14]. The impaired barrier function of atopic and psoriatic skin is reflected by 
the increased TEWL [77]. The penetration into diseased or experimentally disrupted skin (e.g., 
by phonophoresis, electroporation, or tape stripping) can significantly differ from the penetration 
into healthy skin, even allowing the penetration of larger molecules, which would normally not 
penetrate (Fig. 2-4) [54].  
 
 
 
 
 
Fig. 2-4: Influence of the molecular weight and the state of the skin on human skin penetration. Normal human 
skin (NS), atopic dermatitis skin (AD), mucosa (M), and ultrasound treated skin (US) [54]. 
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Turpeinen et al. observed a statistically significant enhanced percutaneous absorption after 
application of hydrocortisone cream in children [78, 79] and adults [80] suffering from atopic 
dermatitis. The percutaneous absorption correlated with the severity of the dermatitis, and 
diminished with the restoration of the skin. With patients suffering from psoriasis, Schaefer et al. 
observed an enhanced TACA penetration after application of ointment and cream preparations. 
TACA concentrations 3-10 times higher than in healthy skin were quantified within epidermis 
and dermis [81]. Yet, Wester el al. observed similar hydrocortisone absorption in stable psoriatic 
plaques and healthy skin [82]. 
Age seems to exert a minor effect on percutaneous absorption. Whereas the stratum corneum 
barrier of premature infants is not completely mature, the skin of term infants seems to possess 
barrier properties already comparable to that of adult skin, and a similar percutaneous 
absorption can be expected [83]. Reports of drug toxicity after topical drug applications in 
children are mainly due to the higher surface area-to-weight ratio [84]. With increasing age, the 
skin undergoes important morphological, physiological, and biochemical changes. The number 
of dermal capillary loops, the skin lipid content, and the hydration status of stratum corneum 
decrease, and the dermis undergoes atrophy [85]. This leads to a decreased percutaneous 
absorption, particularly observed for hydrophilic compounds [86]. 
Racial differences in skin properties have been reported. Black skin has higher TEWL, variable 
blood vessel reactivity, decreased skin surface pH, and larger mast cell granules compared to 
white skin. The results about Asian and Hispanic skin are inconclusive [87]. Reed et al. 
observed that the skin type is a more relevant determinant of barrier function than race itself. 
Despite a comparable stratum corneum thickness, darkly pigmented skin (type V/VI) requires 
more tape strips to remove the stratum corneum by tape stripping, showing a superior barrier 
capacity. The permeability barrier function in skin type II/III does not seem to be affected by 
race or gender [88]. Also independent of gender are stratum corneum thickness, sebum rate, 
hydration status, and TEWL [7, 89], and a similar percutaneous absorption can be expected in 
men and women. In conclusion, percutaneous absorption seems to be more influenced by inter-
individual differences than by racial or gender related differences. 
The reported circadian rhythm in TEWL (highest in the night), skin surface pH (highest in the 
afternoon), and skin temperature (highest in the night) suggest higher skin permeability in the 
evening and the night [90]. Moreover, many endogenous compounds follow a circadian rhythm. 
In the specific case of corticosteroids, the time period with the lowest circulating concentration 
of endogenous cortisol is between 8 p.m. and 4 a.m. Consideration of this factor could be 
critical for bioequivalence assessment of topical corticosteroids using the vasoconstriction 
assay (see chapter 3.1), since the vasoconstrictive effect of the endogenous cortisol could 
interfere with the effect of the topically applied steroid [91].  
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3. Assessment of topical bioavailability 
3.1. Regulatory requirements 
In the US, the following general approaches, listed in order of preference, are regarded as 
acceptable by the Code of Federal Regulations (CFR) of the FDA for bioavailability and/or 
bioequivalence assessment: 1) pharmacokinetic approach based on measurements of the 
concentration of the active moiety and/or metabolites in blood, plasma, serum, or other 
appropriate biological fluid as a function of time; 2) pharmacokinetic approach based on the 
measurement of the urinary excretion of the active moiety and/or metabolites as a function of 
time (only appropriate if urinary excretion is a significant mechanism of elimination); 
3) pharmacodynamic approach based on the measurement of an appropriate acute 
pharmacological effect of the active moiety and/or metabolites (particularly appropriate to 
dosage forms not intended to deliver the active moiety to the bloodstream for systemic 
distribution); 4) comparative clinical trials; and 5) in vitro studies (21CFR320.24). For drug 
products that are not intended to be absorbed into the bloodstream, bioavailability may be 
assessed by measurements intended to reflect the rate and extent to which the active moiety 
becomes available at the site of action (21CFR320.23) [31].  
In the EU, the “Note for guidance on investigation of bioavailability and bioequivalence” 
released by the EMEA states that for products for local use (after oral, nasal, inhalative, ocular, 
dermal, rectal, vaginal administration) intended to act without systemic absorption, the approach 
to determine bioequivalence based on systemic measurements is not applicable and 
pharmacodynamic or comparative clinical trials are required. The determination of the systemic 
exposure resulting from locally applied products is only relevant if there is a risk of systemic 
adverse reactions [30].  
Comparative clinical efficacy trials are relatively insensitive, highly variable, time consuming, 
costly, and need a high number of volunteers. Pharmacodynamic investigations can only be 
performed if the topically applied compound produces a measurable pharmacodynamic 
response, and this is not always the case. Nevertheless, there are two outstanding examples. 
Corticosteroids induce a vasoconstriction, and the degree of skin blanching can be correlated 
with the efficacy and potency of the steroid. A relevant guidance (“Topical dermatological 
corticosteroids: in vivo bioequivalence”) has been released by the FDA [92]. Furthermore, 
retinoids induce an enhanced TEWL, which can be used as pharmacodynamic measure for 
bioavailability assessment.  
An explicit approach for measurements intended to reflect the rate and extent to which the 
active moiety becomes available at the site of action is still missing in the regulatory 
specifications. It was against this background that the FDA proposed in 1998 a draft guidance 
for the bioavailability assessment of topical dermatological drug products (“Topical 
dermatological drug products NDAs and ANDAs – In vivo bioavailability, bioequivalence, in vitro 
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release, and associated studies”) [1]. The guidance focused on the DPK approach, which is 
based on the measurement of the active moiety in the stratum corneum. The DPK approach is 
comparable to a blood, plasma, or urine pharmacokinetic approach applied to the stratum 
corneum. Generally, DPK studies are performed in healthy volunteers, since diseased skin is 
highly variable and changes over time. Among different models, tape stripping showed the 
highest potential for the DPK characterization of topically applied drugs, since the percutaneous 
penetration was assessable without invasive procedures. Yet, the draft guidance was withdrawn 
in 2002 because of the following two reasons6. The first concern considered the adequacy of 
the DPK method to assess the bioequivalence of topical dermatological drug products, because 
the products are used to treat a variety of diseases in different part of the skin, not just the 
stratum corneum. Yet, despite the fact that the target site for topical dermatological drug 
products may not always be the stratum corneum, the drug must still pass through the stratum 
corneum barrier to reach deeper sites of action. In certain cases, the stratum corneum itself is 
the site of action (e.g., for antimykotika). For antiacne drug products, the target sites are the hair 
follicles and the sebaceous glands, and it has been shown that there is a positive correlation 
between stratum corneum and follicular concentrations. The second concern considered the 
reproducibility of the DPK method between laboratories. The detailed presentation of the tape 
stripping technique in the next chapter will provide a better understanding of this second 
concern. 
3.2. Tape stripping 
Tape stripping is a technique which enables the removal of the stratum corneum layer by layer. 
Adhesive tapes are sequentially pressed onto the same skin region, and then stripped off [93]. 
Using a standardized technique, Jacobi et al. showed that 66% of the stratum corneum is 
removed with 20 tapes (using Tesa® Multi-Film Crystal-Clear tape), and nearly the complete 
stratum corneum (95%) is removed with 50 tapes [94]. Yet, depending on the adhesive tapes 
used, up to 100 tapes may be required to remove the entire stratum corneum from one skin site 
[95] (Fig. 3-1). With the tapes, corneocytes and substances previously applied on the skin are 
removed and can be quantified with an appropriate analytical method (e.g., HPLC, 
spectroscopy, scintillation counting). 
Fig. 3-1: Microscopic depiction of the skin. A) Epidermis with intact stratum corneum; B) Epidermis after 
stripping off 10 tapes; C) Epidermis after stripping off 50 tapes; D) Epidermis after stripping off 100 tapes [95]. 
                                                     
6
 The report of withdrawal is available at the site: www.fda.gov/OHRMS/DOCKETS/98fr/98d-0388-nwl0001-vol1.pdf 
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The tape stripping technique was introduced in the early 40’s by Wolf. He investigated the 
topography of the skin by removing layers of corneocytes with transparent adhesive tapes and 
by examining them microscopically [96, 97]. In the 50’s, Pinkus applied the new technique to 
investigate the epidermal regeneration process. By taking punch biopsies of stripped skin sites, 
he observed that tape stripping stimulated the mitotic rate in the stratum basale [98, 99]. The 
mitotic rate was maximal after 3 days, and a couple of weeks were required for complete skin 
renewing. Further studies investigating the epidermal growth kinetic after standardized injury of 
healthy [100-102] and atopic dermatitis skin [103] by tape stripping were performed. Recently, 
Choi et al. showed that tape stripping induces the production of cytokines such as interleukins, 
tumor necrosis factor α, and γ-interferon [104], enhances the enzymatic activity, and increases 
the ceramides synthesis [105]. The artificial removal of the stratum corneum barrier by tape 
stripping has become a frequently used model for simulating diseased skin [106], and for 
assessing the efficacy of skin care products in restoring the barrier [107, 108]. Moreover, a 
percutaneous penetration enhancement of macromolecules like peptides and oligonucleotides, 
which usually do not penetrate healthy skin, was observed after removal of the stratum 
corneum, thus opening the possibility of topical vaccinations [104, 109]. 
 
In the 80’s, the methodology was standardized by Dupuis et al. [110, 111], making of tape 
stripping a method widely used in dermatological research to non-invasively investigate the 
topical bioavailability and percutaneous penetration of topically applied substances. The 
investigation of the topical activity of antiviralia [112, 113] and antimykotika [114, 115], the 
investigation of vehicle effects [116, 117], barrier function and reservoir formation within the 
stratum corneum [118-120], and the investigation of the percutaneous penetration and 
absorption of topical corticosteroids [91, 121-123] are some important examples of application 
areas. Furthermore, tape stripping has been used to investigate stratum corneum lipids [124] 
and epidermal enzymes [125].  
A prerequisite for making the tape stripping technique a capable, robust, accurate, and 
reproducible method to investigate the bioavailability of topically applied drugs is the strict 
standardization and a clear definition of the stripping parameters. The technique is susceptible 
to numerous confounding factors, both intrinsic and extrinsic. Among the intrinsic factors, the 
anatomical site, the hydration status of the skin, the cohesion of the corneocytes (influenced as 
well by the vehicle used [126]), and the presence of furrows have to be mentioned [127]. Van 
der Molen observed that topically applied titanium dioxide could still be detected after removal 
of 40 tapes because of an accumulation in superficial skin furrows, thus falsifying the results 
[128]. In addition, interseasonal differences have been observed [129]. Among the extrinsic 
factors, the type of tape used (e.g., cellophane, polyester, polypropylene, polyethylene, rayon) 
[130, 131], the pressure with which the tape is applied onto the skin, the duration of the 
pressure, and the force of removal (slow/quick) influence the stratum corneum removal [127]. 
These are the parameters which can and must be standardized. Surber et al. outlined a 
standard protocol for tape stripping experiments [93]. The protocol implies the use of a template 
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to delineate the stripping area, and the exertion of a definite pressure (e.g., with a roller [132]) 
on each tape before removal. The use of a roller has been shown to prevent artifacts due to 
furrows and wrinkles [133]. Because of inter-individual differences in stratum corneum 
thickness, the complete stratum corneum of one skin site should be stripped. In newer 
investigations, Weigmann et al. used the tape stripping method to calculate horny layer profiles, 
in which the amount of drug penetrated is correlated not only to the tape number stripped but 
also to the depth of the stratum corneum. This correlation enables the localization of the drug 
within the stratum corneum layers. For this purpose, the removal of the entire stratum corneum 
and the quantification of both corneocytes and drug on the tapes are required [134]. Recently, 
Jacobi et al. reported a procedure for the estimation of the removed stratum corneum amount 
on each tape, thus providing a possibility to avoid the complete removal of the stratum 
corneum [94].  
After a review of all the influencing and confounding factors affecting the tape stripping 
technique, the withdrawal of the DPK draft guideline for the bioavailability assessment of topical 
dermatological drug products [1] becomes more comprehensible. The concern of inadequate 
reproducibility between laboratories is not at all amazing. The FDA draft guidance 
recommended the application of the test formulation on ≥ 8 skin sites on each forearm, with 
tape stripping performed at incremental times after application. Only 12 tapes, without 
specification of the type of tape to be used, had to be stripped. Moreover, the first 2 tapes were 
discarded from evaluation and the remaining 10 tapes pooled and extracted together. The 
protocol described in the draft guidance was not yet mature and did not satisfy the regulatory 
requirements for bioavailability/bioequivalence assessment at the time of withdrawal. In the 
future, the proposal of a more realistic and elaborated protocol could ensure a successful 
regulatory basis for a promising and already widely used DPK method like tape stripping. 
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3.3. Further techniques 
Other approaches for the assessment of the drug concentration profile in the skin following 
topical application do exist (reviewed in [65]). The most invasive method is represented by the 
direct excision of skin tissue. The punch biopsy is performed with round disposable knives 
(diameter 2-10 mm), and the biopsy contains epidermis, dermis, and part of the subcutis. The 
shave biopsy is more superficial, contains epidermis and part of the dermis, and is usually 
performed with a razor blade [135]. The skin scraping (curettage) technique usually removes 
the superficial stratum corneum with a dermal curette, but deeper parts of the epidermis can be 
sampled as well with a more vigorous scraping [136]. The skin surface biopsy uses quick 
drying cyanoacrylate glue to remove the stratum corneum in few samplings. The glue is applied 
to a glass slide, pressed onto the skin surface, and then removed after polymerization of the 
glue [137].  
Cutaneous microdialysis enables the real-time assessment of cutaneous drug delivery in a 
minimally invasive manner. A probe, consisting of a semipermeable dialysis membrane tube 
and simulating a blood vessel, is inserted into the dermis and perfused by a physiological 
solution, which equilibrates with the extracellular fluid of the surrounding tissue. Topically 
applied compounds can thus be determined in the dermal extracellular water [138].  
The suction blister technique is usually performed to assess drug levels in the skin after 
systemic administration. Intra-epidermal blisters are artificially produced by placing a chamber 
with several holes onto the skin and applying a vacuum. The suction blister fluid displays 
approximately the same composition of the interstitial fluid [139].  
In addition to these invasive techniques, several imaging methods have been applied to the skin 
in the last years. The most promising optical methods seem to be the confocal scanning laser 
microscopy [140] and the confocal Raman microspectroscopy [141, 142]. These new 
techniques allow to focus a beam to a given depth within the skin and to determine the 
concentration of the topically applied compound at this level in an absolutely non-invasive 
manner. 
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4. Stratum corneum reservoir 
4.1. Definition  
The term “reservoir” referred to the skin can be defined as an accumulation of a topically 
applied compound within the skin or within a particular skin layer for a longer time period. This 
accumulation can be due to: 1) temporary sequestration of compound because of binding to 
specific structures of the skin (e.g., to keratin, proteins, amino acids [143], collagen fibers [144], 
stratum corneum lipids [145]); or 2) high partitioning into a specific skin layer (e.g., into the 
intercellular lipids of the stratum corneum) and relatively slow release into the next layer. The 
consequence is either a hindered diffusion to deeper skin layers in the first case, or a low 
diffusional flux of minimal amounts into deeper tissues in the second case [53, 146]. In both 
cases, the reservoir is not a time-stable state, and the factors rate and extent have to be 
considered [42]. 
The formation and the duration of a reservoir can affect the topical application in terms of dose 
and application frequency and should be considered when assessing DPK. During topical 
therapy with corticosteroids, it is desiderable that the drug remains for a long time at the site of 
action, i.e. within the skin, and that it exerts a local and not a systemic action. In this case, the 
formation of a stratum corneum reservoir and a slow drug release to deeper skin tissues over a 
longer time period is advantageous and desired.  
4.2. Localization of the reservoir 
The ability of the skin to store topically applied drugs was already suggested in the 50’s, when 
Malkinson and Ferguson detected 14C-hydrocortisone in the urine of 2 volunteers 7 days after 
topical application [147]. Possible localizations of the reservoir were: the upper dermis, the 
viable epidermis, the stratum corneum, the skin appendages, or a drug film on the skin surface. 
In 1963, Vickers demonstrated the existence of a reservoir for corticosteroids within the stratum 
corneum of healthy volunteers [148]. After application of fluocinolone acetonide and TACA in 
95% ethanol and 16 h-occlusion, he observed the typical blanching effect due to the 
vasoconstrictive property on the dermal blood vessels. After simple re-occlusion, the 
vasoconstriction could be observed for 14 days. Vickers concluded that a depot of corticosteroid 
was present within the skin and that it could be re-activated by occlusion. Tape stripping 
experiments demonstrated that it was not possible to induce a reservoir on stripped skin, and 
that a reservoir induced on intact skin could be eliminated by tape stripping the stratum 
corneum [149]. The participation of the drug film on the skin surface could be excluded by 
washing the skin with several methods (soap and water, ether, 95% ethanol) [148, 150, 151]. 
Vicker’s reservoir was confirmed and quantified in 1966 by Carr and Wieland with 14C-labeled 
TACA applied in 95% ethanol under occlusion. More than 75% of the steroid was detected in 
the upper stratum corneum [152]. Schaefer et al. showed that less than 5% of topically applied 
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TACA (in both an ointment and cream vehicle) was systemically absorbed. The healthy stratum 
corneum was able to retain up to 30% of the steroid as a reservoir, and 70-90% remained on 
the skin surface [81]. 
McKenzie and Stoughton excluded the participation of the dermis to the reservoir development 
by intradermally injecting TACA in one arm and topically applying under occlusion a comparable 
amount on the contralateral arm of 12 volunteers [153]. Initially, a vasoconstriction was 
observed on both arms, but the vasoconstriction on the “intradermal-injection-arm” faded after a 
couple of hours and did not reappear, whereas a re-occlusion of the “topical-application-arm” 
still developed a vasoconstriction.  
Yet, the participation of epidermis, dermis, and underlying tissues to a reservoir formation has 
recently been revised [146]. Binding to specific skin structures as well as high partitioning in one 
skin layer and low release to the next layer is not only possible for the stratum corneum, but 
also for epidermis and dermis. A high binding to dermal tissue has been observed for diclofenac 
in the Wistar rat [154]. Cross et al. observed with human skin in vitro a decreased dermal 
permeation for the more lipophilic alcohols of a homologous series (C2-C10), which resulted in 
an (epi-)dermal accumulation. They postulated that the dermis may represent a more lipophilic 
compartment than originally believed [53]. In an in vitro investigation of the fate of 
dihydroxyacetone (DHA) in human and rat skin, Yourick et al. observed that 24 h after 
application of a realistic DHA dose, 22% of the applied dose was still within the whole skin, with 
half the amount residing within the stratum corneum and half within the viable epidermis/dermis. 
Approximately 5% of the DHA was covalently bound to proteins, and the majority of DHA was 
probably noncovalently bound to free amino acids [155]. Jacobi et al. measured high amounts 
of flufenamic acid, which remained constantly high for 21 h, in porcine dermis in vitro after 
infinite dosing in wool alcohol ointment [156]. An accumulation of dexamethasone and 
hydrocortisone was observed in dermis, deeper epidermis, and hair follicles after application of 
a Transcutol® (diethylene glycol monoethyl ether) containing vehicle on human and rat skin in 
vitro [144, 157]. In newer studies, the participation of skin appendages, especially the follicles, 
to the reservoir formation was also reconsidered [158, 159]. A higher lipophilicity of the applied 
compound [155, 160] as well as the application in polar vehicles like propylene glycol [161] and 
ethanol [162] seem to improve the follicular targeting. The formation of a follicular reservoir can 
become relevant in skin regions with high follicular density like the forehead [46]. 
In conclusion, the accumulation of topically applied compounds within the skin and thus the 
formation of a reservoir is possible for both lipophilic and hydrophilic compounds. The reservoir 
is usually located within the stratum corneum, but can sometimes occur also in viable 
epidermis, dermis, and follicles. Though the reservoir formation was initially studied with 
corticosteroids, it is not restricted to this drug class. A stratum corneum reservoir has been 
observed for several other compounds, for example antimicrobials (hexachlorophene [151], 
fusidic acid [149]), vitamin E [163], nicotine [164], caffeine [165], cationic β-blockers [166], 
sunscreen agents [167, 168], hair dyes [169], surfactants in soaps [170], and carcinogenic 
aromatic amines [171]. 
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4.3. Factors influencing the reservoir 
The factors promoting a reservoir formation are substantially the same as those influencing their 
percutaneous penetration (see chapter 2.4) [172].  
Among the physicochemical properties of the drug, a high lipophilicity and protein affinity is 
favorable for a reservoir development in the stratum corneum [53, 173]. A minimal, defined 
amount of drug has to be applied to induce a reservoir. Clarys observed the formation of a 5-
day-lasting halcinonide reservoir after application in an oil-in-water vehicle, but only for the 
highest tested concentration (0.2% vs. 0.05% and 0.005%) [174]. Carr and Tarnowsky obtained 
similar findings with TACA ointments (0.1% vs. 0.01%) [175]. 
The ability to develop a reservoir is highly dependent on the vehicle. Vickers observed in vivo 
that the application of steroids in alcoholic solutions always induced a reservoir (lasting 9.6 
days), hydrophilic creams induced a reservoir in 92% of the volunteers (lasting 7.4 days), and 
ointments induced a reservoir in 68% of the volunteers (lasting 4.6 days). Presumably, the 
intercellular lipids of the stratum corneum were partly damaged by the alcoholic solvent, thus 
facilitating drug penetration [149]. In contrast, with fluocinolone acetonide in vitro, Munro 
observed the highest stratum corneum retention after application in white petrolatum [172]. 
Particularly, the presence of penetration enhancers like urea [174], dimethyl sulfoxide (DMSO) 
[150], dimethylacetamide (DMAC) [151], dimethylformamide [176], Transcutol (diethylene 
glycol monoethyl ether) [144, 157], or propylene glycol [177] has been shown to promote a 
reservoir formation. Stoughton observed that the addition of 40% DMSO to different 
formulations could induce an accumulation of 15-100% more steroid (hydrocortisone, 
fluocinolone acetonide) within the stratum corneum compared to a DMSO-free vehicle. Even 
without the need of an application under occlusion, a 16-day-lasting reservoir was formed [150]. 
The addition of urea to an oil-in water vehicle induced a 5-day-lasting reservoir after application 
of low amounts of halcinonide (0.005%). This was not observed after application of the urea-
free formulation [174]. The addition of Transcutol to a gel vehicle increased the penetration of 
hydrocortisone into rat skin, decreased its permeation across the skin, and induced a skin depot 
lasting 7 days after a single infinite application under occlusion [144]. 
As already described in chapter 4.2, a reservoir is often induced after application under 
occlusion. The enhanced hydration can considerably change the affinity of the applied 
compound to the stratum corneum and its partitioning between the different skin layers (stratum 
corneum, epidermis, dermis) [153]. The duration of occlusion seems to play an important role: 
an occlusion ≤ 8 hours does not induce a reservoir or induces a reservoir of short duration 
[149].  
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4.4. Relevance of the reservoir 
The therapeutical and physiological relevance of the reservoir formation has been the subject of 
discussions since its discovery. In 1966, Carr and Tarnovsky doubted its relevance. They 
observed that the percutaneous absorption out of the stratum corneum reservoir after 
application of a TACA ointment on the whole body under occlusion was not sufficient to 
suppress the pituitary-adrenal axis [175]. Yet, the suppression of the pituitary-adrenal axis is not 
really a phenomenon which can be correlated with the topical clinical effect. In a therapeutically 
more relevant study, Stoughton showed that the induction of a hexachlorophene reservoir after 
application of a DMAC-containing formulation increased and prolonged the bacteriostatic 
efficacy of hexachlorophene compared to a commercial formulation [151]. 
The main problem during the investigation of topical bioavailability or percutaneous absorption 
of topically applied compounds is the application on usually healthy skin, whereas clinically the 
compounds are usually applied on diseased skin. In atopic dermatitis, eczema, or psoriasis, the 
skin displays an impaired stratum corneum barrier and a different composition of the stratum 
corneum lipids. An enhanced penetration and systemic absorption have to be expected if an 
intact stratum corneum barrier is not guaranteed. The induction of a reservoir in diseased skin 
was not successful in several experiments, for example with volunteers displaying psoriasis or 
Lichen simplex [149]. Schäfer et al. measured a 3-10 times higher TACA concentration in 
psoriatic epidermis and dermis after application of TACA in ointment and cream formulations, 
and a marked higher systemic absorption compared to healthy skin [81]. Yet, in patients 
suffering from atopic dermatitis, a hydrocortisone reservoir could be formed, and the steroid 
could be released from the reservoir after 12 h by application of a propylene glycol-containing 
moisturizer [177]. 
During therapy with corticosteroids, the reservoir formation seems to have a more preventive 
than therapeutical relevance [149]. For the formation of a long-lasting reservoir, a more or less 
intact stratum corneum is required, and this is in contradiction with the acute therapeutical 
indication for topical corticosteroids. Nevertheless, already after a partial regeneration of the 
stratum corneum, the development of a reservoir becomes relevant again. Several established 
application regimens of corticosteroids take advantage of the fact that “stored” steroids can be 
remobilized out of the reservoir by a simple application of moisturizing cream (compare the 
interval and tandem therapy outlined in chapter 5.1, “Application regimen”). 
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5. Topical glucocorticosteroids 
5.1. Overview 
Classification 
Topical corticosteroids are classified according to their efficacy into four potency classes7 where 
class I represents mildly potent, class II moderately potent, class III potent, and class IV very 
potent corticosteroids. The same drug can be classified into a different potency class depending 
on the concentration and the vehicle (Table 5-1). This classification is based upon the 
vasoconstrictive properties of the corticosteroids, macroscopically visible as a paling of the skin 
(“blanching effect”) [178]. 
Table 5-1: Potency of selected glucocorticosteroids (modified after Niedner [180]). 
Corticosteroid mild 
(class I) 
moderately strong 
(class II) 
strong 
(class III) 
very strong 
(class IV) 
Hydrocortisone 0.25-2.5%    
Prednisolone 0.4%    
Clobetasole butyrate 0.05%    
Dexamethasone 0.01% 0.05-0.1%   
Triamcinolone acetonide  0.01-0.1%   
Hydrocortisone butyrate  0.1%   
Betamethasone valerate  0.05%   
Fluocinolone acetonide  0.01% 0.025%  
Betamethasone dipropionate   0.05%  
Halcinonide   0.1%  
Diflucortolon valerate    0.3% 
Clobetasol propionate    0.05% 
 
 
Independently of the potency classification, topical corticosteroids can be classified into four 
generations. Starting from hydrocortisone and prednisolone (1st generation), several chemical 
modifications have been performed to enhance the desired pharmacological effects (e.g., anti-
inflammatory, anti-proliferative effects) and to reduce the adverse effects (e.g., the 
mineralocorticoid effect). The halogenation of the compounds led to a higher efficacy but also to 
a higher rate of side effects (2nd and 3rd generation). The design of ester prodrugs led to highly 
effective compounds with a better side effect profile [180].  
                                                     
7
 In the Anglo-American region, the potency classification includes 7 classes, where class 1 represents the superpotent, 
and class 7 the mildly potent corticosteroids [178]. 
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Glucocorticoid effects and indications  
The antiphlogistic, immunosuppressive, and antipruriginous effects of corticosteroids are used 
for the treatment of the atopic dermatitis, of the seborrhoeic, nummular, and allergic contact 
dermatitis, as well as of the dishydrotic eczema. More potent corticosteroids additionally 
exerting an antiproliferative effect are used in the treatment of psoriasis, lichenifications, Lichen 
planus or sclerosus, and discoid lupus erythematodes [181].  
The molecular effects result by binding of the corticosteroid to the intracellular gluco-
corticosteroid receptor. After molecular transformation, the complex is translocated into the 
nucleus, where it represses or activates the expression of various genes. Moreover, non-
genomic effects result by binding of the steroid to membrane-associated receptors [182, 183]. 
Table 5-2 summarizes the effects observable at the cellular level. 
Table 5-2: Cellular effects of topical glucocorticosteroids [184]. 
Cell type Cellular effect 
Keratinocytes Inhibition of proliferation and normalization of the hornification process 
Fibroblasts Inhibition of the synthesis of collagene and mucopolysaccharides 
Lymphocytes, granulocytes Inhibition of immigration and proliferation 
Mast cells, basophils Inhibition of the release of inflammatory mediators 
Langerhans cells Inhibition of proliferation and function 
Melanocytes Inhibition of pigment formation 
Adipocytes Inhibition of proliferation 
Blood vessels Vasoconstriction 
 
Adverse effects and contraindications 
The antiproliferative effect of potent corticosteroids can lead to local effects such as atrophy of 
epidermis and dermis. This has been reported with very potent steroids, after a long treatment 
period, and after application under occlusion. The atrophogenic potential of the very potent 
corticosteroids is clinically used for the treatment of keloids, where the steroid is directly injected 
into the skin. Furthermore, the development of striae, folliculitis, hypertrichosis, 
hypopigmentation, perioral dermatitis, steroid-inducted acne, and a disturbed wound healing are 
possible. Skin infections can occur because of the immunosuppressive effect. Allergy to the 
steroid or to the vehicle has been reported, as well as the development of glaucoma if potent 
corticosteroids (class 3 and 4) are applied near the eye. Tachyphylaxis and rebound 
phenomena have been described after prolonged therapy and abrupt discontinuing of the 
therapy. Therefore, a short-term therapy and a gradual withdrawal of the steroid are indicated. 
Systemic side effects are possible if the percutaneous penetration of the topical corticosteroid is 
enhanced, e.g. by occlusion, in intertriginous skin regions, or during acute skin affection where 
the skin barrier is highly damaged. The worst case can result in an adrenocortical suppression 
and in a cushing-syndrome, which, however, is very rare and has been reported only with very 
potent corticosteroids [185]. Contraindications for a therapy with topical corticosteroids are skin 
infections, rosacea, perioral dermatitis, urticaria, corticosteroid allergy, pregnancy, and breast 
feeding.  
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Triamcinolone acetonide (TACA) 
TACA (9α-fluoro-11β,21-dihydroxy-16α,17α-isopropylidenedioxy-1,4-pregnadiene-3,20-dione) is 
a synthetic, moderately potent glucocorticosteroid with pronounced antiallergic, antiphlogistic, 
antipruriginous, and vasoconstrictive properties. Common topical concentrations are 0.025-
0.5%. The derivatization of triamcinolone (orally available, logP 1.02) to the more lipophilic 
acetonide (logP 2.27) confers on TACA topical bioavailability [186] and a 200 times higher 
affinity to the glucocorticosteroid receptor [187]. The compound is almost insoluble in water and 
more easily soluble in organic solvents. Table 5-3 displays its chemical structure and the 
solubility in different solvents [188].  
Table 5-3: Chemical structure of TACA (C24H31FO6) and solubility in different solvents. 
Triamcinolone acetonide (TACA) Solubility [mg/ml] Solvent 
            0.04 water (pH 7) 
 25  chloroform 
 40  isopropyl alcohol 
 50  95% ethanol 
 90  acetone 
                      MW 434.5 250  dimethylformamide 
 
The acetonide group protects TACA against oxidative degradation by epidermal enzymes [189]. 
Absorbed TACA is extensively metabolized in the liver (6β-hydroxy-TACA, 21-carboxy-6β-
hydroxy-TACA, 21-carboxy-TACA) and excreted mainly by the kidney (85% as metabolites, 
15% unchanged) and, to a minor extent, by the bile [190]. 
Application regimen 
The efficacy of corticosteroids depends on several factors. The most relevant are: the 
concentration of the applied formulation (and simultaneously the applied dose), the frequency of 
application, the potency of the corticosteroid, the properties of the vehicle (e.g., occlusive, 
emollient, drying, volatile), the application conditions (e.g., under occlusion or extreme rubbing), 
the contact time, and the skin disease [191]. The effect of concentration, application frequency, 
and occlusion on the percutaneous penetration and the efficacy of low dose topical 
corticosteroids are outlined in detail in chapters 5.2, 5.3, and 5.4, and were investigated 
experimentally in Projects II, III, and IV. First, an overview of different application regimens is 
given. 
In current dermatopharmacotherapy, a step-down therapy is generally advised (Fig. 5-1). The 
treatment of an acute dermatosis should begin with a potent corticosteroid (class III, 
occasionally class IV) until a good clinical response is observed. Then, the potent corticosteroid 
can be replaced with a moderately potent (class II) one, and finally a mildly potent (class I) can 
be used. This procedure prevents local side effects and rebound [192].  
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Fig. 5-1: Therapy scheme of topical corticosteroids. Step-down and interval therapy (modified from Hatz [192]). 
A valuable alternative is the interval therapy (Fig. 5-1). Instead of abruptly stopping the 
therapy, corticosteroid-free intervals during which only the cream base is used are alternated 
with the corticosteroid applications [192]. The duration of the corticosteroid-free intervals can be 
quite variable, and every-other-day (alternate-day), twice-weekly, or weekend-only (pulse 
therapy) corticosteroid applications are not uncommon [193]. In a double-blind, randomized, 
vehicle-controlled, bilateral-paired comparison with 32 psoriatic patients treated with 
betamethasone dipropionate cream, Singh did not observed any significant difference between 
alternate-day vs. once-daily corticosteroid applications. On the contrary, the application every 
third day or weekly was less effective than the once-daily application [194]. In patients suffering 
from atopic dermatitis, the twice-weekly application of fluticasone propionate combined with the 
daily emollient significantly reduced the risk of a relapse, and was thus paradoxically steroid 
sparing [195]. 
Corticosteroid applications often follow a tandem therapy: the corticosteroid is alternated with 
the cream base, for example the corticosteroid is applied in the evening, the cream base in the 
morning. The adjunctive skin care with the cream base is of extreme importance in most 
dermatoses. Moreover, the intermittent steroid application has proved useful in preventing 
tachyphylaxis, observed after prolonged and intensive therapy, especially after multiple-daily 
applications [196, 197]. 
A more specific treatment regimen is the topical rotational therapy [198], known especially 
from the psoriasis treatment: corticosteroid applications are alternated with applications of other 
topical agents (e.g., calcipotriol, tazarotene). This offers certain advantages, since monotherapy 
with topical corticosteroids for psoriasis generally results in a limited total clearance of the 
lesions (4-36%) [199]. Singh et al observed that the use of betamethasone and calcipotriol on 
alternate weeks was more effective than the daily application of the corticosteroid alone. This 
new treatment strategy seems to prevent or minimize tachyphylaxis [198]. 
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5.2. Concentration and dose 
Pharmacodynamic aspect 
Potency and efficacy of corticosteroids are usually assessed using the skin blanching assay, 
which estimates the potency based on the skin whitening side effect due to vasoconstriction 
[153]. The blanching assay is suited for bioequivalence testing of different proprietary 
formulations and for efficacy testing of different concentrations of the same glucocorticosteroids 
in the same vehicle [92]. 
The dose-response curves obtained by blanching assessment of topically applied 
corticosteroids can usually be divided into 2 parts (Fig. 5-2). The first part displays a relatively 
steep dose-response relationship where small changes in concentration lead to a high potency 
increase. The second part displays a rather flat dose-response relationship where large 
increases in concentration lead only to small changes in potency. The typical concentration of 
proprietary corticosteroid formulations usually resides in the flat, second part of the dose-
response curve, and often a 10-to-20-fold dilution is needed to achieve a detectable change in 
potency [191]. In the case of TACA, the 4-fold dilution of different proprietary formulations 
(0.5%-0.025%) did not change its efficacy significantly [200]. 
 
 
Fig. 5-2 : AUC / concentration curve 
for a betamethasone valerate 
ointment. The AUC scores are a 
measure of the vasoconstrictive 
potency, and were obtained from 
blanching response profiles from 7 to 
24 h after application of the 
formulation [191]. 
For this reason, it could be assumed that marketed corticosteroid formulations contain much 
more drug than necessary for their efficacy. Actually, in clinical practice, proprietary formulations 
are often diluted with the cream base to decrease the corticosteroid concentration.  
The topic concerning the efficacy of low-dose corticosteroid formulations as well as advantages 
and risks of dilution has been investigated and discussed in the experimental section (Project 
IV: Efficacy of low-dose corticosteroids in atopic dermatitis).  
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Pharmacokinetic aspect 
Increasing the concentration of the active compound in a topical formulation does increase its 
percutaneous penetration, provided that the compound is dissolved. The relationship between 
dose applied and absolute absorption can be defined as roughly linear, but only over a finite 
range. After surpassing the threshold, a surplus of the compound may not be absorbed from the 
skin because of skin saturation or because of compound precipitation. In case of skin 
saturation, the compound diffusion through the skin is not expected to follow Fick’s law of 
diffusion [201, 202].  
Wester and Maibach thoroughly investigated the percutaneous penetration of hydrocortisone, 
testosterone, benzoic acid, and nitroglycerine in a wide concentration range (Table 5-4) [203]. 
After application of a 10-fold increased concentration of hydrocortisone (4 vs. 40 µg/cm2), only a 
4-fold increase in hydrocortisone absorption was observed. After application of increasing 
concentrations of nitroglycerin, the absolute percutaneous absorption increased roughly linearly 
in the concentration range of 10-7000 µg/cm2, but then decreased abruptly at 10000 µg/cm2. As 
shown in Table 5-4, the application of high drug concentrations always results in a decreased 
relative absorption [204]. In contrast, low-dose formulations are absorbed more efficiently 
(higher relative absorption). Moreover, the saturation degree of the drug within the formulation 
plays a determinant role [196] 
Table 5-4: Percutaneous absorption of different topical doses of hydrocortisone, testosterone, benzoic acid, 
and nitroglycerin in the rhesus monkey model and in human volunteers (data for hydrocortisone, testosterone, 
and benzoic acid from [203, 204]; data for nitroglycerine from [205]). 
Compound Dose applied  Percutaneous absorption 
(monkey) 
 
Percutaneous absorption 
(human) 
 [µg/cm2]  Absolute [µg] Relative [%]  Absolute [µg] Relative [%] 
Hydrocortisone 4   0.12 2.9  0.06 1.6 
 40   0.84 2.1  0.24 0.6 
Testosterone 3   - -    0.35 11.8 
 30   - -  2.6   8.8 
 40    2.7 6.7  - - 
 250    7.2 2.9  - - 
 400    8.8 2.2  11.2   2.8 
 1600   46.4 2.9  - - 
 4000   56.0 1.4  - - 
Benzoic acid 3   - -      1.1 37.0 
 4      2.4 59.2  - - 
 400   134.4 33.6  102.8 25.7 
 2000   348.0 17.4  288.0 14.4 
Nitroglycerine 10   - -     0.004 41.8 
 100   - -   0.04 43.5 
 1000   - -  0.4 36.6 
 7000   - -  1.9 26.6 
 10000   - -  0.8 7.8 
Similar results were observed with other compounds, e.g. parathion and lindane [203], phenol 
[202], and 4-cyanophenol [61]. The percutaneous penetration of TACA after application of a 
higher and a lower concentration was experimentally investigated in Project II: Effect of dose 
and application frequency. 
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5.3. Application frequency 
Pharmacodynamic aspect 
The application frequency of topical corticosteroids is a recurrently debated topic. Traditionally, 
the application of topical corticosteroids followed a multiple-daily scheme, with the application of 
the product up to 3-4 times a day. Yet, this habit had no scientific basis [206]. Newer guidelines 
usually recommend once- or twice-daily applications [193], and most clinicians follow the twice-
daily application schedule until a clinical response is obtained and then reduce the application 
frequency [179]. 
Two systematic reviews of atopic dermatitis treatment revealed a similar clinical efficacy of 
once-daily vs. more frequent applications. There was no clear evidence to support the multiple-
daily corticosteroid use [207, 208]. In a review involving both atopic dermatitis and psoriasis 
patients, Lagos et al. found no significant difference in the treatment response of once vs. twice 
daily applications with very potent corticosteroids, and no difference or only a slight difference 
with potent or moderately potent corticosteroids [209]. The once-daily application may also be 
preferable to minimize the risk of side effects and tachyphylaxis [196, 197], to improve patient 
compliance, and to reduce the therapy costs. 
The individual circumstances have always to be considered to ensure an optimal therapy. 
Relevant factors determining the choice of application frequency are: the severity, localization, 
and type of the dermatosis, as well as the potency and type of the corticosteroid. Whereas 
once-daily applications may be sufficient to cure mild or moderate skin affections, a more 
frequent application might be needed in severe forms to achieve a higher total clearance of the 
lesions [210] and an accelerated onset of action [211-213]. Severe psoriasis, for example, may 
require a more frequent application compared to atopic dermatitis [214]. For very potent 
corticosteroids, once-daily applications are usually recommended, and the new generation 
corticosteroids like mometasone furoate [215, 216] and fluticasone propionate [217, 218] are 
marketed as “once-daily” preparations.  
Table 5-5 gives an overview of the most important pharmacodynamic studies comparing the 
treatment efficacy of once-daily and multiple-daily applications of the same corticosteroid 
formulation. The once-daily application schedule always followed the tandem therapy (see 
chapter 5.1), with applications of the corticosteroid in the evening alternating with applications of 
an emollient in the morning and in the afternoon. On the whole, the results show that a once-
daily application can be as effective as multiple-daily applications, but that a twice- or thrice-
daily application may accelerate the onset of action. The adjunctive skin care with emollients 
increases the efficacy of the treatment and has steroid-sparing quality [199, 219]. 
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Table 5-5: Overview of the pharmacodynamic studies investigating the efficacy of once-daily vs. multiple-daily 
topical corticosteroid applications. All the studies are randomized, prospective and vehicle-controlled 
(additional applications of emollient cream in case of the once-daily schedule), and are displayed in 
chronological order.  
Preferred regimen Author Study design Disease Corticosteroid 
Once 
daily 
Multiple
daily 
Fredriksson et al. 
(1980) [211] 
Double-blind  
bilateral-paired 
multi-centered 
3 weeks 
Psoriasis (n=35)  
Atopic dermatitis (n=60) 
Halcinonide cream 
0.1%  
X  
Sudilovsky et al. 
(1981) [214] 
Double-blind  
bilateral-paired 
multi-centered 
3 weeks 
Psoriasis (n=194) 
Atopic dermatitis (n=149) 
Halcinonide cream 
0.1%  
 X 
thrice 
daily 
Gärtner et al. 
(1984) [220] 
Double-blind 
parallel 
2-centered 
2 weeks 
Atopic dermatitis (n=100) Betamethasone 
dipropionate cream 
0.05%  
X  
English et al. 
(1989) [212] 
Double-blind 
parallel 
2-centered 
3 weeks 
Atopic dermatitis (n=63)  
Psoriasis (n=34) 
Betamethasone 
dipropionate cream 
0.05%  
 X 
twice 
daily 
Watsky et al. 
(1992) [219] 
Open-label 
bilateral-paired 
4 weeks 
Psoriasis (n=96) Betamethasone 
dipropionate cream 
0.05%  
X  
Singh et al.  
(1995) [221] 
Double-blind 
bilateral-paired 
9 days 
Psoriasis (n=36) Betamethasone 
dipropionate 
ointment 0.05%  
X  
Koopmans et al. 
(1995) [210] 
Double-blind 
parallel 
multi-national 
4 weeks 
Atopic dermatitis (n=150) Hydrocortisone 17-
butyrate fatty cream 
0.1%  
 X 
twice 
daily 
Bleehen et al. 
(1995) [217] 
Double-blind 
parallel 
multi-centered 
4 weeks 
Atopic dermatitis (n=270) Fluticasone 
propionate cream 
0.05%  
X  
Tharp  
(1996) [213] 
Double-blind 
parallel 
multi-centered 
4 weeks 
Atopic dermatitis (n=238) Fluticasone 
propionate cream 
0.05%  
X  
Singh et al. 
(1998) [215] 
Double-blind 
bilateral paired 
2 weeks 
Psoriasis (n=64) Mometasone furoate 
ointment 0.1% 
X  
Kanzler et al. 
(2001) [199] 
Double-blind 
bilateral-paired 
4 weeks 
Psoriasis (n=24) Triamcinolone 
acetonide cream 
0.1% 
X  
 
5. Topical glucocorticosteroids 
Carolina Pellanda  Page 41 of 186 University of Basel, 2006 
Pharmacokinetic aspect 
Only few pharmacokinetic studies investigating multiple applications have been performed. 
Most of these studies draw their conclusions from data derived from drug concentration 
determination in plasma [222, 223] and urine [224, 225]. This means that percutaneous 
absorption and thus systemic, not topical bioavailability, is measured.  
Melendres et al. investigated the effect of application frequency on the percutaneous absorption 
of 14C-labeled hydrocortisone applied in acetone in human volunteers. The study compared a 
single low dose (1x13.3 µg/cm2) to a threefold higher dose, applied either as a single dose 
(1x40 µg/cm2) or as multiple doses (3x13.3 µg/cm2). Percutaneous absorption was assessed by 
measurement of the urinary excretion over 7 days. A 3-fold increase in dose was supposed to 
yield a 3-fold increase in absorption. This turned out to be correct for application of the single 
high dose (1x40 µg/cm2). Yet, the multiple application (3x13.3 µg/cm2) resulted in a 
percutaneous absorption much higher than expected (Fig. 5-3), as well as in higher drug 
amounts within the stratum corneum [225]. 
A similar trend was obtained after hydrocortisone application in a cream vehicle. The application 
of the single high dose (1x40 µg/cm2) resulted, as expected, in a percutaneous absorption 3 
times higher compared to the single low dose (1x13.3 µg/cm2). Again, the multiple application 
(3x13.3 µg/cm2) resulted in an unexpected higher percutaneous absorption (Fig. 5-3) [226].  
 
 
 
Fig. 5-3: Effect of application frequency on 
the percutaneous absorption of hydro-
cortisone applied on the forearm of human 
volunteers as an acetonic solution (data 
from [225]) and a cream (data from [226]. 
The percutaneous absorption was assessed 
as the total amount excreted in the urine 
over 7 days. 
Investigations on the percutaneous absorption of hydrocortisone [224], testosterone, and 
estradiol [227] in the rhesus monkey were not consistent with human in vivo studies performed 
with the same design. Therefore, in some cases, the extrapolation of results obtained from 
animal studies to estimate percutaneous penetration in humans may be inappropriate. 
The effect of application frequency on the in vivo penetration of TACA into stratum corneum 
was investigated in human volunteers in the experimental section, Project II: Effect of dose and 
application frequency. 
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5.4. Occlusion 
Pharmacodynamic aspect 
Occlusion is a simple method for enhancing the efficacy of topically applied drugs in clinical 
practice. The general effects of occlusion on the skin and on percutaneous absorption have 
already been described in chapter 2.4.4. An increased clinical efficacy of topical drugs under 
occlusion was first documented in 1960 by Garb with podophyllin (applied for the treatment of 
the naevus verrucosus) [228]. An enhanced efficacy of corticosteroids in the treatment of 
psoriasis was then observed for fluocinolone acetonide [229, 230] and hydrocortisone [231] 
applied under occlusion. The combination of topically applied calcipotriol plus occlusion for the 
treatment of psoriasis resulted as well in a significantly higher improvement of the lesion 
compared to calcipotriol or occlusion alone [232]. Interestingly, occlusion alone (without 
application of any topical formulation) also induced a significant improvement of psoriatic 
lesions which was comparable with the effect of fluocinolone acetonide [230]. 
The introduction of the McKenzie-Stoughton vasoconstriction test enabled the correlation of a 
pharmacodynamic endpoint (the vasoconstriction) with the efficacy of topical corticosteroids, 
and showed that the application of corticosteroids under occlusion clearly induced a higher 
vasoconstrictive response compared to non-occluded applications [153]. 
Pharmacokinetic aspect 
The percutaneous absorption of different steroids (hydrocortisone, estradiol, testosterone, 
progesterone) after application under occluded and non-occluded conditions was investigated 
by Bucks et al. [233, 234]. The percutaneous absorption was significantly increased by 24 h-
occlusion for estradiol, testosterone, and progesterone but not for hydrocortisone, the most 
hydrophilic steroid in this experiment. A linear trend of occlusion-induced absorption-
enhancement with increasing compound lipophilicity was observed except for progesterone (the 
most lipophilic compound in the array). Similar results were obtained after application of 
different phenols: occlusion significantly increased the percutaneous absorption of some (the 
more lipophilic) but not of all phenols. The least effect of occlusion was encountered with the 
more hydrophilic phenols [52]. Treffel et al. investigated in vitro the compound-specific effect of 
occlusion. Occlusion enhanced the percutaneous absorption of citropten (a lipophilic 
compound) by a factor of 1.6, whereas the absorption of caffeine (an amphiphilic compound) 
remained unaffected [73]. Thus, occlusion seems to have a higher effect on percutaneous 
penetration and absorption for lipophilic compounds and less for hydrophilic compounds. The 
hydration of the normally lipophilic stratum corneum during occlusion alters the partitioning of 
the applied compound between stratum corneum and the hydrophilic viable epidermis.  
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The absorption enhancement encountered during occlusion appears to be dependent not only 
on the compound but also on the vehicle and on the material of the occlusive device. Cross and 
Roberts observed a clear penetration enhancement of parabens after application in volatile 
solvents (acetone, ethanol) under occlusion, whereas the occlusive application of an ointment 
resulted in a retardation of penetration. Depending on the vehicle, occlusion had significantly 
different effects on both partitioning and epidermal diffusivity. Moreover, occlusion of the volatile 
vehicles prevented their evaporation, and the solvents may have loosened the barrier of the 
stratum corneum by extracting intercellular lipids [235]. The material of the occlusive device 
seems to play a decisive role as well, since different materials display different water vapor 
permeability (Table 5-6) [68, 236].  
Table 5-6: Water vapor permeability characteristics of different materials (data from [68]). 
Material Thickness 
[µm] 
Water-vapor permeability 
[g/m2h] 
Manufacturer 
polypropylene 15 0.9 ± 1.1  Tonen Chemical Co. 
polyester 12 1.9 ± 0.0  Tonen Chemical Co. 
nylon 25 12.0 ± 1.4  Unitika Ltd. 
nylon 15 16.6 ± 0.4  Tonen Chemical Co. 
polyurethane 80 24.9 ± 0.6  Toyo Kagaku Co. Ltd. 
polyurethane 25 30.7 ± 0.2  Toyo Kagaku Co. Ltd. 
polyurethane 60 32.1 ± 0.2  Toyo Kagaku Co. Ltd. 
microporous polyethylene 38 80.9 ± 8.0  Sekisui Chemical Co. Ltd 
polypropylene (non-woven) 18               145.6 ± 11.0  Tonen Chemical Co. 
 
As described in chapter 4, the formation, the extent, and the duration of a reservoir are highly 
favorized by application of the compound under occlusion [148]. After removal of the occlusive 
wrap, the hydration level of the stratum corneum rapidly returns to normal levels, and so does 
the facilitated partitioning between stratum corneum (hydrated by occlusion) and epidermis 
(hydrophilic). Thus, topically applied compounds remain temporarily trapped within the stratum 
corneum, forming a reservoir. In the case of TACA, Carr and Wieland observed an 
accumulation of a double amount of 14C-labeled triamcinolone acetonide within the stratum 
corneum after occlusion compared to non-occluded skin sites [152]. 
The effect of occlusion on the in vivo penetration of unlabeled TACA into human stratum 
corneum was investigated in the experimental section, Project III: Effect of occlusion. 
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6. Project I:           
Validation of the methodology and proof of concept 
 
Abstract 
The aim of the investigations described in this chapter was to develope and validate a method 
set for the in vivo quantification of TACA in human stratum corneum by means of: 1) tape 
stripping as sampling method, 2) UV/VIS-spectroscopy for the quantification of corneocytes, 
and 3) HPLC for the quantification of TACA.  
A standardized tape stripping protocol was developed and included the use of a template 
(ensures the removal of stratum corneum samples from the same skin site) and a hand roller 
(ensures a constant pressure on the tape before stripping), and, most importantly, the removal 
of the entire stratum corneum of one skin site to cope with inter- and intra-individual differences 
in stratum corneum thickness. The UV/VIS-spectroscopical method for quantification of the 
corneocytes had been previously validated and was adopted. The HPLC method for TACA 
quantification was developed and validated according to ICH Guidelines. The analytical 
challenge consisted in the development of a sensitive analytical method capable to quantify low 
amounts of TACA distributed on single tapes after extraction. The HPLC method was 
successfully validated and proved to have suitable specificity, linearity, accuracy, precision, and 
robustness in the working range. The LOQ of 0.1 µg/ml enabled the quantification of 27 ng/cm2 
TACA on single tapes.  
The method set was then applied in a proof of concept performed with 6 healthy volunteers. 
TACA (100 µg/cm2) was applied either as an acetonic solution or as an ethanolic gel. Stratum 
corneum samples were taken 0.5 h, 3h, and 24 h later by standardized tape stripping. Whereas 
the TACA penetration from the acetonic solution was high and TACA reached deeper layers of 
the stratum corneum, the TACA penetration from the ethanolic gel was only superficial, most 
TACA being retained within the cellulose matrix of the gel after evaporation of the solvent. The 
proof of concept proved the suitability of the methods to distinguish between different 
penetration patterns of TACA. 
 
Keywords 
HPLC 
Standardization 
Tape stripping 
Triamcinolone acetonide 
Validation 
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6.1. Introduction 
Specific and sensitive analytical methods for the quantitative evaluation of drugs are decisive for 
the successful execution of preclinical and clinical trials. To demonstrate the suitability of a 
bioanalytical method for the intended use and to ensure reliable and reproducible results, 
validation of the methodology is required [237, 238].  
Tape stripping is a sampling method which enables the removal of the stratum corneum layer 
by layer [93]. The amount of stratum corneum removed is influenced by several factors, e.g. the 
type of tape and the pressure applied on the tape before stripping [131], the topical formulation 
(vehicle effects) [93], and the skin site [6, 127, 239]. Thus, a standardized methodology and a 
critical evaluation of the results are essential. After stratum corneum sampling, the quantification 
of corneocytes and the quantification of drug adhering to the tapes are both required to assess 
the penetration of a drug into the stratum corneum.  
For the quantification of corneocytes, different methods have been described [240-243]. The 
time consuming gravimetric method has been the conventional method over years. However, 
the mass of corneocytes is usually overestimated because of additional weight caused either by 
exogenous and endogenous substances like excess of formulation, sebum, and sweat [134] or 
by interferences caused by electrostatic charge. In addition, this method has to be combined 
with measurements reflecting the disruption status of the stratum corneum barrier, e.g. by 
TEWL, and thus indirectly reflecting the stratum corneum thickness. Recently, TEWL 
measurements have been shown not to be sensitive enough for the measurement of small 
changes in stratum corneum thickness [244]. Moreover, an estimation of the stratum corneum 
density is required and usually arbitrarily set at 1 g/cm3 [131, 243]. Dreher et al. proposed a 
colorimetric assay (modified Lowry total protein assay) for quantification of the stratum corneum 
proteins extracted from the tapes, stained, and measured spectroscopically at 750 nm. The 
method was shown to be an accurate and reproducible alternative to the gravimetric method 
[240, 241]. Nevertheless, the quantification of the stratum corneum proteins directly on the 
tapes would be simpler and faster. Marttin et al. proposed a spectroscopic method based on the 
protein absorption at 278 nm. Unfortunately, this method turned out to be less reliable than the 
gravimetric method, since the light scattering effects caused by the corneocytes on the tape 
overshadowed the weak absorption of the proteins. Even an additional protein staining with 
Brilliant Blue did not improve the quantification [242]. 
Weigmann et al. proposed a novel method based on a spectroscopical measurement of the 
pseudo-absorption of corneocytes in the visible range. The pseudo-absorption was defined as 
the decrease in light transmission due to reflection, diffraction, and scattering by the 
corneocytes aggregates. The pseudo-absorption is nearly independent of the wavelength and 
was arbitrarily set at 430 nm, whereas all other components on the tapes usually absorb in the 
UV range [134]. The comparison of the novel spectroscopical method with established methods 
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has shown that UV/VIS-spectroscopy allows rapid, accurate, and reproducible quantification of 
corneocytes removed by tape stripping [245, 246].  
For the quantification of drugs, HPLC represents a simple and common analytical method 
which, nevertheless, requires validation to prove specificity, accuracy, precision, and robustness 
in the working range. The analytical challenge concerns the development of a method capable 
of quantifying low drug amounts distributed on several tapes without the necessity of pooling the 
tapes. 
The aim of the investigations described in this chapter is the validation of an HPLC method for 
the quantification of TACA, a moderately potent corticosteroid, on tape strips removed by tape 
stripping after topical application of a TACA formulation. The combination of: 1) the 
standardized tape stripping as sampling method, 2) the UV/VIS-spectroscopical method for 
quantification of corneocytes validated by Weigmann et al. [245], and 3) the new validated 
HPLC method for quantification of TACA, is then applied to a preliminary investigation (proof of 
concept). For this purpose, the TACA penetration into human stratum corneum was assessed in 
vivo after application of TACA in two different vehicles (acetonic solution, ethanolic gel). 
 
6.2. Materials and methods 
6.2.1. Material and formulations 
Micronized TACA Ph.Eur. was purchased from Caesar & Loretz GmbH, Hilden, Germany. 
Hydroxypropylcellulose GF Ph.Eur. (Klucel GF®) was obtained from Synopharm GmbH, 
Barsbüttel, Germany and acetone Ph.Eur. from Hänseler AG, Herisau, Switzerland. HPLC 
grade methanol was obtained from Scharlau Chemie S.A., Barcelona, Spain. Water was 
purified by reverse osmosis (Osmostil LN 4/2 PH - Spetron 500 PH, Christ Aqua Ecolife AG, 
Aesch, Switzerland).  
Because of the low solubility of TACA in methanol 60% (v/v), a stock solution of 2 mg/ml TACA 
in methanol 100% was prepared. TACA solutions of different concentrations were then diluted 
from the stock solution with methanol 60% (v/v).  
For topical application, two TACA formulations were prepared: an acetonic solution (TACA 
2 mg/ml) and an ethanolic gel consisting of 1% TACA, 4% hydroxypropylcellulose GF, and 95% 
ethanol 96% (v/v) (modified formulation from the “Neues Rezeptur-Formularium NRF”) [247]. 
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6.2.2. Validation of the HPLC method 
Chromatographic conditions  
TACA was quantified by HPLC using a Waters Alliance HPLC System (2690 Separation 
Module, 996 Photodiode Array Detector, Millenium32 Software), all Waters Corporation, Millford, 
Massachusetts, USA. An overview of the chromatographic conditions is given in Table 6-1.  
Table 6-1: Chromatographic conditions of the HPLC method for TACA quantification. 
Parameter Setting 
Column Symmetry ShieldTM RP18, 2.1 x 100 mm, 3.5 µm particle size 
Mobile phase methanol; water (60%;40%) (v/v)  
Flow rate 0.3 ml/min 
Running time 7 min 
Temperature 35°C (column); 20°C (samples) 
Injection volume 20 µl 
DAD spectrum 210-300 nm 
TACA quantification wavelength 240 nm 
 
Validation  
The validation of the HPLC method was performed according to the guidance of the 
“International Conference on the Harmonization of Technical Requirements for the Registration 
of Pharmaceuticals for Human Use” (ICH) [237]. Specificity, limit of detection and quantification, 
linearity and range, accuracy, precision (repeatability and intermediate precision), and 
robustness were assessed. The method of assessment of each validation parameter is 
presented together with the definition, results, and discussion in chapter 6.3. 
The MVA software (Method Validation in Analytics, Novia GmbH, Saarbrücken, Germany), 
specifically designed for the calculation of validation data and based on the ICH-guidelines, was 
used to conduct the statistical tests.  
Tape spiking and tape extraction 
Tape spiking was performed to determine specificity and accuracy. A solution volume of 50 µl 
was applied with a Hamilton Syringe (250 µL, 22/2’’/2, Supelco, Buchs, Switzerland) on the 
adhesive side of tape strips (approximate length of 3 cm). After evaporation of the solvent, each 
tape was individually placed in a scintillation vial (20 ml, glass, metal-foil sealing, polypropylene 
lock, VWR International AG, Dietikon, Switzerland) and extracted with 1.5 ml 60% methanol 
during 30 min on a horizontal shaker at 140 rpm (Heidolph Unimax 2010, Heidolph, Germany). 
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6.2.3. Proof of concept 
Application of the formulations 
The experiments were conducted on the volar aspect of the forearm of 6 healthy Caucasian 
volunteers of skin phototype II-III (4 female and 2 male, aged 22-38 years). The volunteers were 
divided into 2 groups (Table 6-2), and 3 skin sites per volunteer were treated with 100 µg/cm2 
TACA delivered either from an acetonic solution (group 1) or from an ethanolic gel (group 2). 
For the acetonic solution, a skin area of 10.5 cm2 was delineated by a rectangular glass frame 
glued onto the skin (Sauer® skin glue, Manfred Sauer GmbH. Lobbach, Germany). A volume of 
500 µl formulation was uniformly applied with a Hamilton® Syringe (Supelco, Buchs, 
Switzerland), and the solvent was allowed to evaporate. For the ethanolic gel, the application 
area was delineated by an adhesive template (HAWE® adhesive film, HAWE, Hugentobler AG, 
Bern, Switzerland) displaying a rectangular aperture of 10.5 cm2. A mass of 100 mg gel was 
applied with a Gilson Microman pipette (Gilson AG, Mettmenstetten, Switzerland) and 
homogeneously distributed with a glass rod. No skin washing was performed to remove excess 
of formulation. 
Table 6-2: Overview of application and tape stripping procedure during the proof of concept experiments. The 
two TACA formulations (acetonic solution, ethanolic gel) were applied on 3 sites per arm (time 0 h, at 9 a.m.). 
Tape stripping followed at 3 different times (0.5 h, 3 h, 24 h). D = Dosing, T = Tape Stripping. 
  0 h 0.5 h 3 h 24 h 
      Acetonic solution group (n=3)     
Site 1 TACA 100 µg/cm2 D T   
Site 2 TACA 100 µg/cm2 D  T  
 
Site 3 TACA 100 µg/cm2 D   T 
Ethanolic gel group (n=3)     
Site 1 TACA 100 µg/cm2 D T   
Site 2 TACA 100 µg/cm2 D  T  
 
Site 3 TACA 100 µg/cm2 D   T 
      
  9 a.m. 9.30 a.m. 12 a.m. 9 a.m. 
Skin sampling by tape stripping 
Stratum corneum removal occurred by tape stripping at 0.5 h, 3 h, and 24 h after application 
(Table 6-2). In order to remove the skin in a standardized way from the same skin area, a 
laminated paper template (protective film of HAWE® adhesive film, HAWE, Hugentobler AG, 
Bern, Switzerland) delineating a constant aperture of 3.3 x 1.7 cm (5.6 cm2) was fixed onto the 
application area with adhesive tape. Tape stripping was carried out with Tesa tape (Tesa Multi-
Film Crystal-Clear No. 57315, 19 mm width, Tesa, Beiersdorf, Hamburg, Germany). A hand 
roller supplying a pressure of 140 g/cm2 was uniformly passed over the tapes 10 times for each 
stripping. Each tape was removed with a rapid, firm movement, and then fixed across a 
photographic slide frame, the adhering corneocytes being exposed through the frame aperture. 
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This procedure was repeated with new tapes, alternating the direction of tape removal (elbow-
to-wrist, wrist-to-elbow). 
The endpoint of tape stripping (total stratum corneum removal) was determined by UV/VIS-
spectroscopy. When the amount of corneocytes adhering to the stripped tapes started to 
decrease macroscopically, the tapes were periodically measured as described below. As soon 
as transmission values ≥ 95% (calculated from the absorbance values and defined as complete 
removal of the stratum corneum) were attained, tape stripping was stopped. 
Quantification of corneocytes by UV/VIS-spectroscopy 
The amount of corneocytes adhering to each tape was quantified by measuring the pseudo-
absorbance of the corneocytes at 430 nm as described in Weigmann et al. [245]. Each tape 
was directly measured against a blank tape in a Lambda 35 spectrophotometer (Perkin Elmer, 
Überlingen, Germany), custom-modified to obtain a rectangular light beam of 1 cm2. Blank 
tapes were sequentially sampled from the stock roll of Tesa tape after every fifth stripping, 
allowing a continuous correction for any irregularities in the optical properties of the tape from 
the start to the end of the roll. A solid-sample holder allowed a direct positioning of the 
photographic slide frame into the spectrophotometer. Continuous spectra of each tape were 
recorded between 400-500 nm, and absorbance values at 430 nm were extracted for 
quantification of the corneocytes.  
Quantification of TACA by HPLC 
After quantification of the corneocytes, each tape was individually extracted with 1.5 ml 60% 
methanol during 30 min on a horizontal shaker at 140 rpm (Heidolph Unimax 2010, Heidolph, 
Germany). TACA concentrations in the extract were quantified by the validated HPLC method 
described in chapter 6.2.2.  
Data analysis 
Qualitative TACA penetration into stratum corneum: penetration profiles 
To localize the drug within the stratum corneum, TACA concentrations quantified on each tape 
were correlated to the tape number and to the depth of penetration into stratum corneum. 
Removal of the entire stratum corneum is a prerequisite for the profile calculation, as the total 
sum of corneocytes-(pseudo-)absorbance on one skin site (cumulative absorbance) represents 
100% stratum corneum thickness. Thus, the relative amount of stratum corneum removed by 
each tape could be calculated from the individual corneocyte absorbance values as depicted in 
Fig. 6-1 [126]. To depict the penetration profiles, a Macro was programmed in Microsoft® Excel. 
Mean and standard deviation of the number of tapes required to remove the entire stratum 
corneum were calculated. 
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Fig. 6-1: Calculation of the penetration 
profiles. The pseudo-absorbance of the 
corneocytes on each tape is summed up to 
the cumulative absorbance values. The total 
cumulated absorbance (3.57 in this example) 
corresponds to 100% stratum corneum. From 
this value, the relative stratum corneum 
thickness can be deducted. After Jacobi et 
al. [126]. 
 
Quantitative TACA penetration into stratum corneum 
The TACA amount on each tape of one skin site was added up to obtain the total TACA amount 
penetrated into stratum corneum. The total TACA amounts were then evaluated statistically. 
The difference between the treatment groups at each stripping time was tested in a 2-sided t-
test (α = 0.05). Two different types of evaluation were performed: the evaluation of a) the total 
TACA amount penetrated into the stratum corneum (sum of TACA amounts on all tapes), and b) 
the TACA amount without tapes 1-3 (on which formulation excess, e.g. TACA crystals and a 
thin gel film, could be located). Statgraphics PLUS 5 software (Manugistic, Inc., Rockville, 
Maryland, USA) was used to conduct the statistical analysis. 
 
Raster-electron-microscopic (REM) recording 
Selected stripped tapes with adhering corneocytes and drug were observed with a Philips XL 30 
ESEM scanning electron microscope. Sample preparation included fixation on a metal cylinder 
with a carbon adhesive tape and sputtering with gold (20 nm). 
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6.3. Validation of the HPLC method 
6.3.1. Specificity  
Definition 
Specificity is the ability to unequivocally assess the analyte in the presence of components 
which may be expected to be present. Typically, this might include impurities, degradants, and 
matrix [237].  
Method 
To determine the retention time of TACA, a methanolic TACA solution (0.5 µg/ml) was assayed 
by HPLC (n = 3). Then, all the components which could possibly interact with the TACA peak, 
namely solvents (methanol 60%, acetone), tape matrix (e.g., polymer, adhesive), and stratum 
corneum constituents were individually assayed (each n = 3). The solvents were directly 
injected into the HPLC system. To obtain tape matrix samples, tape strips (n=3) were extracted 
by the standard extraction procedure described in chapter 6.2.2. To obtain stratum corneum 
constituents samples, tape strips (n=3) were placed on and peeled off the forearm skin of a 
healthy volunteer and were then extracted. The relative retention times were determined, and 
the chromatograms were visually searched for peak overlay of any component with the TACA 
peak. 
In addition, tape strips of about 3 cm length were spiked with TACA solution following the 
standard spiking procedure described in chapter 6.2.2. A low (15 µg/ml) and a high (450 µg/ml) 
concentrated methanolic TACA solution was used as spiking solution (n=3 for each 
concentration). The spiking procedure was repeated with tape strips previously peeled off the 
forearm skin of a healthy volunteer (n=3 for each concentration). After evaporation of the 
solvent, the tapes were extracted, and the extracts were assayed by HPLC. 
Results and discussion 
Fig. 6-2 displays the chromatograms of methanol 60%, TACA solution (0.5 µg/ml), tape extract, 
and the extract of a spiked tape. The relative retention time (Rt) of TACA was 2.9 min, with the 
absorption maximum at 243.8 nm. The following additional peaks were recorded: methanol at 
2.0 min and tape matrix at 1.0 min, 4.8 min, and 5.4 min. The relative Rt of acetone was 1.3 min 
and did not interfere with the TACA peak. Acetone is not expected to be present in the extracts, 
as it evaporates completely after application. The extract of tapes with and without adhering 
corneocytes resulted in identical chromatograms, indicating that stratum corneum constituents 
are not interfering in this wavelength range. No interference between the TACA peak and any 
other peak could be observed, assuring the specificity of the method for TACA. 
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Fig. 6-2: Chromatograms for specificity evaluation: A) Methanol 60% (Rt 2.0 min), B) TACA solution 0.5 µg/ml 
(TACA Rt 2.9 min), C) Tape extract (tape matrix Rt 1.0 min, 4.8 min, 5.4 min), D) extract of a tape with 
corneocytes spiked with TACA solution (15 µg/ml). 
6.3.2. Limit of detection (LOD) and Limit of quantification (LOQ) 
Definitions 
The limit of detection (LOD) of an analytical procedure is the lowest amount of analyte in a 
sample which can be detected but not necessarily quantitated as an exact value. The limit of 
quantification (LOQ) of an analytical procedure is the lowest amount of analyte in a sample 
which can be quantitatively determined with suitable precision and accuracy [237]. 
Method  
LOD and LOQ were assessed by calculating the signal-to-noise ratios from the chromatograms. 
The signal is defined as the height of the peak of interest (in this case the TACA peak), and the 
noise as the height of the baseline. The LOD was determined by diluting TACA solutions until a 
signal-to-noise ratio of ≥ 3-to-1 was obtained (n = 6), the LOQ until the signal-to-noise ratio was 
≥ 10-to-1 (n = 6). The deviation of the LOQ signals should not exceed 20%, as described in 
chapter 6.3.3, Linearity and Range [238]. 
Results and discussion 
The following signal-to-noise ratios were achieved for different TACA solutions: 2.8±0.2 to 1 for 
a TACA concentration of 0.030 µg/ml (n=3), 4.2±0.7 to 1 for 0.035 µg/ml (n=6), 5.2±0.4 to 1 for 
0.040 µg/ml (n=3), and 11.1±0.7 to 1 for a TACA concentration of 0.1 µg/ml (n=6). Therefore, 
the LOD was set at 0.035 µg/ml (corresponding to a TACA amount of 9 ng/cm2 on the tape) and 
the LOQ at 0.1 µg/ml (corresponding to 27 ng/cm2). The deviation of the LOQ signals calculated 
with the linear weighted model was < 4%, thus not exceeding the maximal allowed value of 20% 
(compare chapter 6.3.3). The accuracy (chapter 6.3.4) and precision (chapter 6.3.5) achieved at 
LOQ were considered suitable. 
A) Methanol 60% B) TACA solution C) Tape extract D) Extract of tape with skin  
spiked with TACA solution 
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6.3.3. Linearity and Range 
Definitions 
The linearity of an analytical procedure is its ability, within a given range, to obtain test results 
which are directly proportional to the concentration or the amount of an analyte in the sample. 
The range of an analytical procedure is the interval between the upper and lower concentration 
or amount of analyte in the sample, including those concentrations for which it has been 
demonstrated that the analytical procedure has a suitable level of precision, accuracy, and 
linearity [237]. 
Method 
Standard TACA solutions of following concentrations were prepared: 20.0 µg/ml, 15.0 µg/ml, 
10.0 µg/ml, 5.0 µg/ml, 1.0 µg/ml, 0.5 µg/ml, and 0.1 µg/ml. Each standard solution was assayed 
5 times by HPLC. The measured signals (peak area) were plotted as a function of analyte 
concentration. The procedure was repeated on 3 different days with new standard solutions, 
yielding a total of 3 calibration curves.  
To determine the model best describing the obtained calibration curves, the function of the 3 
curves was calculated with following regression models: a) the linear unweighted model, b) the 
linear weighted model (weighting factor 1/x, where x = concentration), and c) the nonlinear 
(quadratic) model. The function, the correlation coefficient, the standard error of the slope (sx0), 
the residual sum of square (SS), the residual standard deviation (SD), and the residual variance 
were calculated for each model [248].  
Variance-homogeneity of the signals over the whole working range is a prerequisite for linear 
regression [249] and was tested in a Cochran test using peak-area data. If the signal variances 
displayed homogeneity, the residual variance of the linear regression models (both unweighted 
and weighted) could be tested against the non-linear model in a Mandel test [248, 250]. The 
best suitable model was chosen for TACA quantification. In addition, an analysis of the 
residuals was performed separately for each concentration level, with a maximal accepted 
deviation of 20% for the lowest concentration (LOQ) and 15% for the other concentrations [238]. 
Results and discussion 
The key data of the 3 curves calculated with the different regression models are listed in Table 
6-3. The correlation coefficient was good in all the models, but the evaluation of the simple 
correlation coefficient is a poor measure of the curve-fit quality of the data. The standard error of 
the slope (sx0), representing the standard deviation of the procedure, displayed lower values 
with the linear unweighted model compared to the linear weighted model. However, the lowest 
residual variance was achieved with the linear weighted model.  
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Table 6-3: Key data of the calibration curves calculated with the linear unweighted, linear weighted (weighting 
factor 1/x, x = concentration), and nonlinear regression models. R = correlation coefficient, SD = standard 
deviation, SE = standard error, SS = sum of squares, ND = not determinable. 
  Residual Calibration curve   Function  R2 
 
SE of slope 
(sx0) 
 SS Variance 
1   y = -731 + 35840 x  1.00000  0.20%  1.4 E+06 2.7 E+05 
2   y = -941 + 35780 x  0.99999  0.34%  4.0 E+06 7.9 E+05 
Linear 
unweighted  
3   y = -1154 + 35510 x  0.99999  0.31%  3.3 E+06 6.7 E+05 
1   y = -545 + 35815 x  0.99997  0.94%  1.6 E+05 3.1 E+04 
2   y = -509 + 35718 x  0.99998  1.56%  4.2 E+05 8.4 E+04 
Linear 
weighted 
 
 
3   y = -660 + 35440 x  0.99997  1.88%  6.0 E+05 1.2 E+05 
1   y = -704 + 35820 x + 0.9 x2  1.00000  ND  1.3 E+06 3.4 E+05 
2   y = -477 + 35500 x + 1.5 x2  1.00000  ND  1.8 E+06 4.4 E+05 Non-linear  
3   y = -998 + 35410 x + 5.0 x2  0.99999  ND  3.1 E+06 7.7 E+05 
According to the Cochran test, the variances were distributed homogeneously (test value 
0.47 < critical value 0.75). Thus, the Mandel test could be performed, and the comparison of the 
linear models (unweighted/weighted) with the non-linear model resulted in a best fit achieved by 
the linear regression models. 
To choose the best model between the linear unweighted and the linear weighted model, a 
residual analysis was performed for each concentration level of the curve. The values are 
summarized in Table 6-4. The residues displayed a normal distribution in all the models and 
randomly scattered around the zero line. The lowest concentration level (0.1 µg/m = LOQ) 
showed the highest residues with maximal values of 25% (linear unweighted model), 18% (non-
linear model), and 4% (linear weighted model). The residues of the other concentration levels 
displayed maximal values of 1.2% (linear weighted model), 1.0% (linear unweighted model), 
and 0.8% (non-linear model).  
Table 6-4: Mean percentage residual variance of the different concentration levels calculated with the linear 
unweighted, the linear weighted, and the non-linear model. The percentage residual variance is the percentage 
difference between experimental and calculated values divided by the calculated value. 
Calibration curve 
 0.1µg/ml 0.5µg/ml 1.0µg/ml 5.0µg/ml 10.0µg/ml 15.0µg/ml 20.0µg/ml 
1  7.9 0.8 -0.7 0.0 -0.2 0.2 -0.0 
2  20 0.8 -0.2 0.2 -0.5 -0.0 0.1 
Linear 
unweighted 
3  25 1.0 0.2 -0.9 0.2 -0.0 0.0 
1  1.5 -0.2 -1.2 -0.0 -0.2 0.2 0.0 
2  3.2 -1.5 -1.3 0.1 -0.4 0.1 0.2 
Linear 
weighted 
3  3.9 -1.8 -1.0 -1.0 0.3 0.1 0.1 
1  7.0 0.7 -0.8 0.0 -0.2 0.2 -0.0 
2  2.9 -1.1 -0.8 0.5 -0.2 0.1 0.0 Non-linear 
3  18 0.3 0.0 -0.8 0.3 -0.0 -0.0 
According to the Mandel test and the residual analysis, the best results were achieved with the 
linear weighted regression model (curves displayed in the appendix, Fig. 11-1), which was 
chosen for data processing. The weighting of the calibration with the reciprocal of concentration 
(1/x) enables the curve adjustment to the lower concentration levels. The range for TACA 
quantification was set at 0.1-20.0 µg/ml. 
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6.3.4. Accuracy by recovery 
Definitions 
The accuracy of an analytical procedure expresses the closeness of agreement between the 
value which is accepted either as a conventional true value or an accepted reference value, and 
the experimental value [237]. 
Methods 
The accuracy was evaluated in terms of recovery. For this purpose, tapes with adhering 
corneocytes were spiked with known amounts of TACA, extracted and assayed by HPLC. The 
measured TACA amount was then compared to the effective spiked TACA amount. To obtain 
tapes with adhering corneocytes, a skin area of 5.6 cm2 on the forearm of a healthy volunteer 
was delineated by a template. A total of 18 tapes was subsequently applied and removed from 
this skin area. The tapes were then divided into 3 groups of 6 tapes each and spiked with 50 µl 
of the following methanolic TACA solutions: tape 1-6 with 450 µg/ml (corresponding to a high 
concentration level of 15 µg/ml on the calibration curve), tape 7-12 with 150 µg/ml (middle 
concentration level of 5 µg/ml) and tapes 13-18 with 15 µg/ml (low concentration level of 
0.5 µg/ml). After evaporation of the solvent, each tape was extracted by the standard extraction 
procedure described in chapter 6.2.2. The extracts were assayed by HPLC and the data 
processed with the linear weighted (1/x) regression model to obtain recovery values. An 
accurate method should achieve recoveries of 80-120% [238]. 
Results and discussion 
All the recovery values are displayed in the appendix (Table 11-1). The recovery was very good 
in the higher and middle calibration range (15 µg/ml and 5 µg/ml) with mean recovery values of 
97 ± 2% (ranging from 94% to 99%) and 94 ± 2% (from 91% to 96%), respectively. In the lower 
calibration range (0.5 µg/ml), the mean recovery displayed values of 87 ± 4% (from 82% to 
92%). The overall experimental recovery ranged from 82% to 99%, thus fulfilling the 
requirements for accuracy (80-120%).  
6. Project I: Validation of the methodology and proof of concept 
Carolina Pellanda  Page 59 of 186 University of Basel, 2006 
6.3.5. Precision 
Definitions 
The precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogenous sample under the prescribed conditions. Precision may be considered at 3 levels: 
repeatability, intermediate precision, and reproducibility. Repeatability expresses the precision 
under the same operating conditions over a short interval of time (intra-assay precision). 
Intermediate precision expresses within-laboratories variations (e.g., different days, different 
analysts, or different equipment). Reproducibility expresses the precision between laboratories. 
The precision of an analytical procedure is usually expressed as the variance, standard 
deviation and relative standard deviation (coefficient of variation) of a series of measurements. 
A minimum of 3 concentration levels and 3 replicates each are required to assess repeatability 
[237]. 
Methods 
Repeatability was evaluated together with linearity, using the same data measured for the 
calculation of the 3 calibration curves. Absolute and relative standard deviations of the peak 
area were calculated for each concentration level of the calibration curve (n = 5 for each 
concentration level). A relative standard deviation of ≤ 15% was required except for LOQ, for 
which a relative standard deviation of ≤ 20% was accepted [238].  
Repeatability and intermediate precision were calculated using the normalized peak areas 
(peak area divided by the respective concentration value) in the range with and without LOQ. 
The homogeneity of variance was tested in a Cochran test, and a variance analysis (ANOVA) 
was performed.  
Repeatability was defined as:  
100
x
2
rrCV s
⋅=
 (Equation 6) 
sr
2
 
being the intra-serial variance and x  being the overall mean. 
Intermediate precision was defined as: 
 
(Equation 7) 
 
sR
2 being the overall variance (sum of intra- and inter-serial variances). 
Reproducibility was not assessed, since the method was designed for use within the same 
laboratory on the same HPLC apparatus. 
100
x
2
RRCV s
⋅=
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Results and discussion 
The peak area data for the different concentration levels are displayed in Table 6-5 (the 
complete data set is listed in the appendix, Table 11-2). The relative standard deviation of all 
the values excluding LOQ was ≤ 2% (≤ 15% required). At LOQ, a higher relative standard 
deviation (≤ 10%) was measured (≤ 20% required). Thus, repeatability was defined as good in 
the range of 0.1-20 µg/ml. 
Table 6-5: Overview of the mean peak area, standard deviation (SD), and relative standard deviation (RSD) of 
the concentration levels for 3 different calibration curves (n=5 for each concentration level). 
Calibration curve  0.1µg/ml 0.5µg/ml 1.0µg/ml 5.0µg/ml 10.0µg/ml 15.0µg/ml 20.0µg/ml 
No. 1 mean 3078 17328 34855 178501 356972 537682 715799 
 SD 300 351 450 327 1205 857 812 
  
RSD 9.7 2.0 1.3 0.2 0.3 0.2 0.1 
No. 2 mean 3160 17086 34769 178324 355164 535626 715462 
 SD 126 208 194 736 944 620 1280 
  RSD 4.0 1.2 0.6 0.4 0.3 0.1 0.2 
No. 3 mean 2998 16758 34420 174852 354667 531264 709124 
 SD 148 169 177 628 619 774 1080 
  RSD 4.9 1.0 0.5 0.4 0.2 0.1 0.2 
Overall  mean 3079 17057 34681 177226 355601 534857 713462 
 SD 203 338 339 1822 1353 2857 3330 
  RSD 6.6 2.0 1.0 1.0 0.4 0.5 0.5 
The mean values of the normalized peak areas are displayed in Table 6-6 for both the whole 
range and the range without LOQ. According to the Cochran test, the variances were 
homogenous. Repeatability (intra-serial precision) and intermediate precision (overall precision) 
calculated by ANOVA gave good precision values (1.88% and 1.89%, respectively) within the 
range excluding LOQ. If LOQ was included in the calculation, a value of 5.15% was obtained for 
both precision types, indicating that precision at LOQ was not optimal, but acceptable.  
Table 6-6:  Mean values and variance of the normalized peak areas (peak areas divided by the correspondent 
concentration) of 3 different calibration curves (whole range except LOQ). 
  Range 0.5-20 µg/ml  Range 0.1-20 µg/ml 
Normalized peak area 
 
             Mean   Variance               Mean   Variance 
Series 1  3.54 E+04  2.75 E+05  3.48 E+04  3.31 E+06 
Series 2  3.52 E+04  4.24 E+05  3.47 E+04  2.27 E+06 
Series 3  3.48 E+04  6.09 E+05  3.42 E+04  3.93 E+06 
Overall  3.51 E+04  4.43 E+05  3.46 E+04  3.17 E+06 
Cochran Test 
   
Test value 0.47  0.41 
Critical value 0.71  0.68 
                                               The variances are homogenous (test value < critical value) 
ANOVA 
   
Intra-serial variance 4.36 E+05  3.17 E+06 
Inter-serial variance 7.47 E+03  -3.42 E+05 
Overall mean x  3.51 E+04  3.46 E+04 
Overall variance 4.43 E+05  3.17 E+06 
                                            No significant difference of the means 
Repeatability CVr                  1.88%  5.15% 
Intermediate Precision CVR                  1.89%  5.15% 
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6.3.6. Robustness 
Definitions 
The robustness of an analytical procedure is a measure of its capacity to remain unaffected by 
small, but deliberate variations in method parameters, and provides an indication of its reliability 
during normal usage [237]. 
Method 
To evaluate method robustness, several method parameters were varied: ± 5% methanol in the 
mobile phase (methanol 55%, methanol 65%), ± 5% variation of the flow rate (0.285 ml/min, 
0.315 ml/min), ± 5°C variation of the column temper ature (30°C, 40°C) and ± 2 nm variation of 
the detection wavelength (238 nm, 242 nm). The extraction solutions used for accuracy 
evaluation were measured under these modified conditions (n = 6 per concentration). Recovery 
values of 80%-120% were aimed at [238]. 
Results and discussion 
The variation of chromatographic and analytical conditions resulted in an overall mean recovery 
(± SD) of: 96.0 ± 1.2% in the higher concentration range of the calibration curve (15 µg/ml), 
93.0 ± 2.2% in the middle concentration range (5 µg/ml), and 81.9 ± 9.7% in the lower 
concentration range (0.5 µg/ml). The mean recoveries obtained after variation of the different 
method parameters are depicted in Fig. 6-3. In particular, the variation in the mobile phase 
composition (methanol 65%) resulted in recoveries below 80% (70.2% to 82.2%) in the lower 
concentration range. Except for these unsatisfactory values, the recovery for all other 
parameters in the low range was 81-87%. 
The robustness of the method was good in the mid and high concentration range but limited in 
the lower concentration range. The results were considered acceptable provided that the 
composition of the mobile phase is periodically checked. 
 
 
 
 
 
 
 
 
 
Fig. 6-3: Assessment of method robustness by variation of different chromatographic and analytical 
parameters such as mobile phase, flow rate, detection wavelength, and column temperature. 
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6.3.7. Overview of the validation 
The HPLC method was successfully validated and proved to have suitable specificity, accuracy, 
precision, and robustness in the linear range of 0.1-20 µg/ml. The calibration curves were 
calculated with the linear weighted regression model, weighting factor 1/x (where 
x = concentration). The LOQ of 0.1 µg/ml enabled the quantification of corresponding 
concentrations of 27 ng/cm2 TACA on each stripped tape, whereas the LOD of 0.035 µg/ml 
enabled the detection of 9 ng/cm2 TACA. The validation results are summarized in Table 6-7. 
Table 6-7: Overview of the validation parameters.  
Specificity n=3 (per component) Rt (TACA) 2.9 min, no peak overlay 
LOD n=6 35 ng/ml (corresponding to 9 ng/cm2) 
LOQ n=6 100 ng/ml (corresponding to 27 ng/cm2) 
Linearity 
3 calibration curves 
7 conc. levels 
n = 5 (per concentration) 
y = -573 + 35660 x 
R2 = 0.99997 
linear weighted (1/x, x = concentration) 
Range n=5 (per concentration) 0.1-20 µg/ml 
Accuracy by recovery n=6 (per concentration) 
Overall: 
0.5 µg/ml: 
5.0 µg/ml: 
15.0 µg/ml: 
93% ± 5% 
87% ± 4% 
94% ± 2% 
97% ± 2% 
Repeatability n=5 (per concentration) 1.9% without LOQ (range 0.5-20 µg/ml) 5.1% with LOQ (range 0.1-20 µg/ml)  
Intermediate precision n=5 (per concentration) 1.9% without LOQ (range 0.5-20 µg/ml) 5.1% with LOQ (range 0.1-20 µg/ml) 
Robustness n=6 (per concentration) 
8 different conditions 
0.5 µg/ml: 
5.0 µg/ml: 
15.0 µg/ml: 
81.9 ± 9.7% 
93.0 ± 2.2% 
96.0 ± 1.2% 
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6.4. Proof of concept 
6.4.1. Qualitative TACA penetration into stratum corneum: penetration profiles  
Typical profiles of TACA penetration into stratum corneum over time are depicted in Fig. 6-4 
(the entire set of profiles is displayed in the appendix, chapter 11.1.2). A clear vehicle effect can 
be observed: after application of the acetonic solution, TACA quickly penetrated and permeated 
the stratum corneum, reaching deeper skin layers. In contrast, the ethanolic gel formed a 
superficial film in which considerable TACA amounts remained trapped. This film was removed 
with the first stripped tape. 
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Fig. 6-4: Penetration profiles of TACA (100 µg/cm2) into stratum corneum at 0.5 h, 3 h, and 24 h after application 
of the two different formulations acetonic solution (dark grey) and ethanolic gel (light grey). Note that the TACA 
concentration scale of the acetonic solution and ethanolic gel profiles differs by a factor of 10.  
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The mean tape number required to remove the entire stratum corneum was 56 ± 17 after 
application of the acetonic solution and 40 ± 5 after application of the alcoholic gel (Table 6-8). 
The intra-individual variability in the number of tapes used to remove the stratum corneum was 
low, but inter-individual differences were high. This is not unusual and has to be taken into 
account when drug penetration into stratum corneum is investigated. 
Table 6-8: Number of tapes required to remove the entire stratum corneum of each skin site treated either with 
the acetonic solution or the ethanolic gel (TS = Tape Stripping; SD = Standard Deviation) 
 Skin Site 1 
(TS 0.5h) 
Skin Site 2 
(TS 3h) 
Skin Site 3 
(TS 24h) 
 Mean SD 
Acetonic solution group 
      
Volunteer 1  56 53 64  58 6 
Volunteer 2  82 70 69  74 7 
Volunteer 3  38 34 35  36 2 
Overall acetonic solution group   56 17 
Ethanolic gel group 
      
Volunteer 4  40 40 50  43 6 
Volunteer 5  40 37 42  40 3 
Volunteer 6  35 35 40  37 3 
Overall ethanolic gel group   40 5 
Overall (solution and gel group) 
     
Mean  49 45 50  48 4 
SD  18 14 14  15 2 
 
6.4.2. Quantitative TACA penetration into stratum corneum 
A high amount of TACA was always recovered on the first stripped tapes, which also removed a 
large amount of corneocytes. On the skin surface not only corneocytes but also TACA crystals 
(in case of the acetonic solution) and a thin gel film (in case of the ethanolic gel) could be 
discerned.  
The TACA amounts penetrated into stratum corneum after application of the two different 
formulations are displayed in Fig. 6-5, and the individual data are listed in the appendix (Table 
11-3). If all tapes were considered, a significantly higher TACA amount was recovered within 
the stratum corneum after application of the ethanolic gel compared to the acetonic solution 
(94 µg/cm2 vs. 24 µg/cm2 at 0.5 h; p < 0.01). Over time, the amount recovered within the 
stratum corneum decreased with both formulations. At 3 h, mean TACA amounts of 84 µg/cm2 
vs. 13 µg/cm2 (p < 0.01) were recovered after application of the ethanolic gel and the acetonic 
solution, and at 24 h still 7 µg/cm2 vs. 0.8 µg/cm2 (p > 0.05). 
By excluding tapes 1-3, a statistically higher TACA amount was observed at 0.5 h after 
application of the acetonic solution (13 µg/cm2 vs. 4 µg/cm2; p < 0.01). This inversion of the 
results, i.e. higher penetration with the ethanolic gel (if all tapes were considered) vs. higher 
penetration with the acetonic solution (if tapes 1-3 were discarded), shows that a high TACA 
amount remained on tapes 1-3. Especially after application of the ethanolic gel, a high TACA 
amount remained bound to the gel matrix on the skin surface. Thus, the gel can be regarded as 
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a slow release formulation with a superficial drug reservoir. At 3 h, the penetrated TACA amount 
after application of the acetonic solution decreased, whereas the amount was unchanged after 
application of the ethanolic gel (6 µg/cm2 vs. 4 µg/cm2; p > 0.05). At 24 h, TACA amounts of 
0.5 µg/cm2 vs. 1.6 µg/cm2 (p > 0.05) were measured after application of the acetonic solution 
and the ethanolic gel. 
 
 
 
 
 
 
 
 
 
 
Fig. 6-5: TACA amounts penetrated into stratum corneum including all tapes (left diagram) and excluding tapes 
1-3 (right diagram). Mean and standard deviation are displayed. The double asterisk (**) denotes a highly 
significant difference (p < 0.01, 2-sided t-test) between the formulations at the specified stripping time. 
 
6.4.3. Raster-electron-microscopic (REM) recording 
Tape stripping does not remove single, homogeneous layers of stratum corneum but rather skin 
frazzles. This is shown in Fig. 6-6 (A). The use of a hand roller to stretch the skin before 
stripping the tape from the skin also allowed removal of the stratum corneum of furrows 
(Fig. 6-6 B). Single, flat corneocytes can easily be discerned at higher magnifications, as well as 
their overlapping (“imbricated”) arrangement (Fig. 6-6 C, D). TACA crystals precipitated on the 
skin surface after application of the acetonic solution could be observed on some tapes (Fig. 6-6 
E, F). 
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STRATUM CORNEUM ON THE TAPE 
  
CORNEOCYTES  
  
TACA CRYSTALS  
  
Fig. 6-6: Raster-electron-microscopic view of stratum corneum, corneocytes, and TACA crystals adhering to 
tapes removed from the skin by stripping. Tape stripping does not remove single layers of stratum corneum, 
but rather skin frazzles (A). Furrows can easily be discerned (B), as well as imbricatedly arranged corneocytes 
(C, D). TACA crystals could sometimes be observed on the first stripped tapes (E, F). 
Tape 1 Tape 6 
Tape 1 Tape 20 
Tape 1 Tape 1 
A B 
C D 
E F 
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6.5. Discussion 
The set of methods 
In a first step, the HPLC method for the quantification of TACA on tapes removed by tape 
stripping was successfully validated. In a second step, the whole set of methods, i.e.: 1) the 
standardized tape stripping technique for stratum corneum sampling, 2) the UV/VIS-spectrosco-
pical method for quantification of corneocytes on the tapes, and 3) the HPLC method for 
quantification of TACA on the tapes had to be tested. The preliminary tape stripping 
experiments described in this chapter should therefore be regarded as a proof of concept rather 
than an in-depth investigation of vehicle effects. The number of volunteers was small, and there 
was no intra-individual (contra-lateral) comparison of the 2 different formulations. 
The amount of corneocytes removed by tape stripping is influenced by several factors 
(described in extenso in chapter 3.2). Therefore, a standardization of the tape stripping 
procedure is indispensable to obtain reproducible results. Our standardization included: a) the 
use of a template which ensured the removal of stratum corneum from the same skin area; 
b) the application of a constant pressure on the tape before stripping by the use of a hand roller; 
c) the removal of each tape with a rapid, firm movement; d) the alternation of tape removal 
(elbow-to-wrist, wrist-to-elbow); and e) the definition of a stripping endpoint (measured 
spectrosco-pically). 
The quantification of corneocytes by UV/VIS-spectroscopy is based on the measurement of the 
pseudo-absorption of the corneocytes. In contrast to a real absorption (e.g. shown by sunscreen 
agents), the corneocytes aggregates, as particles, decrease the intensity of the transmitted light 
by reflection, scattering, and diffraction [134]. This happens nearly independently of the 
wavelength. Therefore, any wavelength which is undisturbed by other components, e.g. by the 
applied drug, could be used for quantification of the corneocytes. In our experiments, the 
corneocytes were quantified at 430 nm, as already described in the literature [134]. On the skin 
surface, the corneocyte cohesion is low, and large amounts of corneocytes were removed with 
the first tapes, displaying high pseudo-absorbance values. In the deeper stratum corneum, the 
measured pseudo-absorbance decreased, reflecting the decreasing amount of corneocytes.  
The UV/VIS-spectroscopical method offers the advantage of a simultaneous quantification of 
both corneocytes and drug directly on the tape [251]. However, this is only possible if the drug 
has an absorption maximum which is not masked by the matrix of the tape, i.e. an absorption 
maximum > 300 nm in the case of Tesa Multi-Film Crystal-Clear® (compare Fig. 11-2 of the 
appendix for a UV/VIS-spectrum of a blank tape). Since the absorption maximum of 
corticosteroids is approximately at 240 nm, the simultaneous quantification of corneocytes and 
corticosteroids is not feasible. Thus, TACA has to be quantified with other methods, e.g. by the 
HPLC method successfully validated in this chapter. 
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The validated HPLC method was able to detect TACA on each stripped tape. Yet, on some of 
the last stripped tapes (deeper stratum corneum) and especially 24 h after application, TACA 
could be detected but not always quantified. In addition, the sampling of up to 82 tapes to 
remove the entire stratum corneum in some volunteers implied a higher TACA “dilution” 
compared to a lower tape number, and the probability to surpass the LOQ was higher. 
Formulation and vehicle 
The composition of the applied formulation plays a decisive role on the penetration of drugs into 
the stratum corneum. The application of a finite amount of drug was desired, and therefore 2 
volatile formulations were compounded: a simple solution in acetone as a good solvent for 
TACA and a lesser volatile ethanolic gel. Acetone does not represent a vehicle normally used in 
dermatology. Yet, the investigation of the penetration of topical corticosteroids applied in 
acetone is known in the literature, since a volatile vehicle allows the application of a finite 
amount of drug [49, 59], and since organic solvents can play a relevant role in occupational skin 
exposure [61]. Comparisons with older investigations are possible. 
Both acetone and ethanol are lipid solvents. The property of dissolving skin lipids, thus causing 
damage to the normal skin structure, has been described especially for acetone. In our study, 
skin damage is improbable, since the applied volume was low and the contact time short (about 
30 seconds). At worst, only a superficial skin damage due to extraction of skin surface lipids is 
expected to occurr, whereas the stratum corneum structure would remain intact [252, 253]. 
Skin washing 
Some authors are used to washing the skin after a definite application time to remove eventual 
excesses of formulation. Yet, different solvents wash the skin more or less successfully, and the 
washing procedure has been related to an enhanced penetration of the drug into deeper skin 
layers [224, 225] because of a remobilization of the drug through the solvent. Moreover, the 
washing procedure can affect the barrier function of the skin [254]. To minimalise any additional 
exogenous influence, no skin washing was performed in these experiments.  
Tape evaluation 
The number of tapes required to completely remove the stratum corneum is dependent on the 
cohesion of the corneocytes (depending on the volunteer and on the anatomical site), and on 
the vehicle, which can loosen the structure of the stratum corneum. 
According to the withdrawn draft guidance “Topical dermatological drug products NDAs and 
ANDAs – In vivo bioavailability, bioequivalence, in vitro release, and associated studies“ of the 
FDA (compare chapter 3.1) [1], some researchers are used to discarding the upper stripped 
tape from the evaluation, claiming that it contains excess formulation. Yet, discarding tapes is 
always a precarious and arbitrary procedure, and it is not well defined how many tapes are 
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sufficient to really eliminate potential formulation excesses. Furthermore, drug adhering to the 
skin can form a surface reservoir, from which the drug can be released at a later stage if re-
dissolved. 
Instead of discarding tapes, it was preferred for evaluation of the current experiments to present 
two different types of data. First, the total TACA amount calculated including all the tapes, which 
gives information about how much drug is in the entire stratum corneum, including the drug on 
the skin surface (e.g. as crystals or bound to the gel matrix). Second, the TACA amount 
calculated without the tapes 1-3 (usually up to 3 tapes were required to remove TACA crystals), 
which gives information about the TACA fraction penetrated into the stratum corneum that is not 
going to be removed by skin exfoliation and/or friction with clothes. 
TACA penetration into stratum corneum 
After application of the two different formulations, the vehicles rapidly changed their composition 
(metamorphosis of the vehicle) [255]. Acetone evaporated very quickly, and TACA partially 
precipitated on the skin as a solvent-deposited solid [49, 59]. After application of the ethanolic 
gel, the ethanol evaporated as well, but more slowly. A thin film of gel matrix (mainly cellulose) 
was macroscopically visible on the skin surface after evaporation of the ethanol. Since most 
TACA was bound within the cellulose matrix, the TACA penetration into stratum corneum after 
application of the ethanolic gel formulation was slow. The ethanolic gel resulted to be a slow 
release formulation, forming a superficial drug reservoir. Therefore, it was important to leave the 
cellulose film on the skin until tape stripping and not to remove any excess of formulation.  
The existence of a surface TACA reservoir after application of the ethanolic gel is reflected by 
the high total TACA amount recovered at both 0.5 h (94%) and 3 h (84%). The lower TACA 
amount recovered at 24 h (7%) can be explained by the removal of the surface reservoir by 
textile friction and corneocyte desquamation. Nevertheless, after 24 h the total TACA amount 
recovered after application of the ethanolic gel is still higher than the TACA amount after 
application of the acetonic solution (1%).  
The acetonic solution displayed a low total penetrated TACA amount (24%) already at 0.5 h, 
shortly after application. There are two possible explanations: either the acetonic vehicle 
enhanced the penetration of TACA to such an extent that the drug rapidly permeated through 
the stratum corneum into deeper, living skin layers (enhanced vertical diffusion), or TACA 
spread laterally (horizontal diffusion). A 5-fold enhanced penetration of cortisone after 
application in an acetonic solution compared to aqueous solutions was observed by Scheuplein 
and Ross [59], supporting the enhanced-vertical-penetration theory. Yet, horizontal diffusion has 
also been observed in experiments with clobetasol propionate applied in different vehicles [123], 
and the vehicle played a crucial role in inducing lateral diffusion. Thus, both explanations are 
possible, although the vertical diffusion was probably the predominant route of penetration. 
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6.6. Conclusions 
An HPLC method for quantification of TACA on tapes obtained by tape stripping was validated. 
The combination of standardized tape stripping as sampling method and UV/VIS-spectroscopy 
and HPLC as validated analytical methods enabled the quantification of the penetration of 
TACA into human stratum corneum in vivo. This was successfully proven in a preliminary 
experiment investigating the vehicle effect on the TACA penetration into stratum corneum. The 
set of methods allowed a clear distinction of the penetration pattern of TACA after application in 
an acetonic solution and an ethanolic gel. The ethanolic gel resulted to be a slow-release 
formulation forming a surface TACA reservoir, whereas the acetonic solution displayed a good 
penetration into the stratum corneum. 
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7. Project II:                   
Effect of dose and application frequency 
The findings of this project have been accepted for publication: Pellanda C, Ottiker E, Strub C, 
Figueiredo V, Rufli T, Imanidis G, Surber C. Topical bioavailability of triamcinolone acetonide: 
effect of dose and application frequency. Arch Derm Res. The original publication is available at 
www.springerlink.com. 
 
Abstract 
The application frequency of topical corticosteroids is a recurrently debated topic. Multiple-daily 
applications are common, although a superior efficacy compared to a once-daily application is 
not unequivocally proven. Only few pharmacokinetic studies investigating application frequency 
exist. The aim of the study was to investigate the effect of dose (experiment 1) and application 
frequency (experiment 2) on the penetration of triamcinolone acetonide (TACA) into human 
stratum corneum in vivo. The experiments were conducted on the forearms of 15 healthy 
volunteers. In experiment 1, single TACA doses (300 µg/cm2 and 100 µg/cm2) were applied on 
3 sites per arm. In experiment 2, single (1x300 µg/cm2) and multiple (3x100 µg/cm2) TACA 
doses were similarly applied. Stratum corneum samples were harvested by tape stripping after 
0.5, 4, 24 h (experiment 1) and after 4, 8, 24 h (experiment 2). Corneocytes and TACA were 
quantified by UV/VIS-spectroscopy and HPLC, respectively. The amounts of TACA penetrated 
into stratum corneum were statistically evaluated by a paired-sample t-test. In experiment 1, 
TACA amounts within stratum corneum after application of 1x300 µg/cm2 compared to 
1x100 µg/cm2 were only significantly different directly after application and similar at 4 and 24 h. 
In experiment 2, multiple applications of 3x100 µg/cm2 yielded higher TACA amounts compared 
to a single application of 1x300 µg/cm2 at 4 and 8 h. At 24 h, no difference was observed. In 
conclusion, considerable TACA amounts were retained within the stratum corneum 
independently of dose and application frequency. A low TACA dose applied once should be 
preferred to a high dose, which may promote higher systemic exposure. 
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7.1. Introduction 
In current dermato-pharmacotherapy, the application frequency of topical corticosteroids is a 
recurrently debated topic. Several studies have been performed to propose recommendations 
for optimal therapy. Once- or twice-daily applications are common [193], and many 
dermatologists usually follow twice-daily applications, although a superior efficacy of a multiple-
daily application is not unequivocally proven. Recently, a systematic review reported a similar 
efficacy of once-daily versus multiple-daily applications of topical corticosteroids of the same 
potency in atopic dermatitis [208]. In addition to pharmacodynamic investigations, only few 
pharmacokinetic studies investigating application frequency exist (reviewed in [256]). 
Unfortunately, these studies make their statements on data derived from drug concentration 
determination in plasma [222, 223] and urine [224, 225]. This information is incomplete because 
these data document systemic bioavailability and not topical bioavailability.  
Topical bioavailability can be estimated from the drug concentration within the stratum corneum, 
which is expected to be related to the drug concentration at the target site (i.e. viable epidermis 
or dermis) since the stratum corneum is the rate limiting barrier for percutaneous absorption. 
Similarly to the determination of the drug concentration in blood and/or urine as surrogate for 
the real concentration in the target tissue, the determination of the drug concentration in the 
stratum corneum is a surrogate for the concentration in the viable (epi-)dermis [257]. A useful 
dermato-pharmacokinetic technique for the assessment of drug amounts in stratum corneum as 
a function of time is tape stripping, which enables removal of the stratum corneum layer by 
layer [93]. 
Human stratum corneum has the property to store previously applied drugs depending on the 
drug, the formulation, the application procedure, and the state of the skin [146]. Drug 
accumulation in the skin forms a reservoir, from which minor amounts are released during a 
prolonged time period. The existence of a reservoir within the stratum corneum has been 
documented for several xenobiotics [146], particularly for topical corticosteroids [148]. This is a 
welcome phenomenon for topical corticosteroids and affects the choice of application frequency 
and dose.  
Our investigation is focused on topical bioavailability. We determined the in vivo penetration of 
triamcinolone acetonide (TACA), a moderately potent corticosteroid often used in dermatology, 
into human stratum corneum after different application modes. The investigation was divided 
into two parts. In experiment 1, the influence of the dose was investigated by comparing the 
TACA penetration into stratum corneum after application of a high (1x300 µg/cm2) and a low 
(1x100 µg/cm2) TACA dose. In experiment 2, the influence of application frequency was 
investigated by comparing TACA penetration after a once-daily application of a high TACA dose 
(1x300 µg/cm2) to TACA penetration after a thrice-daily application of a low TACA dose 
(3x100 µg/cm2). 
7. Project II: Effect of dose and application frequency 
Carolina Pellanda  Page 73 of 186 University of Basel, 2006 
7.2. Subjects and methods  
7.2.1. Material and formulations 
Micronized TACA Ph.Eur. was purchased from Caesar&Loretz GmbH, Hilden, Germany and 
acetone Ph.Eur. from Hänseler AG, Herisau, Switzerland. Solutions of 4.2 mg/ml (for the 
application of 100 µg/cm2) and 12.6 mg/ml (application of 300 µg/cm2) TACA in acetone were 
prepared following current GMP guidelines. 
7.2.2. Subjects and study design 
A total of 15 healthy adult volunteers with skin phototype II-III (Caucasian) and with minor 
hairiness of the volar aspect of the forearm were recruited and underwent a preliminary 
dermatological examination one week prior to study-start. The experiments were conducted on 
the volar aspect of the forearms during 2 days as an open study with half-side intra-individual 
comparison. Experiment 1 (influence of dose) was regarded as explorative, whereas 
experiment 2 (influence of application frequency) was the main investigation. TACA in acetone 
was applied on selected skin sites, from which the stratum corneum was harvested afterwards 
by tape stripping at 3 different time points according to the protocol described below. No skin 
treatments were allowed during 24 h before study-start, and volunteers were not allowed to 
shower or practise sports during the 2-day experiment. Within 1 month after tape stripping, the 
wound healing was evaluated in a second dermatological examination8. Fig. 7-1 displays the 
flow chart of the study. The study was conducted according to the ethical rules stated in the 
Declaration of Helsinki and was approved by the local ethical committee and the national 
authorities (Swissmedic). The volunteers signed written consent for participation.  
Fig. 7-1: Flow chart of the study: from recruitment to dismissal of the volunteers. The effect of dose 
(experiment 1) and application frequency (experiment 2) was investigated. 
                                                     
8
 The forms of the dermatological pre- and post-examination are displayed in the appendix (chapter 11.2.1 and 11.2.2). 
Recruitment
(n=15)
Dermatological Pre-Examination
(n=15)
- Assessment for eligibility
- Written consent
Entered EXPERIMENT 1
(n=5)
- 3 women / 2 men
- 23-37 years (mean 30)
Entered EXPERIMENT 2
(n=10)
- 5 women / 5 men
- 20-44 years (mean 26)
ARM 1
Application
1 x 300 µg/cm2
at 9 a.m.
(on 3 different skin sites)
Tape Stripping
0.5h / 4h / 24 h after application
ARM 2
Application
1 x 100 µg/cm2
at 9 a.m.
(on 3 different skin sites)
Tape Stripping
0.5h / 4h / 24 h after application
ARM 1
Application
1 x 300 µg/cm2
at 9 a.m.
(on 3 different skin sites)
Tape Stripping
4h / 8 h / 24 h after application
ARM 2
Application
3 x 100 µg/cm2
at 9 a.m. / 1 p.m. / 5 p.m.
(on 3 different skin sites)
Tape Stripping
4h / 8 h / 24 h after (first) 
application
Dermatological Post-Examination
(n=15)
- Wound-healing assessment
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7.2.3. Application of the formulations 
Three skin sites per arm were treated (total of 6 skin sites per volunteer). The application area 
was delineated by a rectangular glass frame (10.5 cm2) glued onto the skin (Sauer skin glue, 
Manfred Sauer GmbH, Lobbach, Germany). A volume of 250 µl formulation was uniformly 
applied with a Hamilton Syringe (Supelco, Buchs, Switzerland), and the vehicle was allowed to 
evaporate. In experiment 1, the high TACA dose (300 µg/cm2) and the low TACA dose 
(100 µg/cm2) were applied all at the same time (time 0 h, at 9 a.m.) on 3 different sites per arm. 
In experiment 2, the high TACA dose was applied at once on one arm (at 9 a.m.), whereas the 
low TACA dose was applied thrice on the other arm (at 9 a.m., 1 p.m., 5 p.m.) Details of 
application and tape stripping procedure are given in Table 7-1. Skin sites not stripped within 
0.5 h after application were covered with non-occlusive cotton gauzes until tape stripping. No 
skin washing was performed to remove potential excess of formulation, because washing 
procedures have been correlated with an enhanced percutaneous absorption [258]. 
 
Table 7-1: Overview of application and tape stripping procedure. 
  0 h 4 h 8 h 24 h 
      EXPERIMENT 1      
Site 1 1 x 300 µg/cm2    D T    
Site 2 1 x 300 µg/cm2    D T    
AR
M
 
1 
Site 3 1 x 300 µg/cm2    D   T 
Site 4 1 x 100 µg/cm2    D T    
Site 5 1 x 100 µg/cm2    D T    
AR
M
 
2 
Site 6 1 x 100 µg/cm2    D   T 
EXPERIMENT 2      
Site 1 1 x 300 µg/cm2     D  T   
Site 2 1 x 300 µg/cm2     D  T   
AR
M
 
1 
Site 3 1 x 300 µg/cm2     D   T 
Site 4 2 x 100 µg/cm2 (*) D  D T   
Site 5 3 x 100 µg/cm2    D D D T   
AR
M
 
2 
Site 6 3 x 100 µg/cm2    D D D T 
      
  9 a.m. 1 p.m. 5 p.m. 9 a.m. 
 
D = Dosing (application of the formulation), T = Tape Stripping (skin sampling). When tape stripping followed just after 
dosing (D T), a time span of 0.5 h was maintained between dosing and tape stripping to ensure an initial penetration of 
TACA into the stratum corneum. (*) Note that in experiment 2 just 2 doses were applied at 4 h (skin site 4); following the 
multiple application design, the total dose of 3 x 100 was not applied before 8 h. 
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7.2.4. Skin sampling by tape stripping 
Stratum corneum tape stripping was performed after the following time intervals: in 
experiment 1 at 0.5 h, 4 h, and 24 h after application; in experiment 2 at 4 h, 8 h, and 24 h after 
(first) application (Table 7-1). To remove the stratum corneum in a standardized manner from 
the exact same skin area, a template delineating a constant aperture of 3.3 x 1.7 cm (5.6 cm2) 
was fixed on the skin. An adhesive tape (Tesa Multi-Film Crystal-Clear 57315, 19 mm width, 
Tesa, Beiersdorf, Hamburg, Germany) was placed on this skin site, and a hand roller supplying 
a pressure of 140 g/cm2 was passed over the tape 10 times. The tape was removed with a 
rapid, firm movement and fixed across a photographic slide frame. This procedure was 
repeated with new tapes until total removal of the stratum corneum, which was defined as light 
transmission through the tape ≥ 95%, measured by UV/VIS-spectroscopy (see next section). 
Tape stripping of one skin site lasted about 15 min. No significant further drug diffusion into 
deeper skin layers is expected during the tape stripping time, since the highest amount of drug 
is removed with the first tapes [259]. 
7.2.5. Quantification of corneocytes 
The amount of corneocytes adhering to each tape was quantified by measuring the pseudo-
absorbance of the corneocytes at 430 nm as described by Weigmann et al. [245]. The slide 
frames on which the tapes had been fixed were inserted in the sample holder of a Lambda 35 
spectrophotometer (Perkin Elmer, Überlingen, Germany, custom-modified to obtain a 
rectangular light beam of 1 cm2), and each tape was directly measured against a blank tape. 
7.2.6. Quantification of TACA 
After quantification of the corneocytes, each tape was disassembled from the frame and 
extracted with 1.5 ml 60% methanol during 30 min on a horizontal shaker at 140 rpm (Heidolph 
Unimax 2010, Heidolph, Germany). To allow the calculation of a mass balance, the gauzes 
used to cover the treated skin sites were extracted similarly with 10 ml 60% methanol. TACA 
amounts in the extracts were quantified by an ICH-validated [237] HPLC method  using a 
Symmetry ShieldTM RP18 column (2.1 x 100 mm, 3.5 µm particle size) and a Waters Alliance 
HPLC System (2690 Separation Module, 996 Photodiode Array Detector), all Waters 
Corporation, Millford, Massachusetts, USA. The mobile phase consisted of methanol 60% in 
water (v/v) with a flow rate of 0.3 ml/min. Sample aliquots of 20 µl were injected, and 
quantification occurred at 240 nm. The limit of quantification (LOQ) was 100 ng/ml 
(corresponding to 27 ng/cm2), the limit of detection (LOD) 35 ng/ml (9 ng/cm2). 
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7.2.7. Data analysis 
Sample size 
The method deviation (intra-individual standard deviation) had been determined previously and 
was ± 40%. To provide a power of 80% in detecting a 50% difference between the 2 treatments 
groups at the 5% significance level, a total of 10 volunteers are needed according to the two-
sided t-test nomogram for paired values after logarithmic transformation [260], and were thus 
enrolled in the main experiment 2. For the explorative experiment 1, a power of 50% was 
accepted, implicating the enrolment of 5 volunteers. 
Qualitative TACA penetration into stratum corneum (penetration profiles) 
To graphically visualize the drug distribution within the stratum corneum, TACA amounts 
quantified on each tape were correlated with tape number and depth of penetration into stratum 
corneum. Removal of the entire stratum corneum is a prerequisite for the profile calculation, 
since the sum of corneocytes (pseudo-)absorbance on one skin site represents 100% stratum 
corneum. Thus, the relative amount of stratum corneum removed by each tape can be 
calculated from the individual absorbance values as fully described in Jacobi et al. [126, 251]. 
Quantitative TACA penetration into stratum corneum 
The TACA amounts on each tape (area 5.6 cm2) of each skin site were added up to the total 
TACA amount penetrated into stratum corneum, which was evaluated statistically. The 
significance of differences between the treatment groups at each time was tested in a 2-sided 
paired-sample t-test after logarithmic transformation. Two different types of evaluation were 
performed: the evaluation of a) the total TACA amount within stratum corneum (sum of TACA 
amounts on all tapes) and of b) the TACA amount without tapes 1 to 3 (on which formulation 
excess, e.g. TACA crystals, could be located). Statgraphics PLUS 5 software (Manugistic, Inc., 
Rockville, Maryland, USA) was used to conduct the analysis of the trial. 
Mass balance 
To gain further information on the fate of TACA, a mass balance was performed. The following 
TACA amounts were calculated: a) TACA in the gauzes used to protect the application sites 
until tape stripping; b) TACA in tapes 1-3; c) TACA in the stratum corneum (without tapes 1-3); 
and d) TACA not recovered and presumably penetrated into deeper skin layers or diffused 
laterally.  
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7.3. Results 
7.3.1. Demographics of the subjects 
A total of 15 healthy adult volunteers (7 male and 8 female) aged 20-44 years (mean 27) were 
recruited and finished the study. Five volunteers were assigned to experiment 1 and ten 
volunteers to experiment 2 (Fig. 7-1). The tape stripping experiments were conducted from 
March 2004 to July 2004 at the University Hospital Basel. The stripped skin sites displayed a 
good wound healing and no scarring at the final dermatological investigation. Slight 
hyperpigmentation was observed in some volunteers. 
 
7.3.2. Qualitative TACA penetration into stratum corneum (penetration profiles) 
The depiction of the results as penetration profiles visualizes the localization of TACA within the 
stratum corneum. The typical penetration profile displayed large TACA amounts in the upper 
stratum corneum and lower TACA amounts in the deeper stratum corneum, indicating TACA 
permeation through the stratum corneum and penetration into deeper tissues. In both 
experiments, similar penetration profiles of TACA over time were achieved, apart from a higher 
TACA amount usually located on the first stripped tape after application of the higher dose 
(300 µg/cm2) in experiment 1 or after multiple application (3x100 µg/cm2) in experiment 2. The 
penetration profiles obtained after the different applications of experiment 2 in one volunteer are 
displayed in Fig. 7-29. 
The mean number of tapes required to remove the entire stratum corneum in both experiments 
was 55, with a minimum of 29 tapes and a maximum of 80 (independently of gender and age). 
                                                     
9
 The penetration profiles for each volunteer are displayed in the appendix (chapter 11.2.1 for experiment 1 and chapter 
11.2.6 for experiment 2). 
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Fig. 7-2: Typical penetration profiles of TACA into stratum corneum over time (4 h, 8 h, 24 h) after application of 
1x300 µg/cm2 vs. 3x100 µg/cm2 TACA in the same volunteer (experiment 2). TACA amounts on each tape 
(horizontal grey bars) are correlated to the tape number (right scale) and to the depth of penetration into 
stratum corneum, displayed as percentage of the total stratum corneum thickness (left scale). This correlation 
is enabled because the entire stratum corneum was stripped from each skin site, the total number of tapes thus 
representing 100% stratum corneum thickness. 
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7.3.3. Quantitative TACA penetration into stratum corneum 
Experiment 1 - Effect of dose (1x300 µg/cm2 vs. 1x100 µg/cm2) 
The total amounts of TACA penetrated into stratum corneum at the different time points are 
depicted in Fig. 7-3 (left side)10. At 0.5 h, almost the entire TACA dose applied was quantified 
within the stratum corneum: 245 ± 78 µg/cm2 after application of 300 µg/cm2 and 
101 ± 17 µg/cm2 after application of 100 µg/cm2. At 4 h, lower TACA amounts of 80 ± 19 µg/cm2 
(after application of 300 µg/cm2) and 52 ± 13 µg/cm2 (after application of 100 µg/cm2) were 
observed, and after 24 h still 46 ± 18 µg/cm2 vs. 33 ±19 µg/cm2 were quantified.  
By excluding tapes 1-3, a dramatically lower amount was measured at 0.5 h within the stratum 
corneum, with TACA amounts of 74 ± 12 µg/cm2 (after application of 300 µg/cm2) vs. 
55 ±14 µg/cm2 (after application of 100 µg/cm2). No difference in the TACA amounts recovered 
after application of the two different doses was observed at later time points: 31 ± 15 µg/cm2 vs. 
30 ± 16 µg/cm2 at 4 h, and 27 ± 13 µg/cm2 vs. 23 ± 14 µg/cm2 at 24 h after application of 
300 µg/cm2 and 100 µg/cm2, respectively. The extremely lower TACA amount obtained by 
exclusion of tapes 1-3 showed that considerable amounts are retained on the skin surface. 
Fig. 7-3: Total TACA amounts penetrated into the stratum corneum in experiment 1 and experiment 2. Mean and 
standard deviation calculated with all tapes (including tapes 1-3) are displayed. The double asterisk (**) denotes 
a highly significant difference (p < 0.01, 2-sided paired-sample t-test) between the pair differences at the 
specified time. 
Statistical evaluation of the corresponding pair differences yielded a highly significant difference 
of the TACA amounts quantified at 0.5 h when all tapes were considered (p < 0.01) but no 
significance when tapes 1-3 were excluded (p > 0.05). At 4 h and 24 h, no statistically significant 
difference was observed for both evaluations (all tapes / without tapes 1-3). 
                                                     
10
 The data table as well as the statistical evaluation are displayed in the appendix (chapter 11.2.4 and 11.2.5). 
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Experiment 2 - Effect of application frequency (1x300 µg/cm2 vs. 3x100 µg/cm2) 
The total TACA amounts penetrated into stratum corneum at the different time points are 
depicted in Fig. 7-3 (right side)11. At 4 h, the total TACA amount quantified within the stratum 
corneum (all tapes) amounted to 65 ± 23 µg/cm2 after application of 1x300 µg/cm2 vs. 
84 ± 29 µg/cm2 after 2x100 µg/cm2. This slight difference became inexistent after discarding the 
first 3 tapes (33 ± 12 µg/cm2 and 35 ± 11 µg/cm2, respectively). The pair difference was 
statistically not significant in both cases (p > 0.05). Note that this time point displays a different 
totally applied dose (300 µg/cm2 vs. 200 µg/cm2). Taking this into account, the amount observed 
after multiple application was quite high: despite the application of a lower total dose, a similar 
TACA amount was quantified within the stratum corneum.  
At 8 h, TACA within the stratum corneum amounted to 44 ± 29 µg/cm2 (after application of 
1x300 µg/cm2) vs. 98 ± 45 µg/cm2 (after application of 3x100 µg/cm2). This difference was 
highly significant (p < 0.01) when all tapes were considered, but only a slight trend was seen 
after discarding tapes 1-3 (20 ± 8 µg/cm2 and 29 ± 15 µg/cm2 after application of 1x300 µg/cm2 
and 3x100 µg/cm2, respectively, p = 0.06).  
At 24 h, similar total TACA amounts were quantified within the stratum corneum: 39 ± 31 µg/cm2 
after application of 1x300 µg/cm2 vs. 38 ± 16 µg/cm2 after 3x100 µg/cm2 (24 ± 14 µg/cm2 and 
23 ± 9 µg/cm2, respectively, after discarding tapes 1-3). These values showed no statistically 
significant difference (p > 0.05).  
7.3.4. Mass balance 
The application of a finite TACA dose permits the performance of a mass balance. For each 
treated skin site, 4 different values of recovered TACA amount were determined: 1) in the 
gauze; 2) in tapes 1-3; 3) in the stratum corneum without tapes 1-3 and; 4) the remnant amount 
not recovered and presumably penetrated into deeper tissues or diffused laterally. The results 
of the mass balance are presented in Fig. 7-4 (experiment 1) and Fig. 7-5 (experiment 2). The 
evaluation of both experiments showed that: a) TACA amounts of 10-23 µg/cm2 did not 
penetrate into the stratum corneum and adhered to the gauze (corresponding to 5-12% of the 
applied TACA dose). b) About half the amount recovered in the entire stratum corneum 
persisted within the upper stratum corneum and was found in tapes 1-3 (up to 57% of the 
applied TACA dose). c) TACA amounts recovered in the stratum corneum without tapes 1-3 
were not significantly different between the different application modes. d) TACA seemed to 
permeate the stratum corneum more rapidly after a single application of the high TACA dose 
(300 µg/cm2), since the TACA amounts not recovered (and presumably penetrated into deeper 
tissues) were already observed after 0.5 h (experiment 1) and were high after 4 h (in both 
experiments 1 and 2). 
                                                     
11
 The data table as well as the statistical evaluation are displayed in the appendix (chapter 11.2.7 and 11.2.8). 
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Fig. 7-4: Mass balance of experiment 1. Skin sites are divided into 4 compartments displaying the mean TACA 
amounts [µg/cm2] recovered in gauze (white fields), in tapes (T) 1-3 (light grey), in stratum corneum (SC) 
without T 1-3 (dark grey), and the amounts of TACA not recovered and presumably penetrated into deeper or 
adjacent skin tissues (striped grey). At 0.5 h, no gauze was used, since tape stripping followed just after 
application of the formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7-5: Mass balance of experiment 2. Each skin site is divided into 4 compartments displaying the mean 
TACA amounts [µg/cm2] recovered in gauze (white fields), in tapes (T) 1-3 (light grey), in stratum corneum (SC) 
without T 1-3 (dark grey), and the amounts of TACA not recovered and presumably penetrated in deeper or 
adjacent skin tissues (striped grey). 
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7.4. Discussion 
A prerequisite for investigating topical products is the stringent differentiation between topical 
and systemic bioavailability determination. In previous investigations on percutaneous 
absorption of corticosteroids applied in acetone [224, 225], conclusions for topical therapy were 
drawn from data obtained by urinary excretion. Yet, data yielded from urinary excretion measure 
systemic bioavailability (of the topical application) and not topical bioavailability (of the topical 
application). Measurements of drug concentration in urine and/or blood are only a means for 
bioavailability evaluation when the pharmacological response is correlated to a systemic 
parameter or when the body burden is of interest. Furthermore, systemic drug concentrations 
after topical application do not represent drug concentrations at the target site in the skin but 
purely drug concentrations after permeation through the target site. Thus, the mere assessment 
of systemic bioavailability does not properly reflect topical bioavailability for the treatment of 
local skin diseases [34, 261]. 
This trial has been performed to assess the topical bioavailability of TACA in a simple vehicle 
after different application modes. Acetone does not represent a vehicle normally used in 
dermatology, but has often been used as a vehicle for investigational purposes [224, 225, 262]. 
TACA displays a very good solubility in acetone, and the volatile vehicle allows the application 
of a finite, solvent-deposited drug amount [49, 59]. Therefore, an acetonic vehicle is appropriate 
for the purpose of this study. Especially after application of the high TACA dose, some drug 
crystallized on the skin surface because of the rapid vehicle evaporation. On the one hand, the 
crystals can get lost due to friction with clothes or due to normal desquamation (this amount 
was retained and quantified in the protective gauze during our experiments). On the other hand, 
drug crystals can also become bioavailable at later stages if redissolved, either physiologically 
by humid micro environmental conditions on the skin surface or by fresh vehicle in case of 
multiple applications [61]. This was one reason for not washing the skin during our experiments, 
assuming that the protective gauze would retain the superficial, unbound TACA. Moreover, 
washing procedures have been shown to enhance percutaneous penetration of topically applied 
compounds [258]. 
A frequently debated question arising from tape stripping experiments is the inclusion or 
exclusion of the first tapes into the evaluation. The answer depends on the study design. In our 
case, the drug was solvent-deposited on the skin, and the mass balance required the 
consideration of all the tapes. Thus, a separate evaluation with and without tapes 1-3 was 
chosen.  
In our experiments, the topical bioavailability of TACA was described by the TACA penetration 
into stratum corneum over time. This is possible because the stratum corneum is the rate 
limiting barrier to percutaneous absorption, and thus the amount of drug in the stratum corneum 
may be considered to reflect to the amount of drug at the target site [257]. Experiment 1 
displayed higher TACA amounts within the stratum corneum after application of a high TACA 
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dose (300 µg/cm2) compared to a lower TACA dose (100 µg/cm2). However, this difference was 
only significant immediately after application, when almost the entire TACA dose applied was 
recovered within the stratum corneum, whereas similar TACA amounts were found after 
discarding tapes 1-3. Usually, increasing the applied drug dose leads to a higher absolute (but a 
lower relative) percutaneous penetration, provided that the drug is dissolved [203]. In our 
experiment, after application of the higher TACA dose, the immediate evaporation of acetone 
led to the precipitation of a high TACA amount on the skin surface and on the external layers of 
the stratum corneum.  
Experiment 2 showed slightly higher TACA amounts within the stratum corneum after multiple 
application of a lower TACA dose (3x100 µg/cm2) compared to the single application of the high 
TACA dose (1x300 µg/cm2). As a result of multiple applications, the skin was periodically 
reloaded with new drug, thus achieving temporary higher amounts within the stratum corneum. 
In order to characterize this temporary trend, the stripping times after application of the second 
(at 4 h) and third (at 8 h) dose in case of multiple application were deliberately chosen. The 
highest drug amount was always localized within the upper stratum corneum layers and by 
excluding tapes 1-3 only insignificant differences between the TACA amounts recovered after 
the different application modes were observed (in both experiments). 
At 24 h, still well quantifiable TACA amounts were retained within the stratum corneum 
independently of dose and application frequency. Yet, these TACA amounts were rather due to 
the slow diffusion through the stratum corneum barrier than to a “classical” reservoir formation. 
This was underlined by the slow but existent diffusion of TACA into deeper tissues. 
A similar topical bioavailability within the stratum corneum does not necessarily imply a similar 
systemic bioavailability, not desired in topical therapy with corticosteroids. TACA amounts not 
quantified within the stratum corneum have presumably penetrated vertically into the viable 
epidermis and into the dermis, reaching the systemic blood circulation. In addition, a horizontal, 
lateral diffusion into adjacent stratum corneum has also been observed in the past [123]. Both 
penetration routes may have played a role in our experiments, but the vertical penetration 
usually represents the preferred route.  
The mass balance was performed to estimate the extent of the systemic exposure. After 
application of a total TACA dose of 300 µg/cm2 (either as a single dose or divided into multiple 
doses), a high TACA amount was not recovered and seemed to have penetrated into deeper 
tissues. At 24 h, the extent of percutaneous absorption and thus the extent of systemic 
bioavailability seemed independent of the application mode, but the release rate out of the 
stratum corneum into deeper tissues was lower after application of the multiple doses. On the 
contrary, after application of a total dose of 100 µg/cm2, both extent and release of the drug out 
of the stratum corneum into deeper tissues was lower. Thus, a low TACA dose applied once 
may be preferable to a higher total TACA dose (applied once or thrice daily). This agrees with 
pharmacodynamic investigations [208], which showed that multiple-daily applications usually 
have no superiority. 
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7.5. Conclusions 
In the present study, the effect of dose and application frequency on the topical (cutaneous) 
bioavailability of TACA was determined by standardized tape stripping in human volunteers. 
Actual drug amounts were measured directly within the stratum corneum, a layer preceding the 
target site.  
Independently of the dose and the application frequency, considerable TACA amounts were 
retained for 24 h within the stratum corneum (reservoir formation). A difference between the 
TACA amounts penetrated into the stratum corneum after the different application modes was 
observed immediately after application and was mainly due to a different TACA amount in the 
first 3 tapes. No major differences were observed at later time points. Yet, a faster permeation 
through the stratum corneum and thus a higher systemic exposure, not welcome in topical 
therapy, may be promoted by application of a high TACA dose. Thus, a low TACA dose applied 
once may be preferable to a high TACA dose. 
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8. Project III:                   
Effect of occlusion 
The findings of this project have been accepted for publication: Pellanda C, Strub C, Figueiredo 
V, Rufli T, Imanidis G, Surber C. Topical bioavailability of triamcinolone acetonide: effect of 
occlusion. Skin Pharmacol Physiol. The original publication is available at www.karger.com/spp. 
 
Abstract 
Occlusion by covering the skin with an impermeable wrap enhances skin hydration, affects drug 
absorption, and can induce the formation of a drug reservoir within the stratum corneum. This is 
desired in local therapy with topical corticosteroids. The aim of the study was to investigate the 
effect of occlusion before (pre-occlusion, experiment 1) and after (post-occlusion, experiment 2) 
application on the penetration of triamcinolone acetonide (TACA) into the stratum corneum. 
The experiments were conducted on the forearms of 10 healthy volunteers. In experiment 1, a 
dose of 100 µg/cm2 TACA was applied on 3 sites per arm, one arm having been pre-occluded 
for 16 h. In experiment 2, the same dose was applied on 2 sites per arm, and one arm was 
occluded after application until skin sampling. Stratum corneum samples were removed by tape 
stripping at 0.5, 4, 24 h (experiment 1) and 4, 24 h (experiment 2) after application. Corneocytes 
and TACA were quantified by UV/VIS-spectroscopy and HPLC, respectively. The total TACA 
amount penetrated into stratum corneum was evaluated by multifactor ANOVA. 
TACA penetration into stratum corneum with and without pre-occlusion (experiment 1) showed 
no significant difference and decreased with time. Occlusion after application (experiment 2) 
produced a marked TACA accumulation within the stratum corneum, which persisted for 24 h. 
In conclusion, pre-occlusion showed no effect on the topical bioavailability of TACA in stratum 
corneum. Contrariwise, post-occlusion enhanced the penetration by a factor of 2, favoring the 
development of a drug reservoir. 
 
Keywords 
Occlusion 
Reservoir 
Tape stripping 
Topical bioavailability 
Triamcinolone acetonide 
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8.1. Introduction 
Occlusion by covering the skin with an impermeable wrap inhibits the physiological water loss 
through the skin and increases the skin temperature [67]. The enhanced skin hydration can 
induce morphological changes of the stratum corneum such as swelling of the corneocytes [69], 
water uptake into intercellular lipid domains [70], and deepening of skin furrows [68]. 
Such changes considerably affect the percutaneous absorption of topically applied drugs. 
Vickers observed in the early 60’s that the application of corticosteroids under occlusion 
promoted the formation of a long-lasting drug reservoir within the stratum corneum [148]. This is 
a welcome effect in local therapy with topical corticosteroids. The longer the active drug is 
present within the skin, the longer a therapeutic effect can be expected. 
Occlusion does not enhance the percutaneous absorption of all drugs [52, 233]. The 
enhancement appears to be compound and vehicle dependent [73]. Volatile solvents such as 
acetone and ethanol seem to induce a clear penetration enhancement after application under 
occlusion [235]. 
The aim of the study was to investigate the effect of occlusion on the in vivo penetration of 
triamcinolone acetonide (TACA), a moderately potent corticosteroid, into stratum corneum. In 
experiment 1, the effect of occlusion prior to topical application of TACA in acetone (pre-
occlusion) was investigated. In experiment 2, the effect of occlusion after TACA application 
(post-occlusion) was investigated.  
 
8.2. Subjects and methods  
8.2.1. Material and formulation 
A solution of 4.2 mg/ml micronized TACA Ph.Eur. (Caesar&Loretz GmbH, Hilden, Germany) in 
acetone Ph.Eur. (Hänseler AG, Herisau, Switzerland) was prepared following current GMP 
guidelines. 
 
8. Project III: Effect of occlusion 
Carolina Pellanda  Page 87 of 186 University of Basel, 2006 
8.2.2. Subjects and study design 
A total of 10 healthy adult volunteers with skin phototype II-III (Caucasian) without excessive 
hairiness of the inner forearm were recruited and underwent a dermatological examination one 
week prior to study-start. The experiments were conducted on the volar aspect of the forearms 
during 2 days as an open, explorative study with half-side intra-individual comparison. In 
experiment 1, one arm was pre-occluded prior to TACA application by wrapping it for 16 h in 
polypropylene film (Tangan® wrap). In experiment 2, occlusion of one arm followed TACA 
application, and the occlusive wrap was not removed until tape stripping. In both experiments, 
the contralateral arm served as control and was not occluded. Finite single doses (100 µg/cm2) 
of TACA solution were applied on selected skin areas, which were afterwards sampled by tape 
stripping at different times following the protocol described below. Within 1 month after tape 
stripping, the wound healing was evaluated in a final dermatological examination12. Fig. 8-1 
displays the flow chart of the study.  
The study was conducted according to the ethical rules stated in the Declaration of Helsinki and 
was approved by the local ethical committee and the national authorities (Swissmedic). The 
volunteers signed written consent for participation.  
Fig. 8-1: Flow chart of the study: from recruitment to dismissal of the volunteers. The effect of pre-occlusion 
(experiment 1) and post-occlusion (experiment 2) on the TACA penetration into stratum corneum was 
investigated. 
                                                     
12
 The forms of the dermatological pre- and post-examination are displayed in the appendix (chapter 11.2.1 and 11.2.2). 
Dermatological Pre-Examination
(n=10)
- Assessment for eligibility
- Written consent
TACA-Application
1x100µg/cm2
Entered EXPERIMENT 1
(n=5) 
- 3 women / 2 men
- 24-29 years (mean 25)
Tape Stripping
0.5h / 4h / 24h after application
Pre-Occlusion
(16h)
Recruitment
(n=10)
ARM 1 ARM 2
-
TACA-Application
1x100µg/cm2
Tape Stripping
0.5h / 4h / 24h after application
Post-Occlusion
Entered EXPERIMENT 2
(n=5) 
- 3 women / 2 men
- 23-30 years (mean 25)
Tape Stripping
4h / 24h after application
TACA-Application
1x100µg/cm2
ARM 1 ARM 2
TACA-Application
1x100µg/cm2
-
Tape Stripping
4h / 24h after application
Dermatological Post-Examination
(n=10)
- Wound-healing assessment
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8.2.3. Application of the formulation 
In experiment 1, 3 skin sites per arm were treated (total of 6 skin sites per volunteer). In 
experiment 2, 2 skin sites per arm were treated (total of 4 skin sites per volunteer)13. The 
application area was delineated by a rectangular glass frame (10.5 cm2) glued onto the skin 
(Sauer® skin glue, Manfred Sauer GmbH, Lobbach, Germany). A volume of 250 µl formulation, 
corresponding to a TACA dose of 100 µg/cm2, was uniformly applied on the delineated area 
with a Hamilton Syringe (Supelco, Buchs, Switzerland). The vehicle was allowed to evaporate. 
Skin sites not stripped within 0.5 h after application were protected with non-occlusive cotton 
gauzes until tape stripping. No skin washing was performed to remove excess of formulation, 
and the volunteers were not allowed to shower during the 2-day experiment. 
8.2.4. Skin sampling by tape stripping 
Stratum corneum samples were removed by standardized tape stripping [93] with Tesa tape 
(Tesa Multi-Film Crystal-Clear 57315, 19 mm width, Beiersdorf, Hamburg, Germany) at 0.5 h, 
4 h, 24 h (experiment 1) and at 4 h, 24 h (experiment 2) after application (Fig. 8-1). A template 
delineating an area of 5.6 cm2 was fixed onto the skin. Tapes were successively placed onto this 
area and stripped off with a rapid movement until the entire stratum corneum had been 
removed. A hand roller supplying a constant pressure of 140 g/cm2 was passed 10 times over 
each tape before removal. Total stratum corneum removal was defined as light transmission 
through the tape ≥ 95%, measured by UV/VIS-spectroscopy as described below. 
8.2.5. Analytics 
The amount of corneocytes adhering to each tape was spectroscopically quantified directly on 
the tapes at 430 nm using a spectrophotometer (Lambda 35, Perkin Elmer, Überlingen, 
Germany), custom-modified to obtain a rectangular light beam of 1 cm2, as described in 
Weigmann et al. [245]. The quantification of the corneocytes is required for the calculation of 
penetration profiles. 
The amounts of TACA adhering to each tape were quantified by an ICH-validated [237] HPLC 
method after extraction with 1.5 ml 60% methanol on a horizontal shaker (30 min, 140 rpm, 
Heidolph Unimax 2010, Heidolph, Germany). The protective gauzes were similarly extracted 
with 10 ml 60% methanol. A Symmetry ShieldTM RP18 column and a Waters Alliance HPLC 
System (2690 Separation Module, 996 Photodiode Array Detector), all Waters Corporation, 
Millford, Massachusetts, USA, were used. Methanol 60% (v/v) with a flow rate of 0.3 ml/min was 
the mobile phase, and the injection volume of the samples was 20 µl. Quantification of TACA 
occurred at 240 nm. The limit of quantification (LOQ) was 100 ng/ml (corresponding to 
27 ng/cm2), the limit of detection (LOD) 35 ng/ml (9 ng/cm2). 
                                                     
13
 The detailed protocol of application, tape stripping, and occlusion is displayed in the appendix (chapter 11.3.1). 
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8.2.6. Data analysis 
Sample size 
The method deviation (intra-individual standard deviation) had been determined previously and 
was ± 40%. To provide a power of 50% in detecting a 50% difference between the 2 treatments 
groups at the 5% significance level, a total of 5 volunteers were needed according to the two-
sided t-test nomogram for paired values after logarithmic transformation [260], and were thus 
enrolled in each experiment.  
Quantitative TACA penetration into stratum corneum 
The TACA amounts on each tape (area 5.6 cm2) of each skin site were added up to the total 
TACA amount penetrated into stratum corneum, which was evaluated statistically. The 
significance of differences between the treatment groups at each time was tested after 
logarithmic transformation in a multifactor variance analysis (ANOVA) [30] with the following 
factors: volunteer, time, application and the interaction time/application. For the factors 
displaying a statistical significance in ANOVA (p < 0.05), a post-hoc comparison was performed 
with the least significance difference test (LSD test). Two different types of evaluation were 
performed: the evaluation of a) the total TACA amount within stratum corneum (sum of TACA 
amounts on all tapes) and of b) the TACA amount without tapes 1 to 3 (on which formulation 
excess, e.g. TACA crystals, could be located). Statgraphics PLUS 5 software (Manugistic, Inc., 
Rockville, Maryland, USA) was used to conduct the analysis of the trial. 
Qualitative TACA penetration into stratum corneum: penetration profiles and 
photographic recording 
To visualize the drug distribution within the stratum corneum, TACA amounts quantified on each 
tape were correlated to the tape number and to the depth of penetration into the stratum 
corneum. Removal of the entire stratum corneum is a prerequisite for the profile calculation, 
since the sum of corneocyte (pseudo-)absorbance on one skin site represents 100% stratum 
corneum. Thus, the relative amount of stratum corneum removed by each tape can be 
calculated from the individual absorbance values as fully described in Jacobi et al. [126, 251]. 
The stratum corneum removal pattern was photographically documented. All photographs were 
taken at a standard camera-object distance. 
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8.3. Results  
8.3.1. Demographics of the subjects 
A total of 10 healthy adult volunteers (5 male and 5 female) aged 23-30 years (mean 25) were 
recruited and finished the study. Five volunteers were assigned to each experiment (Fig. 8-1). 
The tape stripping experiments were conducted from April 2004 to July 2004 in Basel. No skin 
damage was observed at the final dermatological investigation. 
8.3.2. Quantitative TACA penetration into stratum corneum 
Experiment 1: Effect of Pre-Occlusion 
Pre-occlusion showed no effect on the TACA penetration into the stratum corneum (Fig. 8-2, left 
side)14. The penetrated TACA amount decreased significantly with time after both application 
modes, with and without pre-occlusion (p < 0.001). At 0.5 h, mean TACA amounts of 
66 ± 28 µg/cm2 and 67 ± 37 µg/cm2 were quantified within the stratum corneum of normal and 
pre-occluded skin, respectively. At 4 h, mean values of 48 ± 17 µg/cm2 and 43 ± 10 µg/cm2 
were recovered on normal and pre-occluded skin, and at 24 h values of 29 ± 12 µg/cm2 and 
18 ± 10 µg/cm2, respectively.  
By excluding tapes 1-3, the TACA amounts were approximately halved: at 0.5 h, mean values 
of 30 ± 12 µg/cm2 and 35 ± 16 µg/cm2 were obtained on normal and pre-occluded skin, 
respectively; at 4 h 25 ± 8 µg/cm2 and 24 ± 8 µg/cm2; and at 24 h 20 ± 9 µg/cm2 and 
12 ± 7 µg/cm2. 
Independently of the application mode (with/without pre-occlusion), 8-13% of the applied TACA 
amount was recovered in the gauzes used to protect the treated skin sites15. 
Statistical evaluation by ANOVA displayed a significant difference only for the factor time 
(p < 0.001), whereas the factors volunteer, application, and the interaction time/application 
showed no influence.  
                                                     
14
 The data table as well as the statistical evaluation are displayed in the appendix (chapter 11.3.3 and 11.3.4). 
15
 The mass balance of experiment 1 is displayed in the appendix (chapter 11.3.8). 
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Experiment 2: Effect of Post-Occlusion  
Post-occlusion induced a marked accumulation of TACA within the stratum corneum. The 
amount of TACA recovered in the stratum corneum in case of post-occlusion showed a highly 
significant difference (p < 0.01) compared to non-occluded skin (Fig. 8-2, right side)16. 
Over time, the TACA amount within the stratum corneum remained constant after both 
application modes: after normal application (without occlusion), the values amounted to 
40 ± 28 µg/cm2 and 42 ± 14 µg/cm2 at 4 h and 24 h, respectively. In case of post-occlusion, a 
twofold higher TACA amount was quantified within the stratum corneum, with values amounting 
to 80 ± 32 µg/cm2 and 79 ± 33 µg/cm2 at 4 h and 24 h, respectively.  
A similar trend was also seen after discarding tapes 1-3: after normal application, TACA 
amounts of 21 ± 12 µg/cm2 and 24 ± 11 µg/cm2 were quantified at 4 h and 24 h, vs. TACA 
amounts of 37 ± 13 µg/cm2 and 42 ± 28 µg/cm2 after application followed by post-occlusion. 
The TACA amount extracted from the gauzes displayed values of 11% of the applied dose after 
normal application and 3-7% after application under occlusion17. 
Fig. 8-2: Total TACA amount penetrated into the stratum corneum after application of 100 µg/cm2 TACA in 
acetone under normal vs. pre-occluded conditions (experiment 1) and under normal vs. post-occluded 
conditions. Mean and standard deviation are displayed.  
 
                                                     
16
 The data table as well as the statistical evaluation are displayed in the appendix (chapter 11.3.6 and 11.3.7). 
17
 The mass balance of experiment 2 is displayed in the appendix (chapter 11.3.9). 
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8.3.3. Qualitative TACA penetration into stratum corneum: penetration profiles 
and photographic recording 
Two exemplar penetration profiles of TACA into the stratum corneum at 24 h after normal and 
post-occluded application are depicted in Fig. 8-318. The profiles show that TACA permeated 
the stratum corneum and reached deeper tissues. The higher TACA amount retained within the 
stratum corneum after application under post-occlusion is clearly visible. 
The increased hydration of the skin due to occlusion caused a decreased corneocyte cohesion. 
Fewer tapes were required to remove the entire stratum corneum of occluded skin sites, since 
larger amounts of corneocytes were removed on single tapes. This happened in both 
experiments 1 and 2 after long-time occlusion and tape stripping following within 0.5 h after 
removal of the occlusive wrap. The removal of larger amounts of corneocytes mostly occurred 
between tapes no. 5 and 10 (Fig. 8-4).  
Fig. 8-3: Typical penetration profiles of TACA into the stratum corneum 24 h after normal application and after 
application followed by occlusion in the same volunteer. TACA amounts on each tape (horizontal grey or black 
bars) are correlated to the tape number (right scale) and to the depth of penetration into the stratum corneum, 
displayed as percentage of the total stratum corneum thickness (left scale). 
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 The penetration profiles for each volunteer are displayed in the appendix (chapter 11.3.2 for experiment 1 and chapter 
11.3.5 for experiment 2). 
8. Project III: Effect of occlusion 
Carolina Pellanda  Page 93 of 186 University of Basel, 2006 
 
 
Fig. 8-4: Photographs of stripped tapes. Long-time occlusion induced a loosening of the stratum corneum 
structure. Larger amounts of corneocytes (skin sheets) were removed on single tapes. (A) 23rd tape stripped 
from a non-occluded skin site: a “normal”, homogenous amount of skin is removed. (B) 4th to 6th tape stripped 
from a skin site occluded for 24 h: larger amounts of corneocytes are removed as sheets on single tapes. This 
artifact due to occlusion does not disturb the assessment of topical bioavailability provided that the entire 
stratum corneum of one skin site is sampled. 
8.4. Discussion 
In the present experiments, the topical bioavailability of TACA was described by the TACA 
penetration into stratum corneum over time. Because the stratum corneum is the rate limiting 
barrier of the skin, the TACA amount within the stratum corneum can be directly correlated to 
the amount of drug at the target site (viable epidermis, dermis). Two different modes of 
occlusion were investigated: pre-occlusion (occlusion before TACA application) and post-
occlusion (occlusion after TACA application). 
Experiment 1 (pre-occlusion) investigated the application on occluded and thus more hydrated 
skin, as it is the case after an extensive bath. Pre-occlusion did not show any effect on the 
TACA penetration into stratum corneum compared to normal application. Agner and Serup 
observed that the effect of occlusion on the stratum corneum hydration is transitory, 
transepidermal water loss (TEWL) returning to baseline values within 0.5-1 h after removal of 
the occlusive device [263]. Accordingly, in our experiment 1, larger amounts of corneocytes 
(skin sheets) due to the increased skin hydration and to the disruption of the stratum corneum 
were only observed at the first stripping time (0.5 h), when the occlusive wrap had just been 
removed. At later times (4 h and 24 h), the corneocyte amount removed by the tapes was 
homogeneous.  
The disruptive effect of water on the stratum corneum structure was especially increased after 
about 5-10 tapes, whereas the outer and the innermost stratum corneum seemed to be less 
affected. Accordingly, swelling of corneocytes and formation of water pools between the cells in 
the middle stratum corneum could be observed microscopically by Bouwstra et al. after 24 h 
hydration of stratum corneum isolated from dermatomed skin [70]. 
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Experiment 2 (post-occlusion) investigated the application followed by occlusion, which can be 
clinically useful to improve the effect of topical corticosteroids in severe forms of skin diseases. 
A “physiological” occlusion is possible as well in intertriginous skin areas, and also certain 
vehicles (e.g., ointments) can be occlusive. Post-occlusion enhanced the TACA retention into 
the stratum corneum by a factor of 2, favoring the development of a drug reservoir. The TACA 
amount retained by the stratum corneum remained constant between 4 h and 24 h and still 
amounted to 80% of the applied dose after 24 h post-occlusion. The amount of drug quantified 
in the gauze used to protect the treated sites until tape stripping was slightly lower after 
occlusion, showing that occlusion probably promoted the dissolution of drug crystals located on 
the skin surface and drug penetration into the skin. 
The post-occlusion results obtained in our investigations agree with preliminary observations of 
Carr and Wieland [152]. They investigated the percutaneous penetration of 14C-labeled TACA 
applied in 95% ethanol on a single male volunteer. After one day, 81% of the applied dose was 
found within the stratum corneum after occlusion vs. 38% without occlusion. Our trial performed 
with a larger number of volunteers and a different volatile vehicle yielded similar results. The 
extent of the topical bioavailability of TACA was significantly enhanced by post-occlusion, 
whereas the release rate from the stratum corneum was delayed because of the temporary 
accumulation of TACA within the hydrated stratum corneum (reservoir formation). 
The standardized tape stripping technique in combination with the quantification of corneocytes 
by VIS-spectroscopy and the quantification of TACA by HPLC has shown to be adequate for the 
quantification of TACA within the stratum corneum. This technique is not influenced by artifacts 
due to occlusion, and does not require radiolabeling of the drug. 
 
8.5. Conclusions 
Pre-occlusion showed no effect on the topical bioavailability of TACA in stratum corneum. 
Contrariwise, occlusion after application enhanced the TACA penetration into stratum corneum 
by a factor of 2, favoring the development of a drug reservoir. 
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9. Project IV:              
Efficacy of low-dose corticosteroids in atopic dermatitis 
An abbreviated version of the findings of this project has been published: Pellanda C, Weber M, 
Bircher A, Surber C. Low-dose triamcinolone acetonide in the phytocosmetic Lichtena® does 
reduce inflammation in mild to moderate atopic dermatitis. Dermatology 2005; 211(4): 338-340. 
The original publication is available at www.karger.com/drm. 
 
 
Abstract 
Background: Previously, we reported the efficacy of Lichtena® – a phytocosmetic cream 
product – in atopic dermatitis (AD). Later, fraudulent triamcinolone acetonide (TACA) was 
detected at low doses (16 to 40 µg/g) in Lichtena®. This suggested that TACA may be effective 
at much lower concentrations than used in commercial products (1000 µg/g). 
Objectives: To investigate the efficacy in AD of low-dose TACA in Lichtena® compared to plain 
Lichtena®. 
Methods: Fourteen patients presenting symmetrical lesions of AD were treated for one month 
with Lichtena® plus 25 µg/g TACA (=verum) and plain Lichtena® (=placebo). The severity of the 
lesions was assessed by SCORAD on day 0 (=baseline), 7, 14, and 28.  
Results: Already after 1 week treatment, significant SCORAD differences to baseline were 
observed comparing verum and placebo treated areas. No improvement was observed using 
plain Lichtena®. 
Conclusions: TACA displayed a significant improvement of AD at doses up to 40 times lower 
than in commercial products. 
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9.1. Introduction 
Atopic dermatitis is a chronic inflammatory pruritic skin disease that is often associated with 
elevated serum IgE levels and a personal or familial history of type I allergies, allergic rhinitis, 
and asthma. The relapsing course of atopic dermatitis requires both preventive and 
therapeutical measures. In the last years, new therapeutical approaches have been described, 
but topical corticosteroid therapy still remains the standard to which other treatments are 
compared [264, 265]. 
Concern and almost phobic fear about the side effect risk of corticosteroids, their chronic use, 
relapses after corticosteroid withdrawal, and lack of information leave more and more patients 
disappointed by steroid therapy [266, 267]. Alternative therapies such as phytotherapy [268, 
269], traditional chinese herbal medicine [270], or complementary therapies [271] are often 
appreciated by patients because of their natural ingredients or the presumed absence of 
adverse effects. Yet, it has been repeatedly shown that some of these alternatives may also 
show potential adverse effects [272]. Cases are known where remedies marketed as “natural” 
were adulterated with non-declared corticosteroids, thus creating a more critical situation 
because of the unawareness of corticosteroid presence [273-279]. 
Previously, we have studied the apparent benefit of Lichtena®, a phytocosmetic cream marketed 
as a skin care product in some European countries and extensively used for its putative anti-
inflammatory activity for different types of skin disorders including atopic dermatitis in children 
[280]. In a placebo controlled double-blind study including 21 patients (age 2 to 56 years) with 
symmetrical atopic eczema on the extremities, a marked reduction on the verum side was 
observed [281]. Later, triamcinolone acetonide (TACA), a moderately potent corticosteroid, was 
identified in Lichtena® at low concentrations ranging from 16 to 40 µg/g (mean 27) [282], 
whereas commercial TACA preparations typically contain 1000 µg/g. Meanwhile, measures 
have been established to control the correct composition of Lichtena®, which has been cleared 
of any corticosteroids (Table 9-1). 
The reported efficacy of the adulterated Lichtena® cream leads to the presumption that 
commercially available corticosteroid formulations may be overdosed and would be effective at 
lower concentrations. We therefore performed a second study, described in this paper, with the 
aim to investigate the effect of a low-dose TACA addition in Lichtena® (verum) compared to 
plain, corticoid-free Lichtena® (placebo). 
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Table 9-1: Ingredients of Lichtena®, their function, and their allergenic potential. CA: contact allergen, 
PA: photo-contact allergen, IR: toxic irritative agent. 
Ingredients Function Allergenic potential 
Water Vehicle  
Peg 8 Beeswax Emollient, emulsifier, film former  
Caprylic-capric triglyceride Emollient, solvent  
Isostearyl isostearate Emollient, binding agent  
Octilmethoxycinnamate  Sunscreen agent (UVB) PA 
Buthylmethoxydibenzoilmethane Sunscreen agent (UVA) PA, CA 
Butyrospermum parkii Emollient  
Sorbityl furfural Antioxidant  
Tocopherol Antioxidant CA 
Glycerrhetinic acid Adjuvant, moisturizer  
Bisabolol Additive, penetration enhancer  
Chamomilla recutita Anti-inflammatory agent, emollient CA 
Allantoin Epithelialization and keratolysis enhancer  
Beta-sitosterol Emulsion stabilizer  
Prunus armeniaca oil Emollient  
Lactic acid Moisturizer, pH-regulator  
Sodium (and) TEA lactate Moisturizer, buffer CA, IR 
Urea Moisturizer, penetration enhancer  
Serine Additive  
Glycerine Moisturizer, solvent  
Sorbitol Moisturizer  
Laurylaminopropylglycine Surface-active agent  
Lauryldiethylendiaminoglycine Adjuvant  
Lecithin Emollient, emulsifier  
Carbomer Emulsion stabilizer, viscosity control agent  
Disodium EDTA Preservative, viscosity control agent  
Methyl-ethyl-propyl-buthyl-paraben Preservative CA 
Ascorbyl palmitate Antioxidant  
Methylchloroisothiazolinone Preservative CA, IR 
Magnesium chloride (and) nitrate Antibacterial agent  
Methylisothiazolinone Preservative CA, IR 
Triethanolamine Buffer CA, IR 
Sodium dehydroacetate Preservative  
Parfum Additive  
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9.2. Subjects and methods  
9.2.1. Subjects 
Patients were recruited at the Allergological and Dermatological outpatient clinic of the 
University Hospital of Basel, Switzerland. A total of 14 patients (9 females and 5 males) aged 3 
to 41 years (median 20), who presented symmetrical lesions of subacute or chronic atopic 
dermatitis of the extremities were enrolled in the study. Atopic skin diathesis was diagnosed 
according to Hanifin and Rajka [283]19 and ranged from 7 to 23 (median 16). Exclusion criteria 
were allergy to Lichtena® or TACA, treatment with systemic corticosteroids, long-term treatment 
with topical steroids, immunosuppression, severe secondary diseases, pregnancy, or breast 
feeding.  
9.2.2. Study design 
A double-blind, vehicle-controlled, randomized explorative study with half-side comparison was 
performed. The study was approved by the local ethical committee and the patients signed a 
written consent for participation. The patients underwent a one-week run-in phase without 
specific therapy, and were then treated twice a day for one month at the corresponding 
symmetrical locations with a) Lichtena to which 25 µg/g of TACA had been added (= verum), 
and b) Lichtena® without any supplement (= placebo). The creams were randomly allocated to 
the left or right side in a double-blinded manner. The randomization was performed at the 
Hospital Pharmacy, Basel, Switzerland using a random number generator, and the number 
sequence was concealed until the end of the study. The Lichtena cream (placebo) was 
purchased from UCB Pharma, Italy. The Lichtena cream with added TACA (verum) was 
prepared at the Hospital Pharmacy, Basel, Switzerland according to GMP-Guidelines. Both 
preparations were filled in identical tubes and blinded. 
The patients were examined on day 0, 7, 14 and 28 (± 2 days) after beginning of the therapy. 
The severity of the lesions was assessed on each symmetrical body side separately by 
SCORAD [284] at each medical examination20 and photographs of the lesions were taken. 
SCORAD (SCORing Atopic Dermatitis) is a score that combines A) the extent of the lesions; B) 
the intensity of six clinical signs: erythema, edema/papules, oozing/crusts, excoriation, 
lichenification, and dryness, ranging from 0 to 3 (0 = absent, 1 = mild, 2 = moderate, 
3 = severe); and C) the subjective symptoms pruritus and sleep loss ranging from 0 to 10 on a 
visual analogue scale. The total score is defined as: SCORAD = (A/5) + (7 B/2) + C. 
                                                     
19
 The criteria for atopic skin diathesis assessment are displayed in the appendix (chapter 11.4.1). 
20
 The form for SCORAD assessment is displayed in the appendix (chapter 11.4.2). 
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In addition, the patients had to record in a diary the daily use of cream (assessed as finger tip 
units FTU [285]), the efficacy of the creams (assessed as itching, erythema/papules, exudation), 
adverse effects (prickling/pricking, erythema after application, others), overall troubles 
(insomnia, well-being, subjective improvement of the skin), and the use of rescue medication. 
Rescue medication against itching consisted of cetirizine 10 mg (Zyrtec drops or tablets). In 
case of aggravation of the skin lesions, a 0.25% prednicarbate cream (Prednitop Cream) could 
be applied after medical consultation. To assess the allergenic potential of the cream, a patch 
test with the European series of contact allergens and a specific array of all Lichtena 
ingredients was performed 2-4 weeks after the end of the study21.  
9.2.3. Comparison of the efficacy of the two different treatments (verum/placebo) 
The assessment of the efficacy of the different treatments (verum, placebo) over time was 
defined as primary outcome of the study. SCORAD differences at day 7, 14, and 28 to the 
baseline (= day 0) were calculated for verum and placebo separately and evaluated statistically 
using the Wilcoxon matched pairs signed rank sum test at the 5% level of significance (2-sided 
analysis). In addition, a modified objective SCORAD was calculated omitting the subjective 
symptoms C: SCORADobjective= (A/5) + (7 B/2), which was evaluated likewise with the Wilcoxon 
matched pairs signed rank sum test. Statgraphics PLUS 5 software (Manugistic, Inc., 
Rockville, Maryland, USA) was used to conduct the analysis of the trial. 
9.2.4. Efficacy within one treatment arm after one month therapy (verum/placebo 
separately)  
As a secondary outcome, to assess the efficacy of the one-month treatment compared to the 
baseline for verum and placebo separately, the SCORAD of day 28 was compared to the 
SCORAD of day 0 in a Wilcoxon matched pairs signed rank sum test (5% level of significance). 
The same analysis was carried out with SCORADobjective.  
9.2.5. Intensity criteria and pruritus 
The intensity of the six clinical signs erythema, edema/papules, oozing/crusts, excoriation, 
lichenification, and dryness as well as the subjective symptom pruritus were plotted in individual 
score-time curves. Significant influence of the one-month therapy on the different criteria was 
tested for verum and placebo separately in a Wilcoxon matched pairs signed rank sum test (5% 
level of significance) using the score pairs of day 28 / day 0. 
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 The patch-test ingredients are listed in the appendix (chapter 11.4.3). 
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9.3. Results 
9.3.1. Demographics of the subjects 
Of the 14 patients enrolled, 12 finished the study. Two drop outs (one male aged 3 years, one 
female aged 18) were recorded because of irregular attending the medical examinations and 
their data were excluded in the analysis. The medical examinations began in February and 
ended in July.  
In addition to atopic dermatitis, 4 patients were suffering from asthma and 8 relatives were 
likewise atopic, suffering from atopic dermatitis, eczema, asthma, or allergic rhinitis. Clinical 
severity of atopic dermatitis, expressed by SCORAD, ranged from 5 to 69 on the verum side 
and from 12 to 77 on the placebo side during the whole study. The data are summarized in 
Table 9-2 22. 
Table 9-2: Summary of total SCORAD recorded during the investigation period, SCORAD differences of each 
treatment day to the baseline, SCORADobjective, and SCORADobjective-differences. To assess significant differences 
between the two treatments, the respective SCORAD differences to baseline were compared in a Wilcoxon 
matched pairs signed rank sum test at the 5% level of significance. The asterisk after the p-value denotes a 
statistically significant (*p < 0.05) or highly significant (**p < 0.01) difference in treatment compared to the 
baseline. 
  
Verum 
(Lichtena®+TACA)  
Placebo 
(Lichtena®)   
  Mean (SD) Median Confidence 
Interval (95%) 
 Mean (SD) Median Confidence 
Interval (95%) 
 Mean 
Difference (SD) 
P-value 
SCORAD          
day 0  43.1 (12.9) 40.1 35.8 to 50.3  42.2 (12.7) 40.1 35.0 to 49.4 -0.9 (2.2)  
day 7  34.5 (13.2) 30.0 27.0 to 42.0  44.2 (11.3) 42.0 37.8 to 50.6 9.8 (12.5)  
day 14  29.8 (17.3) 25.8 20.0 to 39.6  44.1 (15.8) 41.5 35.2 to 53.0 14.3 (18.1)  
day 28  25.8 (18.5) 21.5 15.3 to 36.2  41.4 (20.5) 38.5 29.8 to 52.9 15.6 (15.0)  
SCORAD differences to baseline (day 0)       
day 0  baseline         
day 7  -8.6 (6.6) -9.0 -12.3 to -4.8  -2.0 (11.7) 0.0 -4.6 to 8.6 10.6 (12.3) 0.04* 
day 14  -13.3 (12.1) -10.5 -20.1 to -6.5  1.9 (16.5) -1.0 -7.4 to 11.3 15.2 (17.3) 0.02* 
day 28  -17.3 (10.2) -16.0 -23.1 to -11.5  -0.8 (19.4) 7.8 -11.8 to 10.1 16.5 (15.2)   0.01** 
SCORADobjective           
day 0  36.3 (10.9) 33.4 30.1 to 42.5  35.4 (10.8) 33.4 29.3 to 41.5 -0.9 (2.2)  
day 7  29.9 (11.3) 26.4 23.5 to 36.3  38.7 (10.7) 36.8 32.6 to 44.7 8.8 (11.1)  
day 14  24.9 (13.6) 23.8 17.2 to 32.7  37.2 (12.7) 35.1 30.0 to 44.4 12.3 (14.9)  
day 28  21.4 (15.6) 18.5 12.6 to 30.3  35.4 (17.9) 36.0 25.3 to 45.6 14.0 (13.1)  
SCORADobjective-differences to baseline (day 0)     
day 0  baseline         
day 7  -6.4 (3.9) -7.0 -8.6 to -4.2  3.2 (9.4) 5.3 -2.1 to 8.5 9.6 (10.9) 0.04* 
day 14  -11.4 (9.3) -10.5 -16.7 to -6.1  1.8 (12.7) 0.0 -5.4 to 8.9 13.1 (14.1) 0.02* 
day 28  -14.9 (8.6) -12.3 -19.7 to -10.0  0.0 (15.9) 5.3 -9.0 to 9.0 14.9 (13.2) 0.008** 
                                                     
22
 The data sheets of the single volunteers are displayed in the appendix (chapter 11.4.4). 
9. Project IV: Efficacy of low-dose corticosteroids in atopic dermatitis 
Carolina Pellanda  Page 101 of 186 University of Basel, 2006 
-20
-15
-10
-5
0
5
10
15
20
Di
ffe
re
n
ce
 
o
f S
CO
RA
D
 
to
 
ba
se
lin
e
day 7 day 14 day 28
Treatment effect over time (SCORAD)
Placebo (plain Lichtena)
Verum (Lichtena with TACA)
****
9.3.2. Comparison of the efficacy of the two different treatments (verum/placebo) 
SCORAD at day 0 (baseline) was comparable and ranging from 25 to 69 for the two treatment 
arms (verum, placebo). After beginning the therapy, the SCORAD values of the verum-treated 
side constantly decreased (median SCORAD at day 0 / 7 / 14 / 28 displaying values of 40 / 30 / 
26 / 22 respectively). Contrariwise, the SCORAD values on the placebo-treated side persisted 
near the baseline and were slightly increased at the end of the therapy (median SCORAD 
ranging from 39 to 42 during the whole month). Statistical analyses of SCORAD differences to 
baseline resulted in a significant difference between the side treated with Lichtena® plus TACA 
(verum) compared to plain Lichtena® (placebo) already after 1 week treatment (median 
difference of 9, p = 0.04). This significant difference persisted at day 14 (median 11, p = 0.02) 
and became highly significant at the end of the therapy (median 16 at day 28, p = 0.01) 
(Fig. 9-1, left diagram). 
By omitting the criterion “subjective symptoms” in the calculation of SCORAD 
(= SCORADobjective), it is possible to evaluate the mere objective criteria. The evaluation of 
SCORADobjective  yielded similar results: the difference between placebo and verum treatment 
became statistically different at day 7 (p = 0.04), stayed significant at day 14 (p = 0.02), and 
became highly significant at day 28 (p < 0.01). An additional slight impairment of the lesions 
was visible after one week on the placebo treated side (Fig. 9-1, right diagram). 
 
Fig. 9-1: Median SCORAD differences to baseline (day 0, beginning of therapy) after treatment during 7, 14 and 
28 days with placebo (plain Lichtena®) and verum (Lichtena® with TACA) (diagram on the left) and, analogously, 
median SCORADobjective-difference to baseline (diagram on the right). The verum-treated side shows an 
improvement of the lesion, whereas the placebo-treated side displays an impairment after one month therapy. 
The comparison of the two treatments (verum/placebo) shows a statistically significant difference on day 7 
(p = 0.04*), day 14 (p = 0.02*), and a highly significant difference at the end of the therapy on day 28 (p ≤ 0.01**) 
for both SCORAD and SCORADobjective.  
 
-20
-15
-10
-5
0
5
10
15
20
Di
ffe
re
n
ce
 
o
f S
CO
RA
D
(o
bj
e
ct
iv
e
) t
o
 
ba
se
lin
e
day 7 day 14 day 28
Treatment effect over time (SCORADobjective)
Placebo (plain Lichtena)
Verum (Lichtena with TACA)
****
9. Project IV: Efficacy of low-dose corticosteroids in atopic dermatitis 
Carolina Pellanda  Page 102 of 186 University of Basel, 2006 
Median SCORAD
0
5
10
15
20
25
30
35
40
45
50
day 0 day 7 day 14 day 28
Placebo (plain Lichtena)
Verum (Lichtena with TACA)
9.3.3. Efficacy within one treatment arm after one month therapy (verum/placebo 
separately) 
After beginning the therapy, the SCORAD values of the verum-treated side decreased 
significantly (p < 0.01, day 28 vs. day 0). Median SCORAD at day 0, 7, 14, and 28 displayed 
values of 40, 30, 26, and 22, respectively (Fig. 9-2, left diagram). Contrariwise, the SCORAD 
values on the placebo-treated side persisted near baseline until the end of the therapy (median 
SCORAD ranging from 39 to 42 during the whole treatment period, p > 0.05). Similar results 
were recorded with SCORADobjective-values (Fig. 9-2, right diagram). 
 
Fig. 9-2: Median SCORAD (left diagram) and median SCORADobjective (right diagram) during the one-month 
§treatment with placebo (plain Lichtena®) and verum (Lichtena® with TACA). 
9.3.4. Intensity criteria and pruritus 
The time response of the individual intensity factors erythema, edema/papules, oozing/crusts, 
excoriation, lichenification, and dryness as well as the subjective symptom pruritus are depicted 
in Fig. 9-3 and Fig. 9-4. The intensity factors scores range from 0 to 3 (0 = absent; 1 = mild; 
2 = moderate; 3 = severe), and the pruritus score ranges from 0 to 10 (0 = absent; 10 = severe).  
The analysis of the intensity factors separately showed as well a superiority of the verum 
treatment. On the verum-treated side, the one-month therapy resulted in a significant decrease 
of the score for the following criteria: erythema (p = 0.02), lichenification (p = 0.02), and dryness 
(p < 0.01), when day 28 was compared to day 0. The severity of the criterion edema/papules did 
not show any statistically significant decrease (p > 0.1), and the decrease in the severity of 
excoriation just showed a non-significant trend (p = 0.06). The criterion oozing/crusts was not 
present in our patients. No improvement was recorded on the placebo-treated side (p > 0.9). 
The criteria erythema and edema/papules even showed a temporary impairment during the 
therapy.  
Similarly, a highly significant decrease of the pruritus intensity was recorded on the verum-
treated side (p = 0.008), whereas no difference was reported on the placebo side (p > 0.1). The 
score showed an initial median value of 6 at day 0 and a lower median value of 1 (verum) and 
4.5 (placebo) at day 28. 
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Fig. 9-3 : Progression of the intensity criteria a) erythema, b) edema/papules, c) oozing/crusts, d) excoriation, e) 
lichenification, f) dryness during the one-month therapy with Lichtena®+TACA (verum, black lines) and plain 
Lichtena® (placebo, grey lines). The scores range from 0 to 3 (0=absent; 1=mild; 2=moderate; 3=severe) and the 
median values are depicted. The asterisks near the curves on the verum side denote a statistically significant 
(p < 0.05*) respectively highly significant (p < 0.01**) decrease of the intensity score between day 28 and day 0. 
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Fig. 9-4 : Progression of the criterion pruritus 
during the one-month therapy with 
Lichtena®+TACA (verum, black lines) and plain 
Lichtena® (placebo, grey lines). The scores 
range from 0 to 10 (0=absent; 10=severe) and 
the median values are depicted. The asterisks 
denote a statistically highly significant 
(p = 0.008**) decrease of the pruritus score on 
the verum side between day 28 and day 0. 
 
9.3.5. Rescue medication 
The use of additional topical corticosteroids (prednicarbate) in case of aggravation of the skin 
lesions was low: three patients applied prednicarbate 2-3 times and one patient 7 times during 
the whole month on both extremities. The use of cetirizine in case of itching was higher: two 
patients took 1 tablet once a day during the whole month, seven patients took it occasionally (a 
total of 3-15 tablets over the whole month), and three patients did not use cetirizine at all. 
9.3.6. Adverse effects and subjective evaluation 
Both formulations were well tolerated and no adverse effects were recorded. The qualities of 
quick skin penetration, good consistency, and smoothness of the creams were reported by the 
patients. Slight burning after application was recorded by 3 patients (for both placebo and 
verum). The duration of hydration and lipidization of the lesions was reported to be 1-8 h (mean 
6 h). The amount of cream used was expressed as finger tip unit (FTU). The same amount of 
cream was applied on each side (1-2 FTU, depending on the extension of the lesions). 
9.3.7. Patch test 
Of the 12 patients, 10 accomplished the patch test. A total of 4 patients did not show any 
positive tests. Within the potential allergen ingredients of Lichtena®, the following appeared 
positive: Fudji perfume (2 patients), EDTA (1 patient) and Apifil (1 patient). The following 
standard allergens also gave positive reactions: Nickel(II)sulfate, Lyral, Thiuram-Mix (1 case 
each) and Sorbitan sesquioleate, Iodopropinylbutylcarbamate (2 cases each). 
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9.4. Discussion 
Plain Lichtena® had no significant influence on the severity of atopic dermatitis measured by 
SCORAD. Contrariwise, the addition of TACA in a concentration which is 40 times lower than 
typical therapeutical corticosteroid concentrations (25 µg/g vs. 1000 µg/g) reduced the severity 
of the lesions.  
Particularly, the signs indicating subacute or chronic inflammation displayed a marked 
improvement. These included erythema, lichenification, and dryness (Fig. 9-3a, e, f). Criteria 
representing acute lesions such as oozing and crusts were not present in our patients 
(Fig. 9-3c). While the decrease of the factors edema/papules and excoriation was not 
significant, complete remission indicated by a zero score at day 28 was recorded for their 
median score (Fig. 9-3b, d) as well as for the factor erythema (verum-treated side). For the 
factor edema/papules this may indicate that the initial score was already quite low (median 
score at day 0 = 1 = mild disorders), the following reduction being not large enough to result in a 
statistically significant decrease. Subjective symptoms like pruritus were as well successfully 
improved with the verum treatment (Fig. 9-4), thus contributing to an increased well-being of the 
patients. 
The use of rescue medication as a marker of unsuccessful therapy was quite low, especially the 
use of the additional topical corticosteroid prednicarbate. The consequent intake of cetirizine 
once a day by two patients indicates that its relative high use may be due to additional troubles 
like allergic rhinitis, and not to pruritus alone. 
The additional use of emollients and skin care products is considered to be standard therapy for 
the treatment of atopic dermatitis, but only few studies have tried to assess the effects of 
emollients alone on the severity of atopic dermatitis [286-288]. Interestingly, even the score 
“dryness” does not show a significant reduction after treatment with plain Lichtena®. During an 
acute episode, the simple use of an emollient does not seem to be sufficient to treat the lesions. 
A more aggressive therapy is required, emollients playing a decisive role later on in the skin 
care, particularly to prevent relapses. 
The presence of several allergens in Lichtena® represents an additional exposure of the already 
affected skin to unnecessary irritations. In the patch test, two patients showed a positive 
reaction to Fudge perfume, EDTA, and Apifil, all ingredients of Lichtena®. 
Our trial confirms that Lichtena® alone has no anti-inflammatory activity after topical application 
on atopic dermatitis lesions. However, the addition of TACA in a concentration which is 40 times 
lower than typical therapeutic corticosteroid concentrations reduces inflammation in mild to 
moderate eczema. These findings would justify the use of much lower corticosteroid 
concentrations than typically marketed and used today, particularly in subacute and chronic 
eczema and in children. This is sometimes overcome by dispensing brand corticosteroids which 
are “diluted” by the addition of vehicle or other agents. This extemporaneous dilution of topical 
corticosteroid formulations is intended to reduce the risk of adverse effects while maintaining 
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efficacy. However, improper dilution may compromise several factors such as stability (chemical 
and microbiological), rheology, and bioavailability, thus diminishing or even completely 
deactivating the therapeutical activity of the formulation (compare Table 9-3) [289-292]. 
Table 9-3: Consequences and risks due to improper dilution of drug formulations. 
Factors that are affected by dilution of drug formulations 
Bioavailability Concentration, state of solution/dispersion of the drug in the vehicle, diffusion 
coefficient, and partition coefficient all influence the optimum release of a drug out 
of the formulation. Change in any of these factors may lead to an ineffective 
formulation. 
Chemical stability Change of pH, as well as dilution of antioxidants and preservatives may lead to 
chemical instability and enhance chemical degradation. 
Toxicology and safety Drug degradation can lead to toxic degradation products. 
Interactions Drug-drug interactions but also drug-adjuvant interactions lead to chemical 
instability and can affect the efficacy of the formulation (both increase and decrease 
of the effect possible). 
Microbiological quality Dilution of preservatives below the effective concentration can lead to 
microbiological contamination, which leads to chemical degradation and iatrogenic 
contamination of the treated skin sides.  
Rheology Change of the composition of a formulation changes the rheology of the product 
and its cosmetic elegance.  
Economic aspects Extemporaneous compounding is generally expensive and leads to a higher price of 
the therapy. 
 
Yet, the popularity of diluted corticosteroid formulations reveals the desire and the need for 
properly manufactured corticosteroid formulations to be available in much lower concentrations 
for some clinical situations, particularly for chronic skin disorders such as atopic dermatitis. Our 
trial shows that topical preparations of corticosteroids are possibly overdosed to achieve the 
desired therapeutic effect. Therefore, dose-finding studies should be an integral and important 
part of the clinical evaluation of topical therapeutics. 
 
9.5. Conclusions 
This study showed no anti-inflammatory properties of Lichtena®, a phytocosmetic cream 
marketed as a skin care product and extensively used for its putative anti-inflammatory activity 
for different types of skin disorders including atopic dermatitis in children. However, the addition 
of a low dose (40 times lower than in typical therapeutical concentrations) of the corticosteroid 
TACA to Lichtena® induced an improvement of the eczematous lesions. 
These findings indicate that some corticosteroids may already be effective at much lower 
concentrations than usually used therapeutically, and that marketed formulations may contain a 
much higher concentration of corticosteroids than necessary. 
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10. Final conclusions and perspectives 
The present thesis shows that the investigation of the topical bioavailability of TACA as model 
corticosteroid can successfully be performed using the DPK approach. The basic principle is the 
quantification of drug amounts penetrated into the stratum corneum over time. The analysis of 
the stratum corneum usually requires its removal, and tape stripping is a useful technique for 
this. The layer by layer removal and analysis of the stratum corneum enables the visualization 
of the penetration pattern of the topically applied drug. Even though the target site may not 
always be the stratum corneum, the drug must pass through the stratum corneum barrier to 
reach deeper sites of action. Moreover, the removal of this layer does not induce permanent 
skin damage.  
The combination of following techniques was applied in this thesis for the investigation of topical 
bioavailability: 1) tape stripping for stratum corneum sampling, 2) UV/VIS-spectroscopy for 
quantification of corneocytes, and 3) HPLC for quantification of TACA as model corticosteroid. 
Since tape stripping is susceptible to numerous confounding factors, the technique requires an 
accurately standardized protocol, which was developed in Project I. The tape stripping protocol 
included a) the use of a template to ensure the removal of stratum corneum samples from the 
same skin site, b) the use of a hand roller to ensure a constant pressure on the tape before 
stripping, c) the removal of each tape with a rapid firm movement, d) the alternation of the tape 
removal (elbow-to-wrist, wrist-to-elbow) to ensure a homogenous removal and to minimize skin 
irritation, e) the removal of the entire stratum corneum of one skin site to cope with the inter- 
and intra-individual differences of stratum corneum thickness. The UV/VIS-spectroscopical 
method for quantification of the corneocytes had been validated by Weigmann et al. [245] and 
was adopted. The HPLC method for TACA quantification had to be developed and validated. 
The analytical challenge consisted in the development of a sensitive analytical method, capable 
to quantify low amounts of TACA distributed on single tapes. Therefore, a low limit of 
quantification (LOQ) was aimed at. The HPLC method was successfully validated and proved to 
have suitable specificity, linearity, accuracy, precision, and robustness in the working range. 
The LOQ of 0.1 µg/ml enables the quantification of 27 ng/cm2 TACA on single tapes. The proof 
of concept proved that the set of method is suitable to distinguish between the different 
penetration pattern of TACA applied in different formulations (acetonic solution, ethanolic gel). 
Whereas the TACA penetration from the acetonic solution was high and TACA reached deeper 
layers of the stratum corneum, the TACA penetration from the ethanolic gel was only superficial, 
most TACA being retained within the cellulose-matrix of the gel after evaporation of the solvent. 
After the proof of concept, the method set was ready to be applied for the investigation of 
different factors determining the pharmacotherapy with topical corticosteroids.  
Despite being a relative old drug class, topical corticosteroids are still the gold standard for the 
treatment of several dermatological affections, e.g. atopic dermatitis. A sufficient dose of steroid 
has to be provided in a suitable vehicle with an optimum application frequency to ensure an 
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adequate penetration into the affected skin areas and to finally ensure efficacy. Moreover, the 
accumulation of topically applied drug as a skin reservoir can considerably affect the therapy 
pattern in term of dose and application frequency. Particularly in case of corticosteroids, the 
formation of a stratum corneum reservoir and a slow drug release to deeper skin tissues over a 
longer time period is advantageous and desired to prevent systemic side effects.  
To ensure an optimized pharmacotherapy, both pharmacokinetic and pharmacodynamic 
investigations are required and were performed in this thesis. Project II describes a 
pharmacokinetic clinical trial investigating the influence of dose and application frequency on 
the percutaneous penetration of TACA applied in an acetonic vehicle to 15 healthy human 
volunteers. In the dose experiment, higher TACA amounts were quantified within the stratum 
corneum after application of the high dose (300 µg/cm2 vs. 100 µg/cm2), as intuitively expected. 
However, this difference was only significant immediately after application. A high TACA 
amount crystallized on the skin surface after evaporation of the vehicle. The TACA crystals 
were mainly quantified on tapes 1-3, and are not supposed to be bioavailable unless additional 
solvent is applied or unless the hydration status of the skin is raised, e.g. by occlusion. The 
application frequency experiment showed slightly higher TACA amounts within the stratum 
corneum after multiple application (3x100 µg/cm2) compared to the application of the total TACA 
dose at once (1x300 µg/cm2). As a result of multiple applications, the skin was periodically 
reloaded with new drug, thus achieving temporary higher amounts within the stratum corneum, 
and re-solving eventual TACA crystals on the skin surface. The highest drug amount was 
always localized in the upper stratum corneum layers, and by excluding tapes 1-3, only minor 
differences between the TACA amounts after the different application modes were observed in 
both experiments. The performance of a mass balance showed that a high TACA dose may 
promote a faster permeation through the stratum corneum and thus a possibly higher systemic 
exposure, unwelcome in topical therapy. Thus, a low dose applied once daily may be preferable 
to a higher dose. These findings are in agreement with pharmacodynamic investigations, which 
have shown that usually multiple-daily applications have no superiority to a once-daily regimen.  
The efficacy of low-dose TACA in the treatment of atopic dermatitis was proved by Project IV. 
In a pharmacodynamic clinical trial with 14 patients suffering from atopic dermatitis, the addition 
of low-dose TACA to a marketed skin care cream formulation (Lichtena®), applied twice-daily, 
induced a significant improvement of the eczematous lesions, whereas the application of the 
cream base alone did not. These findings indicate that some corticosteroids may already be 
effective at much lower concentrations than usually used therapeutically, and that marketed 
corticosteroid formulations may contain a much higher concentration than necessary.  
A further factor enhancing the percutaneous penetration of topically applied compounds is 
occlusion, which increases skin hydration and temperature. We can distinguish between: 
1) application on occluded skin (pre-occlusion), as it can be the case if a topical formulation is 
applied on thoroughly hydrated skin (e.g. after a bath), and 2) occlusion after application (post-
occlusion), as is sometimes performed in clinical practice to improve the effect of topical 
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corticosteroids in severe forms of skin diseases. The effects of pre- and post-occlusion were 
investigated in a pharmacokinetic clinical trial with 10 healthy volunteers, described in 
Project III. Pre-occlusion did not show any effect on the percutaneous penetration of TACA into 
stratum corneum over time. On the contrary, post-occlusion showed a clear enhancement of the 
TACA penetration and an accumulation of a double TACA amount within the stratum corneum. 
The choice of TACA as relative lipophilic compound (logP 2.3) and acetone as volatile vehicle 
was advantageous for the investigation of the effect of occlusion, since the occlusion-induced 
penetration enhancement and reservoir formation appear to be compound and vehicle 
dependent. A higher effect is observed with lipophilic compounds and volatile vehicles. 
During the pharmacokinetic investigations performed in this thesis, different types of reservoir 
could be discerned. Post-occlusion (Project III) induced a long-term TACA accumulation in the 
stratum corneum (“classical” reservoir). The TACA diffusion into deeper tissues was inhibited at 
least for 24 h. After application without occlusion (Project II), independently of dose and 
application frequency, considerable TACA amounts were still measured within the stratum 
corneum. Yet, these high TACA amounts were rather due to the slow diffusion through the 
stratum corneum barrier than to a “classical” reservoir formation. This was underlined by the 
slow but existent diffusion of TACA into deeper tissues. In Project I, not a stratum corneum 
reservoir, but a skin surface reservoir was induced after application of the gel formulation. 
The DPK methodology described in this thesis can be applied for the bioavailability investigation 
of other compounds as well, provided that a specific analytical method for their quantification is 
developed and validated. Determinant for successful investigations using tape stripping is the 
awareness that a fixed number of tapes does never remove the same amount of stratum 
corneum. Endogenous (inter- and intra-individual variations) and exogenous factors (e.g., 
vehicle effects, occlusion) can change the stratum corneum amount removed by a single tape, 
as was demonstrated in Project III. The overhydration of the skin after occlusion induced a 
reduced cohesion of the corneocytes, and only half the number of tapes was required to remove 
the entire stratum corneum compared to non-occluded sites. The removal of a fixed tape 
number (e.g., 20 tapes) would have led to incorrect results. The most correct approach is 
without doubt the removal of the entire stratum corneum, as was performed in this thesis. Yet, 
the removal of up to 80 tapes for one test site is correlated to the time-consuming analytical 
analysis of each tape. In a recent investigation, Jacobi et al. developed a promising 
mathematical model for the prediction of the stratum corneum amount removed without the 
need of its complete removal. They observed that the pseudo-absorption, measured to quantify 
the corneocytes, correlates linearly to the cell layers removed, and that a pseudo-absorption of 
0.25 reflects one single corneocyte layer [244].  
The draft guidance “Topical dermatological drug products NDAs and ANDAs – In vivo 
bioavailability, bioequivalence, in vitro release, and associated studies” released in 1998 by the 
FDA already proposed tape stripping as DPK approach for the assessment of bioavailability and 
bioequivalence of topically applied compounds. The withdrawal of the draft guidance in 2002 
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showed that not the technique itself, but the proposed protocol (e.g., removal of a fixed number 
of 12 tapes, discarding of the first 2 tapes) was not yet mature for bioavailability and 
bioequivalence testing. The investigations described in this thesis show how tape stripping, 
correctly performed, asserts itself as a valuable technique for bioavailability assessment. 
Additional bioequivalence investigations with the proposed set of methods could lead to the 
reconsideration of tape stripping also on a regulatory level. 
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11.1. Project I 
11.1.1. Validation of the HPLC method 
Weighted linear regression (1/x) all series
y = -573 + 35660 x
0
100000
200000
300000
400000
500000
600000
700000
0 10 20
Concentration (ug/ml)
Pe
a
k 
ar
e
a 
(U
n
it)
Calc. 95% Pred. int.
Means 1
Multiple determinations 1
Means 2 Means 3
Multiple determinations 2 Multiple determinations 3
 
Fig. 11-1: Linearity assessment - Calibration curves (n=3) for the assessment of linearity; calculation with the 
weighted linear regression model (weighting factor 1/x, x = concentration) 
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Table 11-1: Accuracy assessement - Recovery data from tape spiking experiments for accuracy assessment. 
Amount on tape [ug] Tape Number Conc. level in calibration 
curve [µg/ml] theoretical measured 
Difference  
[µg] 
Recovery  
[%] 
 1 15 22.5 21.8 0.7 96.7 
 2* 15 22.5 22.4 0.1 99.4 
 3 15 22.5 21.9 0.6 97.3 
 4 15 22.5 21.1 1.4 93.8 
 5 15 22.5 21.7 0.8 96.4 
 6 15 22.5 21.5 1.0 95.4 
 mean  22.5 21.7 0.8 96.5 
 SD  0.0 0.4 0.4 1.9 
 7 5 7.5 7.2 0.3 96.0 
 8 5 7.5 7.0 0.5 93.2 
 9 5 7.5 7.1 0.4 95.0 
 10 5 7.5 7.1 0.4 95.0 
 11 5 7.5 6.8 0.7 91.0 
 12 5 7.5 7.0 0.5 92.8 
 mean  7.5 7.0 0.5 93.8 
 SD  0.0 0.1 0.1 1.8 
 13 0.5 0.8 0.7 0.1 88.0 
 14 0.5 0.8 0.7 0.1 90.0 
 15 0.5 0.8 0.7 0.1 92.0 
 16 0.5 0.8 0.7 0.1 88.0 
 17 0.5 0.8 0.6 0.1 82.0 
 18 0.5 0.8 0.6 0.1 82.0 
 mean  0.8 0.7 0.1 87.0 
 SD  0.0 0.0 0.0 4.1 
* tape number 2 accidentally extracted with 1.8 ml instead of 1.5 ml 
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Table 11-2: Precision assessment - Peak areas of the concentration levels for 3 different calibration curves 
measured on 3 different days. 
0.1ug/ml 0.5ug/ml 1.0ug/ml 5.0ug/ml 10.0ug/ml 15.0ug/ml 20.0ug/ml
Day 1 3191 17337 34953 178630 358858 538634 716212
3551 17152 35054 178168 356271 537021 715817
2803 16969 35377 178987 357337 538516 715396
2928 17280 34722 178248 355734 537485 714713
2917 17904 34170 178472 356659 536756 716860
mean 3078 17328 34855 178501 356972 537682 715799
SD 300 351 450 327 1205 857 812
rel. SD 9.7 2.0 1.3 0.2 0.3 0.2 0.1
Day 2 3025 17406 34514 178723 355394 534945 717020
3170 17181 34924 178351 355859 535427 716478
3049 16937 34938 178353 355296 536596 713874
3328 16907 34613 179071 355745 535369 714757
3231 16999 34858 177120 353528 535794 715182
mean 3160 17086 34769 178324 355164 535626 715462
SD 126 208 194 736 944 620 1280
rel. SD 4.0 1.2 0.6 0.4 0.3 0.1 0.2
Day 3 2789 16727 34227 174586 354848 531455 707959
2928 16840 34367 174166 354170 531061 709551
3021 16932 34620 175806 354691 530039 708458
3077 16806 34296 175104 355591 531719 708906
3176 16487 34591 174599 354036 532045 710748
mean 2998 16758 34420 174852 354667 531264 709124
SD 148 169 177 628 619 774 1080
rel. SD 4.9 1.0 0.5 0.4 0.2 0.1 0.2
Overall mean 3079 17057 34681 177226 355601 534857 713462
Overall SD 203 338 339 1822 1353 2857 3330
Relative SD [%] 6.6 2.0 1.0 1.0 0.4 0.5 0.5
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11.1.2. Proof of concept 
Qualitative TACA penetration into stratum corneum: penetration profiles 
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Volunteer 2: Acetonic solution 
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Volunteer 3: Acetonic solution 
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Volunteer 4: Ethanolic Gel 
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Notice:  
After application of the ethanolic gel and evaporation of the solvent, a thin film (consisting of 
cellulose and drug) remained on the skin surface. This film was removed with the first stripped 
tape and interfered with the spectroscopical quantification of the corneocytes. Therefore, a 
normalization of the corneocyte amount adhering on the first tape was necessary, and the 
profiles are depicted with normalized tape 1 (left side). Because the TACA amount on tape 1 
was very large, the TACA concentration scale differs by a factor of 10 compared to the scale of 
the penetration profiles after application of the acetonic solution (50 µg/cm2 vs. 5 µg/cm2). Thus, 
to facilitate the comparison between the 2 formulations, the penetration profiles after application 
of the ethanolic gel are additionally depicted without tape 1 (right side, scale 5 µg/cm2). 
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Volunteer 5: Ethanolic Gel 
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Please consider the notice on page 119. 
11. Appendix 
Carolina Pellanda  Page 121 of 186 University of Basel, 2006 
Volunteer 6: Ethanolic Gel 
 
 ALL TAPES WITHOUT TAPE 1 
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Please consider the notice on page 119. 
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Quantitative TACA penetration into stratum corneum 
Table 11-3: TACA amount penetrated into stratum corneum after application of an acetonic solution and an 
ethanolic gel, both delivering 100 µg/cm2 TACA. Two types of evaluations were performed: total TACA amount 
penetrated (all tapes), and TACA amount calculated excluding tapes 1-3. The difference of the TACA amount 
penetrated after application of the 2 formulations was tested in a 2-sided t-test at the 5% level of significance. 
An asterisk (*) denotes a statistically significant difference (p<0.05), a double asterisk (**) a highly significant 
difference (p<0.01). 
TOTAL TACA AMOUNT PENETRATED INTO STRATUM CORNEUM 
  
0.5 h  3 h  24 h 
No.  Acetonic Sol. Alcoholic Gel  Acetonic Sol. Alcoholic Gel  Acetonic Sol. Alcoholic Gel 
1  25.4 91.8  7.2 79.2  0.4 9.7 
2  20.4 98.5  4.9 82.6  0.7 0.9 
3  26.4 90.5  28.1 89.3  1.4 9.4 
Mean±SD  24.1 ± 3.2 93.6 ± 4.3  13.4 ± 12.8 83.7 ± 5.2  0.8 ± 0.5 6.7 ± 5.0 
95% CI  16.1 to 32.0 82.9 to 104.3  -18.3 to 45.1 70.9 to 96.5  -0.4 to 2.1 -5.8 to 19.1 
p-value  < 0.01**  < 0.01**  0.1 
TACA AMOUNT PENETRATED INTO STRATUM CORNEUM WITHOUT TAPES 1-3 
  
0.5 h  3 h  24 h 
No.  Acetonic Sol. Alcoholic Gel  Acetonic Sol. Alcoholic Gel  Acetonic Sol. Alcoholic Gel 
1  14.7 2.8  3.1 4.0  0.2 2.0 
2  9.3 4.1  2.0 3.5  0.4 0.6 
3  14.3 3.8  13.1 3.8  0.9 2.1 
Mean±SD  12.8 ± 3.0  3.6 ± 0.7  6.05 ± 6.1 3.8 ± 0.3  0.5 ± 0.3 1.6 ± 0.8 
95% CI  5.3 to 20.3 1.9 to 5.3  -9.2 to 21.3 3.0 to 4.5  -0.3 to 1.4 -0.5 to 3.6 
p-value  < 0.01**  0.6  0.1 
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UV/VIS-Spectroscopy 
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Fig. 11-2: UV/VIS-spectrum of a blank tape of Tesa Multi-Film Crystal-Clear®. 
 
 
 
 
11. Appendix 
Carolina Pellanda  Page 124 of 186 University of Basel, 2006 
11.2. Project II 
11.2.1. Pre-Examination Form 
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11.2.2. Post-Examination Form 
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11.2.3. Experiment 1.1 (Dose) - Penetration profiles 
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Volunteer 1.1.2 
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11.2.4. Experiment 1.1 (Dose) - Data overview 
Exp 1.1 (n=5) 
 
Concentration  TACA-amount all tapes  TACA-amount without tape 1-3 
 
Tape 
Stripping  
 Mean ± SD  Mean ± SD 
ORIGINAL VALUES  [µg/cm2] [%]  [µg/cm2] [%] 
        
300 µg/cm2 0.5 h  245 ± 78 82 ± 26  74 ± 12 25 ± 4 
300 µg/cm2 4 h  80 ± 19 27 ± 6  31 ± 15 10 ± 5 
300 µg/cm2 24 h  46 ± 18 15 ± 6  27 ± 13 9 ± 4 
        
100 µg/cm2 0.5 h  101 ± 17 101 ± 17  55 ± 14 55 ± 14 
100 µg/cm2 4 h  52 ± 13 52 ± 13  30 ± 16 30 ± 16 
100 µg/cm2 24 h  33 ± 19 33 ± 19  23 ± 14 23 ± 14 
        
   Mean ± SD  Mean ± SD 
LN-VALUES   [µg/cm2] [%]  [µg/cm2] [%] 
        
300 µg/cm2 0.5 h  5.5 ± 0.3 4.4 ± 0.3  4.3 ± 0.2 3.2 ± 0.2 
300 µg/cm2 4 h  4.4 ± 0.3 3.3 ± 0.3  3.3 ± 0.5 2.2 ± 0.5 
300 µg/cm2 24 h  3.8 ± 0.4 2.7 ± 0.4  3.2 ± 0.6 2.1 ± 0.6 
        
100 µg/cm2 0.5 h  4.6 ± 0.2 4.6 ± 0.2  4.0 ± 0.3 4.0 ± 0.3 
100 µg/cm2 4 h  3.9 ± 0.3 3.9 ± 0.3  3.3 ± 0.6 3.3 ± 0.6 
100 µg/cm2 24 h  3.2 ± 0.9 3.2 ± 0.9  2.8 ± 1.1 2.8 ± 1.1 
        
Pair Differences  
 
 Confidence 
Interval 95% 
p-value 
(2-sided) 
 Confidence 
Interval 95% 
p-value 
(2-sided) 
        
 0.5 h  1.5 to 3.9 0.008 **  0.9 to 2.2 0.1 
 4 h  1.0 to 2.5 0.06  0.6 to 1.8  0.7 
 24 h  0.7 to 4.4 0.2  0.5 to 3.8 0.4 
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11.2.5. Experiment 1.1 (Dose) - Data single volunteers 
 
Experiment 1.1 - TACA-amount penetrated - All Tapes
Volunteer Gender Age 
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.1.1 f 33 349.8 116.6 48.6 16.2 34.2 11.4 115.5 115.5 47.7 47.7 55.9 55.9
1.1.2 f 23 262.2 87.4 89.9 30.0 46.2 15.4 74.8 74.8 59.4 59.4 31.9 31.9
1.1.3 f 26 171.0 57.0 99.2 33.1 74.3 24.8 117.1 117.1 62.1 62.1 42.6 42.6
1.1.4 m 37 163.5 54.5 85.1 28.4 48.5 16.2 99.4 99.4 29.9 29.9 27.7 27.7
1.1.5 m 29 280.5 93.5 78.4 26.1 26.0 8.7 96.2 96.2 59.3 59.3 5.0 5.0
Mean 30 245.4 81.8 80.2 26.7 45.8 15.3 100.6 100.6 51.7 51.7 32.6 32.6
SD 78.5 26.2 19.2 6.4 18.3 6.1 17.2 17.2 13.4 13.4 18.9 18.9
RSD 32.0 32.0 24.0 24.0 40.0 40.0 17.1 17.1 25.9 25.9 58.0 58.0
Experiment 1.1 - TACA-amount penetrated - All Tapes, Logarithm (ln)
Volunteer Gender Age 
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.1.1 f 33 5.9 4.8 3.9 2.8 3.5 2.4 4.7 4.7 3.9 3.9 4.0 4.0
1.1.2 f 23 5.6 4.5 4.5 3.4 3.8 2.7 4.3 4.3 4.1 4.1 3.5 3.5
1.1.3 f 26 5.1 4.0 4.6 3.5 4.3 3.2 4.8 4.8 4.1 4.1 3.8 3.8
1.1.4 m 37 5.1 4.0 4.4 3.3 3.9 2.8 4.6 4.6 3.4 3.4 3.3 3.3
1.1.5 m 29 5.6 4.5 4.4 3.3 3.3 2.2 4.6 4.6 4.1 4.1 1.6 1.6
Mean 30 5.5 4.4 4.4 3.3 3.8 2.7 4.6 4.6 3.9 3.9 3.2 3.2
SD 0.3 0.3 0.3 0.3 0.4 0.4 0.2 0.2 0.3 0.3 0.9 0.9
RSD 6.0 7.6 6.4 8.5 10.5 14.8 3.9 3.9 7.8 7.8 29.4 29.4
4h, 1x100ug/cm2 24h, 30min, 4h, 1x300ug/cm2 24h, 30min, 
1x300ug/cm2 1x100ug/cm2
Tape Stripping at Tape Stripping at
1x300ug/cm2 1x100ug/cm2
Tape Stripping at
4h 24h
Tape Stripping at
0.5h 4h 24h 0.5h
 
 
Experiment 1.1 - TACA-amount penetrated - Without Tapes 1-3
Volunteer Gender Age
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.1.1 f 33 65.1 21.7 16.7 5.6 19.1 6.4 63.1 63.1 27.7 27.7 40.7 40.7
1.1.2 f 23 80.6 26.9 49.5 16.5 32.5 10.8 42.8 42.8 39.0 39.0 25.6 25.6
1.1.3 f 26 61.0 20.4 42.1 14.0 42.9 14.3 72.1 72.1 51.4 51.4 26.2 26.2
1.1.4 m 37 90.4 30.2 29.2 9.7 29.5 9.8 55.9 55.9 17.3 17.3 20.3 20.3
1.1.5 m 29 73.9 24.6 17.8 5.9 10.4 3.5 39.8 39.8 12.7 12.7 2.4 2.4
Mean 30 74.2 24.7 31.1 10.4 26.9 9.0 54.7 54.7 29.6 29.6 23.0 23.0
SD 11.8 3.9 14.5 4.8 12.5 4.2 13.6 13.6 15.9 15.9 13.8 13.8
RSD 16.0 16.0 46.8 46.8 46.6 46.6 24.8 24.8 53.5 53.5 60.0 60.0
Experiment 1.1 - TACA-amount penetrated - Without Tapes 1-3, Logarithm (ln)
Volunteer Gender Age
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.1.1 f 33 4.2 3.1 2.8 1.7 3.0 1.9 4.1 4.1 3.3 3.3 3.7 3.7
1.1.2 f 23 4.4 3.3 3.9 2.8 3.5 2.4 3.8 3.8 3.7 3.7 3.2 3.2
1.1.3 f 26 4.1 3.0 3.7 2.6 3.8 2.7 4.3 4.3 3.9 3.9 3.3 3.3
1.1.4 m 37 4.5 3.4 3.4 2.3 3.4 2.3 4.0 4.0 2.8 2.8 3.0 3.0
1.1.5 m 29 4.3 3.2 2.9 1.8 2.3 1.2 3.7 3.7 2.5 2.5 0.9 0.9
Mean 30 4.3 3.2 3.3 2.2 3.2 2.1 4.0 4.0 3.3 3.3 2.8 2.8
SD 0.2 0.2 0.5 0.5 0.6 0.6 0.3 0.3 0.6 0.6 1.1 1.1
RSD 3.7 5.0 14.7 21.8 17.4 26.6 6.4 6.4 17.6 17.6 39.6 39.6
1x300ug/cm2 1x100ug/cm2
Tape Stripping at 
4h 24h
Tape Stripping at
0.5h 4h 24h 0.5h
1x300ug/cm2 1x100ug/cm2
Tape Stripping at Tape Stripping at
4h 24h0.5h 4h 24h 0.5h
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11.2.6. Experiment 1.2 (Application frequency) - Penetration profiles 
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Volunteer 1.2.3 
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11.2.7. Experiment 1.2 (Application frequency) – Data overview 
Exp 1.2 (n=10) 
 
Application pattern Stripping time 
at 
 TACA-amount penetrated  
(all tapes) 
 TACA-amount penetrated  
(without tapes 1-3) 
 
     
   Mean ± SD  Mean ± SD 
ORIGINAL VALUES  [µg/cm2] [%]  [µg/cm2] [%] 
        
1 x 300 µg/cm2 4 h  65.1 ± 23.0 21.7 ± 7.7  33.2 ± 11.7 11.1 ± 3.9 
1 x 300 µg/cm2 8 h  43.6 ± 29.1 14.5 ± 9.7  19.5 ± 7.5 6.5 ± 2.5 
1 x 300 µg/cm2 24 h  39.3 ± 31.3 13.1 ± 10.4  24.0 ± 14.0 8.0 ± 4.7 
        
2 x 100 µg/cm2 4 h  84.0 ± 28.9 42.0 ± 14.5  35.1 ± 10.8 17.6 ± 5.4 
3 x 100 µg/cm2 8 h  98.0 ± 45.2 32.7 ± 15.1  29.3 ± 15.1 9.8 ± 5.0 
3 x 100 µg/cm2 24 h  37.9 ± 16.1 12.6 ± 5.4  22.9 ± 8.8 7.6 ± 2.9 
        
LN-VALUES   Mean ± SD  Mean ± SD 
   [µg/cm2] [%]  [µg/cm2] [%] 
1 x 300 µg/cm2 4 h  4.1 ± 0.5 3.0 ± 0.5  3.4 ± 0.4 2.3 ± 0.4 
1 x 300 µg/cm2 8 h  3.6 ± 0.6 2.5 ± 0.6  2.9 ± 0.4 1.8 ± 0.4 
1 x 300 µg/cm2 24 h  3.5 ± 0.7 2.4 ± 0.7  3.0 ± 0.5 1.9 ± 0.5 
        
2 x 100 µg/cm2 4 h  4.4 ± 0.4 3.7 ± 0.4  3.5 ± 0.4 2.8 ± 0.4 
3 x 100 µg/cm2 8 h  4.5 ± 0.5 3.4 ± 0.5  3.3 ± 0.5 2.2 ± 0.5 
3 x 100 µg/cm2 24 h  3.6 ± 0.4 2.5 ± 0.4  3.1 ± 0.4 2.0 ± 0.4 
        
Pair Differences  Confidence 
Interval 95% 
p-value 
(2-sided) 
 Confidence 
Interval 95% 
p-value 
(2-sided) 
        
 4 h  0.5 to 1.2 0.2  0.6 to 1.4 0.7 
 8 h  0.3 to 0.7 0.002 **  0.5 to 1.0 0.06 
 24 h  0.5 to 1.7 0.7  0.6 to 1.7 0.9 
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11.2.8. Experiment 1.2 (Application frequency)- Data single volunteers 
Experiment 1.2 - TACA-amount penetrated - All Tapes
Volunteer Gender Age 
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.2.1 f 24 41.7 13.9 17.1 5.7 20.7 6.9 103.0 51.5 38.2 12.7 73.0 24.3
1.2.2 f 25 56.7 18.9 16.3 5.4 15.5 5.2 92.5 46.3 61.2 20.4 40.8 13.6
1.2.3 f 20 73.6 24.5 40.3 13.4 26.8 8.9 79.4 39.7 134.8 44.9 38.4 12.8
1.2.4 m 26 21.5 7.2 47.7 15.9 38.2 12.7 57.4 28.7 85.0 28.3 50.6 16.9
1.2.5 m 23 87.9 29.3 33.4 11.1 26.6 8.9 85.7 42.8 91.4 30.5 18.4 6.1
1.2.6 m 29 80.3 26.8 30.8 10.3 31.8 10.6 104.4 52.2 170.2 56.7 38.0 12.7
1.2.7 m 44 74.6 24.9 110.2 36.7 99.5 33.2 42.1 21.0 128.8 42.9 18.1 6.0
1.2.8 f 21 67.3 22.4 36.7 12.3 20.6 6.9 120.9 60.5 55.3 18.4 40.7 13.6
1.2.9 f 27 49.4 16.5 26.3 8.8 18.0 6.0 114.0 57.0 150.7 50.2 26.3 8.8
1.2.10 m 21 98.2 32.7 77.0 25.7 95.1 31.7 40.2 20.1 64.9 21.6 34.4 11.5
Mean 26 65.1 21.7 43.6 14.5 39.3 13.1 84.0 42.0 98.0 32.7 37.9 12.6
SD 23.0 7.7 29.1 9.7 31.3 10.4 28.9 14.5 45.2 15.1 16.1 5.4
RSD 35.4 35.4 66.8 66.8 79.7 79.7 34.5 34.5 46.1 46.1 42.5 42.5
Experiment 1.2 - TACA-amount penetrated -  All Tapes, Logarithm (ln)
Volunteer Gender Age 
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.2.1 f 24 3.7 2.6 2.8 1.7 3.0 1.9 4.6 3.9 3.6 2.5 4.3 3.2
1.2.2 f 25 4.0 2.9 2.8 1.7 2.7 1.6 4.5 3.8 4.1 3.0 3.7 2.6
1.2.3 f 20 4.3 3.2 3.7 2.6 3.3 2.2 4.4 3.7 4.9 3.8 3.6 2.6
1.2.4 m 26 3.1 2.0 3.9 2.8 3.6 2.5 4.0 3.4 4.4 3.3 3.9 2.8
1.2.5 m 23 4.5 3.4 3.5 2.4 3.3 2.2 4.5 3.8 4.5 3.4 2.9 1.8
1.2.6 m 29 4.4 3.3 3.4 2.3 3.5 2.4 4.6 4.0 5.1 4.0 3.6 2.5
1.2.7 m 44 4.3 3.2 4.7 3.6 4.6 3.5 3.7 3.0 4.9 3.8 2.9 1.8
1.2.8 f 21 4.2 3.1 3.6 2.5 3.0 1.9 4.8 4.1 4.0 2.9 3.7 2.6
1.2.9 f 27 3.9 2.8 3.3 2.2 2.9 1.8 4.7 4.0 5.0 3.9 3.3 2.2
1.2.10 m 21 4.6 3.5 4.3 3.2 4.6 3.5 3.7 3.0 4.2 3.1 3.5 2.4
Mean 26 4.1 3.0 3.6 2.5 3.5 2.4 4.4 3.7 4.5 3.4 3.6 2.5
SD 0.4 0.4 0.6 0.6 0.6 0.7 0.4 0.4 0.5 0.5 0.4 0.4
RSD 10.9 14.9 16.6 23.9 18.8 27.6 9.2 10.9 11.0 14.6 12.1 17.6
1x300 ug/cm2  
4h
1x300ug/cm2   
8h 
3x100 ug/cm2   
8h      
3x100 ug/cm2 
24h     
2x100 ug/cm2   
4h      
1x300 ug/cm2 
24h     
3x100 ug/cm2   
8h      
3x100 ug/cm2 
24h     
1x300 ug/cm2  
4h
1x300ug/cm2   
8h 
1x300 ug/cm2 
24h     
2x100 ug/cm2   
4h      
 
 
Experiment 1.2 - TACA-amount penetrated  -  Without Tape1-3
Volunteer Gender Age 
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.2.1 f 24 26.4 8.8 12.2 4.1 16.7 5.6 33.4 16.7 13.9 4.6 35.0 11.7
1.2.2 f 25 35.7 11.9 11.0 3.7 11.0 3.7 41.3 20.7 36.2 12.1 25.1 8.3
1.2.3 f 20 41.7 13.9 25.9 8.6 19.3 6.4 39.7 19.8 66.6 22.2 29.6 9.9
1.2.4 m 26 12.2 4.1 16.6 5.5 26.4 8.8 24.7 12.4 28.8 9.6 32.7 10.9
1.2.5 m 23 54.3 18.1 19.4 6.5 21.8 7.3 40.4 20.2 27.0 9.0 12.3 4.1
1.2.6 m 29 34.2 11.4 17.2 5.7 24.4 8.1 51.4 25.7 33.8 11.3 29.5 9.8
1.2.7 m 44 38.5 12.8 26.7 8.9 48.7 16.2 25.8 12.9 19.3 6.4 10.9 3.6
1.2.8 f 21 24.9 8.3 19.7 6.6 11.3 3.8 39.9 19.9 31.4 10.5 22.1 7.4
1.2.9 f 27 23.8 7.9 11.9 4.0 11.9 4.0 40.5 20.2 18.9 6.3 15.3 5.1
1.2.10 m 21 39.9 13.3 34.3 11.4 48.2 16.1 14.2 7.1 17.1 5.7 16.3 5.4
Mean 26 33.2 11.1 19.5 6.5 24.0 8.0 35.1 17.6 29.3 9.8 22.9 7.6
SD 11.7 3.9 7.5 2.5 14.0 4.7 10.8 5.4 15.1 5.0 8.8 2.9
RSD 35.4 35.4 38.5 38.5 58.3 58.3 30.6 30.6 51.6 51.7 38.4 38.4
Experiment 1.2 - TACA-amount penetrated - Without Tape1-3, Logarithm (ln)
Volunteer Gender Age 
[years]
[ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%] [ug/cm2] [%]
1.2.1 f 24 3.3 2.2 2.5 1.4 2.8 1.7 3.5 2.8 2.6 1.5 3.6 2.5
1.2.2 f 25 3.6 2.5 2.4 1.3 2.4 1.3 3.7 3.0 3.6 2.5 3.2 2.1
1.2.3 f 20 3.7 2.6 3.3 2.2 3.0 1.9 3.7 3.0 4.2 3.1 3.4 2.3
1.2.4 m 26 2.5 1.4 2.8 1.7 3.3 2.2 3.2 2.5 3.4 2.3 3.5 2.4
1.2.5 m 23 4.0 2.9 3.0 1.9 3.1 2.0 3.7 3.0 3.3 2.2 2.5 1.4
1.2.6 m 29 3.5 2.4 2.8 1.7 3.2 2.1 3.9 3.2 3.5 2.4 3.4 2.3
1.2.7 m 44 3.7 2.6 3.3 2.2 3.9 2.8 3.2 2.6 3.0 1.9 2.4 1.3
1.2.8 f 21 3.2 2.1 3.0 1.9 2.4 1.3 3.7 3.0 3.4 2.3 3.1 2.0
1.2.9 f 27 3.2 2.1 2.5 1.4 2.5 1.4 3.7 3.0 2.9 1.8 2.7 1.6
1.2.10 m 21 3.7 2.6 3.5 2.4 3.9 2.8 2.7 2.0 2.8 1.7 2.8 1.7
Mean 26 3.4 2.3 2.9 1.8 3.0 1.9 3.5 2.8 3.3 2.2 3.1 2.0
SD 0.4 0.4 0.4 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.4 0.4
RSD 12.1 17.8 13.0 20.9 17.9 28.0 10.7 13.3 13.9 20.9 13.8 21.6
1x300 ug/cm2  
4h
1x300ug/cm2   
8h 
3x100 ug/cm2   
8h      
3x100 ug/cm2 
24h     
2x100 ug/cm2   
4h      
1x300 ug/cm2 
24h     
3x100 ug/cm2   
8h      
3x100 ug/cm2 
24h     
1x300 ug/cm2  
4h
1x300ug/cm2   
8h 
1x300 ug/cm2 
24h     
2x100 ug/cm2   
4h      
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11.3. Project III 
11.3.1. Overview of application and tape stripping procedure 
 
   0 h 4 h 24 h 
      EXPERIMENT 1       
Site 1 Pre-Occlusion 16h 1 x 100 µg/cm2 - D T   
Site 2 Pre-Occlusion 16h 1 x 100 µg/cm2 - D T   AR
M
 
 
 
 
 
 
 
 
 
 
 
1 
Site 3 Pre-Occlusion 16h 1 x 100 µg/cm2 - D  T 
Site 4 - 1 x 100 µg/cm2 - D T   
Site 5 - 1 x 100 µg/cm2 - D T   AR
M
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
Site 6 - 1 x 100 µg/cm2 - D  T 
EXPERIMENT 2 
      
Site 1 - 1 x 100 µg/cm2 Post-Occlusion until T D T  
 
AR
M
 
1 
Site 2 - 1 x 100 µg/cm2 Post-Occlusion until T D  T 
Site 3 - 1 x 100 µg/cm2 - D T  
 
AR
M
 
2 
Site 4 - 1 x 100 µg/cm2 - D  T 
       
     9 a.m 1 p.m 9 a.m. 
D = Dosing (application of the formulation), T = Tape Stripping (skin sampling). When tape stripping followed just after 
dosing (D T), a time span of 0.5 h was maintained between dosing and tape stripping to ensure an initial penetration of 
TACA into the stratum corneum.  
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11.3.2. Experiment 2.1 (Pre-occlusion) - Penetration profiles 
 
Volunteer 2.1.1 
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4h Volunteer 2.1.1 - Preocclusion - 4h 
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Volunteer 2.1.1 - Normal - 4h 
0 55 1010 1515 2020 2525
0
10
20
30
40
50
60
70
80
90
100
H
o
rn
y 
la
ye
r 
th
ic
kn
e
ss
 
[%
]
T
ap
e
 n
u
m
b
er
Concentration of triamcinolone acetonide [µg/cm²]
1
5
10
15
20
25
30
35
40
45
55
 
24h Volunteer 2.1.1 - Preocclusion - 24h 
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Volunteer 2.1.2 
 Pre-occlusion 1x100µg/cm2  Normal 1x100µg/cm2 
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Volunteer 2.1.3 
 Pre-occlusion 1x100µg/cm2  Normal 1x100µg/cm2 
0.5h Volunteer 2.1.3 - Preocclusion - 0.5h
0 55 1010 1515 2020 2525 3030 3535 4040 4545 5050
0
10
20
30
40
50
60
70
80
90
100
H
o
rn
y 
la
ye
r 
th
ic
kn
es
s
 
[%
]
T
ap
e
 n
u
m
b
er
Concentration of triamcinolone acetonide [µg/cm²]
1
5
10
15
20
25
30
35
40
 
Volunteer 2.1.3 - Normal - 0.5h
0 55 1010 1515 2020 2525
0
10
20
30
40
50
60
70
80
90
100
H
o
rn
y 
la
ye
r 
th
ic
kn
es
s
 
[%
]
T
ap
e
 n
u
m
b
er
Concentration of triamcinolone acetonide [µg/cm²]
1
5
10
15
20
25
30
39
 
4h Volunteer 2.1.3 - Preocclusion - 4h
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Volunteer 2.1.4 
 Pre-occlusion 1x100µg/cm2  Normal 1x100µg/cm2 
0.5h Volunteer 2.1.4 - Preocclusion - 0.5h
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Volunteer 2.1.5 
 Pre-occlusion 1x100µg/cm2  Normal 1x100µg/cm2 
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Volunteer 2.1.5 - Normal - 0.5h
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24h Volunteer 2.1.5 - Preocclusion - 24h
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11.3.3. Experiment 2.1 (Pre-occlusion) - Data overview  
 
Exp 2.1 (n=5), Application of 1x100µg/cm2 
 
Concentration Tape 
Stripping 
 TACA-amount all tapes  TACA-amount without tape 1-3 
ORIGINAL VALUES  Mean ± SD  Mean ± SD 
      
Preocclusion 0.5 h  67 ± 37  35 ± 16 
Preocclusion 4 h  43 ± 10  24 ± 7.6 
Preocclusion 24 h  18 ± 10  12 ± 6.6 
      
Normal 0.5 h  66 ± 28  30 ± 12 
Normal 4 h  48 ± 17  25 ± 8.1 
Normal 24 h  29 ± 12  20 ± 9.3 
   
  
 
LN-VALUES   Mean ± SD  Mean ± SD 
      
Preocclusion 0.5 h  4.1 ± 0.6  3.5 ± 0.5 
Preocclusion 4 h  3.8 ± 0.2  3.1 ± 0.3 
Preocclusion 24 h  2.8 ± 0.5  2.3 ± 0.6 
      
Normal 0.5 h  4.1 ± 0.4  3.4 ± 0.4 
Normal 4 h  3.8 ± 0.3  3.2 ± 0.3 
Normal 24 h  3.3 ± 0.5  2.9 ± 0.5 
        
ANOVA (ln-values)   All tapes   Without Tapes 1-3 
Factor:         
- volunteer    0.3   0.08  
- time    0.0001 **   0.0008 **  
- application    0.2   0.2 
- Interaction time/application   0.4   0.1 
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11.3.4. Experiment 2.1 (Pre-occlusion) - Data single volunteers 
 
Experiment 2.1 - TACA-amount penetrated - All Tapes [ug/cm2]
Volunteer Gender Age Tape Stripping at Tape Stripping at
 [years] 0.5h 4h 24h 0.5h 4h 24h
2.1.1 f 26 34.02 51.89 19.19 40.57 38.95 35.22
2.1.2 f 24 82.83 54.51 18.51 45.96 41.90 18.60
2.1.3 f 24 122.16 43.07 10.50 89.70 44.86 41.97
2.1.4 m 29 36.09 34.11 10.12 101.27 38.49 14.94
2.1.5 m 24 58.99 33.71 33.64 51.79 78.03 36.54
Mean 25 66.82 43.46 18.39 65.86 48.45 29.46
SD 36.74 9.69 9.54 27.64 16.74 11.92
RSD 54.99 22.30 51.85 41.97 34.54 40.47
Experiment 2.1 - TACA-amount penetrated - All Tapes [ug/cm2], Logarithm (ln)
Volunteer Gender Age Tape Stripping at Tape Stripping at
 [years] 0.5h 4h 24h 0.5h 4h 24h
2.1.1 f 26 3.53 3.95 2.95 3.70 3.66 3.56
2.1.2 f 24 4.42 4.00 2.92 3.83 3.74 2.92
2.1.3 f 24 4.81 3.76 2.35 4.50 3.80 3.74
2.1.4 m 29 3.59 3.53 2.31 4.62 3.65 2.70
2.1.5 m 24 4.08 3.52 3.52 3.95 4.36 3.60
Mean 25 4.08 3.75 2.81 4.12 3.84 3.30
SD 0.55 0.23 0.50 0.41 0.29 0.46
RSD 13.36 6.02 17.67 10.00 7.67 13.91
Preocclusion - 1x100ug/cm2 Normal - 1x100ug/cm2
Preocclusion - 1x100ug/cm2 Normal - 1x100ug/cm2
 
 
Experiment 2.1 - TACA-amount penetrated - Without Tape 1-3 [ug/cm2]
Volunteer Gender Age Tape Stripping at Tape Stripping at
 [years] 0.5h 4h 24h 0.5h 4h 24h
2.1.1 f 26 21.75 33.96 13.53 24.70 17.13 25.52
2.1.2 f 24 55.79 29.22 11.71 31.19 20.69 10.71
2.1.3 f 24 42.44 19.67 5.17 48.63 27.27 31.21
2.1.4 m 29 16.91 17.92 5.85 17.42 20.04 10.49
2.1.5 m 24 38.09 16.82 21.34 29.17 37.40 23.26
Mean 25 35.00 23.52 11.52 30.22 24.51 20.24
SD 15.81 7.62 6.58 11.57 8.11 9.27
RSD 45.18 32.41 57.09 38.28 33.08 45.78
Experiment 2.1 - TACA-amount penetrated - Without Tape 1-3 [ug/cm2], Logarithm (ln)
Volunteer Gender Age Tape Stripping at Tape Stripping at
 [years] 0.5h 4h 24h 0.5h 4h 24h
2.1.1 f 26 3.08 3.53 2.60 3.21 2.84 3.24
2.1.2 f 24 4.02 3.37 2.46 3.44 3.03 2.37
2.1.3 f 24 3.75 2.98 1.64 3.88 3.31 3.44
2.1.4 m 29 2.83 2.89 1.77 2.86 3.00 2.35
2.1.5 m 24 3.64 2.82 3.06 3.37 3.62 3.15
Mean 25 3.46 3.12 2.31 3.35 3.16 2.91
SD 0.49 0.31 0.59 0.37 0.31 0.51
RSD 14.25 10.04 25.77 11.13 9.75 17.61
Preocclusion - 1x100ug/cm2 Normal - 1x100ug/cm2
Normal - 1x100ug/cm2Preocclusion - 1x100ug/cm2
 
11. Appendix 
Carolina Pellanda  Page 153 of 186 University of Basel, 2006 
11.3.5. Experiment 2.2 (Post-occlusion) – Penetration profiles 
Volunteer 2.2.1 
 Post-occlusion 1x100µg/cm2  Normal 1x100µg/cm2  
4h Volunteer 2.2.1 - Postocclusion - 4h
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Volunteer 2.2.2 
 Post-occlusion 1x100µg/cm2 Normal 1x100µg/cm2 
4h Volunteer 2.2.2 - Postocclusion - 4h
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Volunteer 2.2.3 
 Post-occlusion 1x100µg/cm2 Normal 1x100µg/cm2 
4h Volunteer 2.2.3 - Postocclusion - 4h
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Volunteer 2.2.3 - Normal - 24h
0 55 1010 1515 2020 2525
0
10
20
30
40
50
60
70
80
90
100
H
o
rn
y 
la
ye
r 
th
ic
kn
e
ss
 
[%
]
T
ap
e
 n
u
m
b
er
Concentration of triamcinolone acetonide [µg/cm²]
1
5
10
15
20
25
30
39
 
 
 
Volunteer 2.2.4 
 Post-occlusion 1x100µg/cm2 Normal 1x100µg/cm2 
4h Volunteer 2.2.4 - Postocclusion - 4h
0 55 1010 1515 2020 2525
0
10
20
30
40
50
60
70
80
90
100
H
o
rn
y 
la
ye
r 
th
ic
kn
es
s
 
[%
]
T
ap
e
 n
u
m
b
er
Concentration of triamcinolone acetonide [µg/cm²]
1
5
10
15
20
25
30
35
40
45
50
55
64
 
Volunteer 2.2.4 - Normal - 4h
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Volunteer 2.2.5 
 Post-occlusion 1x100µg/cm2 Normal 1x100µg/cm2 
4h Volunteer 2.2.5 - Postocclusion - 4h
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Volunteer 2.2.5 - Normal - 4h
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24h Volunteer 2.2.5 - Postocclusion - 24h
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Volunteer 2.2.5 - Normal - 24h
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11.3.6. Experiment 2.2 (Post-occlusion) - Data overview 
 
Exp 2.2 (n=5), Application of 1x100µg/cm2 
 
Concentration Tape 
Stripping 
 TACA-amount all tapes  TACA-amount without tape 1-3 
ORIGINAL VALUES  Mean ± SD  Mean ± SD 
      
Post-occlusion 4 h  80 ± 32  37 ± 13 
Post-occlusion 24 h  79 ± 33  42 ± 28 
      
Normal 4 h  40 ± 28  21 ± 12 
Normal 24 h  42 ± 14  24 ± 11 
   
  
 
LN-VALUES   Mean ± SD  Mean ± SD 
      
Post-occlusion 4 h  4.3 ± 0.5  3.6 ± 0.4 
Post-occlusion 24 h  4.3 ± 0.6  3.3 ± 1.3 
      
Normal 4 h  3.6 ± 0.6  2.9 ± 0.6 
Normal 24 h  3.7 ± 0.4  3.1 ± 0.4 
        
ANOVA (ln-values)  All tapes  Without Tapes 1-3 
Factor:        
- volunteer    0.08   0.1 
- time    0.8   0.9 
- application   
 0.005 **   0.2 
- Interaction time/application   0.7   0.5 
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11.3.7. Experiment 2.2 (Post-occlusion) - Data single volunteers 
 
Experiment 2.2 - TACA-amount penetrated [ug/cm2] - All Tapes 
Volunteer Gender Age
 [years] 4h 24h 4h 24h
2.2.1 f 25 68.6 86.8 24.1 21.0
2.2.2 m 30 34.8 24.1 21.1 52.3
2.2.3 f 23 102.5 84.6 89.0 39.6
2.2.4 f 24 116.3 85.8 28.3 55.8
2.2.5 m 24 75.6 114.5 39.7 41.0
Mean 25 79.6 79.2 40.4 41.9
SD 31.7 33.2 28.1 13.7
RSD 39.8 42.0 69.4 32.6
Experiment 2.2 - TACA-amount penetrated [ug/cm2] - All Tapes - Logarithm (ln)
Volunteer Gender Age
 [years] 4h 24h 4h 24h
2.2.1 f 25 4.2 4.5 3.2 3.0
2.2.2 m 30 3.5 3.2 3.1 4.0
2.2.3 f 23 4.6 4.4 4.5 3.7
2.2.4 f 24 4.8 4.5 3.3 4.0
2.2.5 m 24 4.3 4.7 3.7 3.7
Mean 25 4.3 4.3 3.5 3.7
SD 0.5 0.6 0.6 0.4
RSD 11.0 14.4 16.2 10.5
Post-Occlusion Normal
Post-Occlusion Normal
Tape Stripping at Tape Stripping at
Tape Stripping at Tape Stripping at
 
Experiment 2.2 - TACA-amount penetrated [ug/cm2] - Without Tapes 1-3
Volunteer Gender Age
 [years] 4h 24h 4h 24h
2.2.1 f 25 32.3 55.6 15.7 16.0
2.2.2 m 30 17.0 2.9 9.0 25.4
2.2.3 f 23 46.0 23.1 37.6 21.3
2.2.4 f 24 43.0 55.7 15.8 43.4
2.2.5 m 24 47.3 71.9 28.9 16.4
Mean 25 37.1 41.8 21.4 24.5
SD 12.7 28.1 11.6 11.3
RSD 34.2 67.1 54.2 46.0
Experiment 2.2 - TACA-amount penetrated [ug/cm2] - Without Tape 1-3 - Logarithm (ln)
Volunteer Gender Age
 [years] 4h 24h 4h 24h
2.2.1 f 25 3.5 4.0 2.8 2.8
2.2.2 m 30 2.8 1.0 2.2 3.2
2.2.3 f 23 3.8 3.1 3.6 3.1
2.2.4 f 24 3.8 4.0 2.8 3.8
2.2.5 m 24 3.9 4.3 3.4 2.8
Mean 25 3.6 3.3 2.9 3.1
SD 0.4 1.3 0.6 0.4
RSD 12.0 40.3 19.2 13.1
Post-Occlusion Normal
Post-Occlusion Normal
Tape Stripping at Tape Stripping at
Tape Stripping atTape Stripping at
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11.3.8. Mass balance experiment 2.1 (pre-occlusion) 
 
11.3.9. Mass balance experiment 2.2 (post-occlusion) 
0
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Gauze 3 7 11 11
Tape 1-3 42 37 19 17
SC without T1-3 37 42 21 24
Not recovered 18 14 49 47
4 h (Post-
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24 h (Post-
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(normal)
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Gauze 0 8 13 0 10 12
T 1-3 32 20 7 36 24 9
SC without T 1-3 35 24 12 30 25 20
Not recovered 33 48 69 34 41 58
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occlusion)
4 h (pre-
occlusion)
24 h (pre-
occlusion)
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4 h             
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11.4. Project IV 
11.4.1. Atopic skin diathesis according to Hanifin and Rajka 
Erlangter Atopiescore 
Nr. Substanz Punkte Patient Bemerkungen 
1 Juckreiz beim Schwitzen 3   
2 Wollunverträglichkeit 3  ev andere Textilien 
3 Xerosis 3  ≠ Ichtyosis vulgaris 
4 Weisser Dermographismus 3  Stirne, Rücken 
5 Herthoge Zeichen 2  laterale Augenbrauen 
6 Ohrläppchenrhagaden 2  ev retroaurikulär 
7 Perlèche, Cheilitis 2   
8 Hyperlineare Palmae 2  Thenar/Hypothenar 
9 Pityriasis alba 2  Gesicht/Oberarme 
10 Atopische Familienanamnese 1  Ekzema flexuarum 
11 Milchschorf 1  exsudativ-ekzematös 
12 Allergische Rhinokonjunktivitis 1  Eigenanamnese 
13 Allergisches Athma 1  Eigenanamnese 
14 Nahrunsgmittelintoleranz 1  Exacerbation des Ekzemes 
15 Metallunverträglichkeit 1  Kontaktallergie (Nickel) 
16 Lichtempfindlichkeit/scheu 1  Photophobie 
17 Zentrofaciale 
Blässe/Wangenerythem 
1   
18 Dennei Morgan Falte 1  Unterlid, ev verdoppelt 
19 Keratosis pilaris 1  Extremitäten 
20 Gesamt-IgE > 150 kU/l 1  > 400 kU/l = 2 Punkte 
21 Phadiatop (SX-1) positiv 1   
Total Patientenscore / Beurteilung   
 
Bei nicht eindeutigen Kriterien halbe Punktzahl, Laborteste (Punkt 20/21) nur bei Bedarf 
bestimmen. 
Hauptkriterien: Pruritus, typische Morphe und Lokalisation, chronisch(-rezidivieren), atopische 
EA/FA. 
Seltene Nebenkriterien (=1 Punkt): Dishydrosis, „atopic foot“, Mamillenekzem, „dirty neck“, 
Orbita-verschattung. 
 
Punkte Beureteilung Patient 
0-6: keine atopische Hautdiathese  
7-9: Grenzbefund (atopische Hautdiathese nicht 
auszuschliessen) 
 
10-14: atopische Hautdiathese  
15-19: deutliche atopische Hautdiathese  
> 19: ausgeprägte atopische Hautdiathese  
Nach Th. Diepgen et al. 1991/1992 Bircher 1/93 
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11.4.2. Form for SCORAD assessment 
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11.4.3. Patch test 
Standard Patch Test (True-Test) 
No Ingredient Conc. 
[µg/cm2] 
Vehicle 48h 72h …h Relevance 
1 Nickel(II)-sulfat 200 Aqua     
2 Wollwachsalkohole 1000 Ethanol     
3 Neomycinsulfat 230 Aceton     
4 Kaliumdichromat 23 MethylenChlorid     
5 Cain-Mix 630 NaBicarbonat     
6 Parfum-Mix 430 NaCarbonat     
7 Kolophonium 850 Polyvidon     
8 Epoxidharz 50 Propylcellulose     
9 Quinolin-Mix 190 Methylcellulose     
10 Perubalsam 800 β-Cyclodextrin     
11 Ethylendiamindihydrochlorid 50 β-Cyclodextrin     
12 Kobalt(II)-chlorid 20 β-Cyclodextrin     
13 p-Butylphenol / 
Formaldehydharz 
40 β-Cyclodextrin     
14 Paraben-Mix 1000 β-Cyclodextrin     
15 Gummi-Mix 250 β-Cyclodextrin     
16 Schwarzgummi-Mix 75 β-Cyclodextrin     
17 Chlormethylisothiazolon 
Kathon 
4 β-Cyclodextrin     
18 Quaternium 15 100 β-Cyclodextrin     
19 Mercaptobenzotriazol 75 β-Cyclodextrin     
20 p-Phenyldiamin 90 β-Cyclodextrin     
21 Formaldehyd 180 β-Cyclodextrin     
22 Mercapto-Mix 75 β-Cyclodextrin     
23 Thiomersal 8 β-Cyclodextrin     
24 Thiuram-Mix 25 β-Cyclodextrin     
 
Standard Additives / M1 
No Ingredient Conc. 
[%] 
Vehicle 48h 72h …h Relevance 
1 Euxyl K 400 0.1 Vaseline     
2 Terpentin 10 Vaseline     
3 Cetylstearylalkohol 20 Vaseline     
4 Bufexamac 5.0 Vaseline     
5 Kompositen-Mix 6.0 Vaseline     
6 Lyral 5.0 Vaseline     
7 Propolis 10 Vaseline     
8 Natriumdisulfit (A) 5.0 Vaseline     
9 Tixocortolpivalat (CT) 1.0 Vaseline     
10 Budesonid 0.1 Vaseline     
   
 
    
Standard M1 
 
 
    
1 Sorbitansesquioleat 20 Vaseline     
2 Iodpropinylbutylcarbamat 0.3 Vaseline     
3 Dispersionsmix Blau 124/106 1.0 Vaseline     
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Patch Test Lichtena Ingredients 
No Ingredient Conc. [%] Vehicle 48h 72h …h Relevance 
1 AC Glycyrrhetic Fitosoma 1 petrolatum     
2 Glycerrhetinic acid 1 petrolatum     
3 Alpha Bisabolol nat. 5 petrolatum     
4 Allantoin 5 petrolatum     
5 Allantoin 0.5 water     
6 Apifil 10 petrolatum     
7 AR-GB 11 1 petrolatum     
8 Ascofluile Palmitate 1 petrolatum     
9 Beta-sitosterol 1 petrolatum     
10 Shea butter 1 petrolatum     
11 Carbopol Ultrez 10 10 petrolatum     
12 Delta-Tocopherol 1 petrolatum     
13 EDTA 2Na 1 petrolatum     
14 Fudji Perfume 1 petrolatum     
15 Hydroviton 1 petrolatum     
16 Hydroviton 5 petrolatum     
17 Isostearyl isostearat 1 water     
18 Labrafac CC 1 petrolatum     
19 Neo Heliopan 357 2 petrolatum     
20 Neo Heliopan AV 1 petrolatum     
21 Chamomile oil 2.5 petrolatum     
22 Paracombin (methyl-,buthyl-, 
ethyl-, propyl-paraben-mix) 
3 petrolatum     
23 Sodium dehydroacetate 3 water     
24 Triethanolamine 2.5 petrolatum     
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11.4.4. Data individual patients 
PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum links appliziert
Patient Nr 1
Geschlecht w
Geburtsdatum 1961
Lokalisation Ellenbeugen
Atopiescore 18
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 9 9 9 9 9 9 9 9 9 9
B Intensität 8 8 9 9 6 13 4 10 4 15
Seite L R L R L R L R L R L R
Erythem 1 1 2 2 1 3 0 2 0 3
Ödem/Papel 1 1 1 1 1 3 1 3 1 3
Nässen/Kruste 0 0 0 0 0 0 0 0 0 1
Exkoriation 1 1 1 1 1 2 1 1 0 2
Lichenifikation 2 2 2 2 1 2 0 1 1 3
Trockenheit 3 3 3 3 2 3 2 3 2 3
C Subjektive Symptome 3 3 4 4 1 5 1 4 6 12
Pruritus (VAS) 3 3 4 4 1 5 1 4 1 7
Schlaflosigkeit (VAS) 0 0 0 0 0 0 0 0 5 5
SCORAD (A/5) + (7B/2) + C 32.8 32.8 37.3 37.3 23.8 52.3 16.8 40.8 21.8 66.3
EPI-Teste Positive
SCORAD ohne Subjektive Symptome 29.8 29.8 33.3 33.3 22.8 47.3 15.8 36.8 15.8 54.3
12.03.200205.02.2002 12.02.2002 19.02.2002 26.02.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum rechts appliziert
Patient Nr 2
Geschlecht w
Geburtsdatum 1997
Lokalisation Handgelenke
Atopiescore 12
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 33.5 33.5 51.5 51.5 51.5 51.5 51.5 51.5 51.5 51.5
B Intensität 9 9 12 12 10 10 12 7 15 9
Seite L R L R L R L R L R L R
Erythem 1 1 2 2 2 2 2 1 3 2
Ödem/Papel 0 0 1 1 0 0 2 1 2 1
Nässen/Kruste 1 1 1 1 0 0 0 0 1 0
Exkoriation 1 1 2 2 2 2 2 1 3 1
Lichenifikation 3 3 3 3 3 3 3 2 3 2
Trockenheit 3 3 3 3 3 3 3 2 3 3
C Subjektive Symptome 5 5 7 7 5 5 4 3 5 4
Pruritus (VAS) 5 5 7 7 5 5 4 3 5 4
Schlaflosigkeit (VAS) 0 0 0 0 0 0 0 0 0 0
SCORAD (A/5) + (7B/2) + C 43.2 43.2 59.3 59.3 50.3 50.3 56.3 37.8 67.8 45.8
EPI-Teste Positive keine Positive
SCORAD ohne Subjektive Symptome 38.2 38.2 52.3 52.3 45.3 45.3 52.3 34.8 62.8 41.8
13.03.200206.02.2002 13.02.2002 20.02.2002 27.02.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum rechts appliziert
Patient Nr 3
Geschlecht m
Geburtsdatum 2002
Lokalisation Handgelenke
Atopiescore 21
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 9 9 9 9 9 9 9 9 9 9
B Intensität 8 8 10 10 9 9 7 7 6 3
Seite L R L R L R L R L R L R
Erythem 0 0 1 1 1 1 1 1 1 0
Ödem/Papel 0 0 0 0 0 0 0 0 1 0
Nässen/Kruste 0 0 0 0 0 0 0 0 0 0
Exkoriation 2 2 3 3 2 2 1 1 1 0
Lichenifikation 3 3 3 3 3 3 2 2 1 1
Trockenheit 3 3 3 3 3 3 3 3 2 2
C Subjektive Symptome 2 2 2 2 2 2 2 2 0 0
Pruritus (VAS) 2 2 2 2 2 2 2 2 0 0
Schlaflosigkeit (VAS) 0 0 0 0 0 0 0 0 0 0
SCORAD (A/5) + (7B/2) + C 31.8 31.8 38.8 38.8 35.3 35.3 28.3 28.3 22.8 12.3
EPI-Teste Positive keine Positive
SCORAD ohne Subjektive Symptome 29.8 29.8 36.8 36.8 33.3 33.3 26.3 26.3 22.8 12.3
19.03.200211.02.2002 19.02.2002 26.02.2002 05.03.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum links appliziert
Patient Nr 4
Geschlecht w
Geburtsdatum 1965
Lokalisation Unterschenkel
Atopiescore 14
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 27 27 27 27 27 27 27 27 27 27
B Intensität 10 10 8 8 8 6 7 4 5 2
Seite L R L R L R L R L R L R
Erythem 2 2 2 2 2 1 1 0 0 0
Ödem/Papel 2 2 1 1 1 1 2 1 1 0
Nässen/Kruste 1 1 0 0 0 0 0 0 0 0
Exkoriation 2 2 2 2 2 1 2 1 2 1
Lichenifikation 1 1 1 1 1 1 0 0 0 0
Trockenheit 2 2 2 2 2 2 2 2 2 1
C Subjektive Symptome 14 14 13 13 12 10 12 10 7 5
Pruritus (VAS) 8 8 8 8 8 6 6 4 4 2
Schlaflosigkeit (VAS) 6 6 5 5 4 4 6 6 3 3
SCORAD (A/5) + (7B/2) + C 54.4 54.4 46.4 46.4 45.4 36.4 41.9 29.4 29.9 17.4
EPI-Teste Positive Nickel(II)sulfat (48h/72h ++)
SCORAD ohne Subjektive Symptome 40.4 40.4 33.4 33.4 33.4 26.4 29.9 19.4 22.9 12.4
20.03.200214.02.2002 21.02.2002 27.02.2002 06.03.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum links appliziert
Patient Nr 5
Geschlecht w
Geburtsdatum 1988
Lokalisation Unterarme/Ellenbeugen
Atopiescore 20
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 9 9 9 9 9 9 9 9 9 9
B Intensität 11 10 13 11 13 12 13 9 13 15
Seite L R L R L R L R L R L R
Erythem 2 2 2 1 2 2 2 1 2 3
Ödem/Papel 1 1 2 2 2 2 2 1 1 1
Nässen/Kruste 0 0 0 0 0 0 1 0 2 2
Exkoriation 2 1 3 2 3 2 2 1 3 3
Lichenifikation 3 3 3 3 3 3 3 3 3 3
Trockenheit 3 3 3 3 3 3 3 3 2 3
C Subjektive Symptome 9 9 9 9 10 11 13 11 13 15
Pruritus (VAS) 4 4 6 6 7 8 9 7 6 8
Schlaflosigkeit (VAS) 5 5 3 3 3 3 4 4 7 7
SCORAD (A/5) + (7B/2) + C 49.3 45.8 56.3 49.3 57.3 54.8 60.3 44.3 60.3 69.3
EPI-Teste Positive fehlen!
SCORAD ohne Subjektive Symptome 40.3 36.8 47.3 40.3 47.3 43.8 47.3 33.3 47.3 54.3
03.04.200227.02.2002 06.03.2002 13.03.2002 20.03.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum rechts appliziert
Patient Nr 6
Geschlecht m
Geburtsdatum 1977
Lokalisation Ellenbeugen
Atopiescore 16
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 9 9 9 9 9 9 9 9 9 9
B Intensität 8 7 6 7 10 5 11 5 9 2
Seite L R L R L R L R L R L R
Erythem 1 1 1 1 2 1 2 1 1 0
Ödem/Papel 1 0 1 1 2 1 2 1 1 0
Nässen/Kruste 0 0 0 0 0 0 0 0 0 0
Exkoriation 1 1 1 2 2 1 2 1 2 0
Lichenifikation 2 2 1 1 2 1 3 1 3 1
Trockenheit 3 3 2 2 2 1 2 1 2 1
C Subjektive Symptome 9 9 5 5 6 3 7 2 5 1
Pruritus (VAS) 7 7 5 5 6 3 7 2 5 1
Schlaflosigkeit (VAS) 2 2 0 0 0 0 0 0 0 0
SCORAD (A/5) + (7B/2) + C 38.8 35.3 27.8 31.3 42.8 22.3 47.3 21.3 38.3 9.8
EPI-Teste Positive (EDTA 72h +)
(Fudji Parfum 72h +)
SCORAD ohne Subjektive Symptome 29.8 26.3 22.8 26.3 36.8 19.3 40.3 19.3 33.3 8.8
05.04.200227.02.2002 08.03.2002 15.03.2002 22.03.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum rechts appliziert
Patient Nr 7
Geschlecht w
Geburtsdatum 1974
Lokalisation Ellenbeugen/Unterarme
Atopiescore 23
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 40.5 40.5 40.5 40.5 40.5 40.5 40.5 40.5
B Intensität 14 14 16 11 16 11 11 11
Seite L R L R L R L R L R L R
Erythem 3 3 3 2 2 1 2 2
Ödem/Papel 2 2 3 2 2 1 1 1
Nässen/Kruste 1 1 1 1 3 1 0 0
Exkoriation 2 2 3 2 3 2 2 2
Lichenifikation 3 3 3 2 3 3 3 3
Trockenheit 3 3 3 2 3 3 3 3
C Subjektive Symptome 12 12 5 5 13 12 9 9
Pruritus (VAS) 6 6 5 5 8 7 7 7
Schlaflosigkeit (VAS) 6 6 0 0 5 5 2 2
SCORAD (A/5) + (7B/2) + C 69.1 69.1 69.1 51.6 77.1 58.6 55.6 55.6
EPI-Teste Positive Lyral 5% (48h +) Apifil (48h +)
Fudji Parfum (48h +)
SCORAD ohne Subjektive Symptome 57.1 57.1 64.1 46.6 64.1 46.6 46.6 46.6
04.04.200206.03.2002 06.03.2002 14.03.2002 21.03.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum links appliziert
Patient Nr 8
Geschlecht w
Geburtsdatum 1991
Lokalisation Kniekehlen
Atopiescore 7
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 36 36 36 36 36 36 36 36
B Intensität 7 7 4 6 4 7 4 12
Seite L R L R L R L R L R L R
Erythem 1 1 1 1 1 2 1 3
Ödem/Papel 0 0 0 0 0 0 0 1
Nässen/Kruste 0 0 0 0 0 0 0 1
Exkoriation 1 1 0 0 0 0 0 1
Lichenifikation 3 3 2 3 2 3 2 3
Trockenheit 2 2 1 2 1 2 1 3
C Subjektive Symptome 8 8 2 2 2 3 1 3
Pruritus (VAS) 6 6 1 1 1 2 1 3
Schlaflosigkeit (VAS) 2 2 1 1 1 1 0 0
SCORAD (A/5) + (7B/2) + C 39.7 39.7 23.2 30.2 23.2 34.7 22.2 52.2
EPI-Teste Positive Thiuram-Mix (72h +)
SCORAD ohne Subjektive Symptome   31.7 31.7 21.2 28.2 21.2 31.7 21.2 49.2
02.05.200202.04.2002 02.04.2002 09.04.2002 16.04.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum rechts appliziert
Patient Nr 9
Geschlecht m
Geburtsdatum 1996
Lokalisation Unterarme/Ellenbeugen
Atopiescore 11
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________  ________
A Ausmass 9 9 9 9 9 9 9 9
B Intensität 5 5 10 4 13 2 5 1
Seite L R L R L R L R L R L R
Erythem 1 1 2 1 2 0 0 0
Ödem/Papel 0 0 2 0 3 0 0 0
Nässen/Kruste 0 0 0 0 1 0 1 0
Exkoriation 1 1 2 1 3 0 1 0
Lichenifikation 1 1 2 1 2 1 1 0
Trockenheit 2 2 2 1 2 1 2 1
C Subjektive Symptome 6 6 11 6 18 9 13 7
Pruritus (VAS) ? ? 5 0 9 0 6 0
Schlaflosigkeit (VAS) 6 6 6 6 9 9 7 7
SCORAD (A/5) + (7B/2) + C 25.3 25.3 47.8 21.8 65.3 17.8 32.3 12.3
EPI-Teste Positive Keine Positive
SCORAD ohne Subjektive Symptome 0 0 19.3 19.3 36.8 15.8 47.3 8.8 19.3 5.3
09.04.2002 16.04.2002 23.04.2002 07.05.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum links appliziert
Patient Nr 10
Geschlecht w
Geburtsdatum 1976
Lokalisation Unterschenkel
Atopiescore 21
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 18 18 18 18 18 18 18 18
B Intensität 7 7 5 9 8 10 5 10
Seite L R L R L R L R L R L R
Erythem 1 1 1 2 1 2 1 2
Ödem/Papel 1 1 1 2 2 2 0 1
Nässen/Kruste 0 0 0 0 1 1 0 0
Exkoriation 2 2 1 2 2 2 2 3
Lichenifikation 1 1 1 1 1 1 1 2
Trockenheit 2 2 1 2 1 2 1 2
C Subjektive Symptome 2 2 6 6 2 3 0 0
Pruritus (VAS) 2 2 2 2 1 2 0 0
Schlaflosigkeit (VAS) 0 0 4 4 1 1 0 0
SCORAD (A/5) + (7B/2) + C 30.1 30.1 27.1 41.1 33.6 41.6 21.1 38.6
EPI-Teste Positive Sorbitansesquioleat 20% in Vaseline (48h/72h) (Standard M1)
Iodpropinbutylcarbamat 0.3% in Vaseline (48h/72h) (Standard M1)
SCORAD ohne Subjektive Symptome    28.1 28.1 21.1 35.1 31.6 38.6 21.1 38.6
17.05.200212.04.2002 12.04.2002 19.04.2002 26.04.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum rechts appliziert
Patient Nr 12
Geschlecht w
Geburtsdatum 1987
Lokalisation Ellenbeugen
Atopiescore 14
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 9 9 9 9 9 9 9 9
B Intensität 10 10 7 8 6 2 5 2
Seite L R L R L R L R L R L R
Erythem 1 1 1 1 1 0 0 0
Ödem/Papel 1 1 1 1 0 0 1 0
Nässen/Kruste 0 0 0 0 0 0 0 0
Exkoriation 2 2 1 2 1 0 0 0
Lichenifikation 3 3 2 2 2 1 2 1
Trockenheit 3 3 2 2 2 1 2 1
C Subjektive Symptome 6 6 4 3 0 0 4 4
Pruritus (VAS) 6 6 4 3 0 0 4 4
Schlaflosigkeit (VAS) 0 0 0 0 0 0 0 0
SCORAD (A/5) + (7B/2) + C 42.8 42.8 30.3 32.8 22.8 8.8 23.3 12.8
EPI-Teste Positive Sorbitansesquioleat 20% in Vaseline (48h) (Standard M1)
Iodpropinbutylcarbamat 0.3% in Vaseline (48h) (Standard M1)
SCORAD ohne Subjektive Symptome 36.8 36.8 26.3 29.8 22.8 8.8 19.3 8.8
21.06.200224.05.2002 24.05.2002 31.05.2002 10.06.2002
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PATIENTENBOGEN KLINISCHE STUDIE LICHTENA  A.I.
Verum rechts appliziert
Patient Nr 13
Geschlecht m
Geburtsdatum 1996
Lokalisation Ellenbogen
Atopiescore 12
Untersuchung Nr 1 2 3 4 5 6
Tag  Voruntersuchung  Tag 0  Tag 7  Tag 14  Tag 28  Tag   ___
Datum  ________
A Ausmass 27 27 27 27 27 27 27 27
B Intensität 8 8 10 5 8 1 2 0
Seite L R L R L R L R L R L R
Erythem 1 1 2 1 3 0 0 0
Ödem/Papel 2 2 2 1 0 0 0 0
Nässen/Kruste 1 1 0 0 2 0 0 0
Exkoriation 0 0 2 1 0 0 0 0
Lichenifikation 2 2 2 1 1 0 1 0
Trockenheit 2 2 2 1 2 1 1 0
C Subjektive Symptome 7 7 0 0 8 0 0 0
Pruritus (VAS) 7 7 0 0 8 0 0 0
Schlaflosigkeit (VAS) 0 0 0 0 0 0 0 0
SCORAD (A/5) + (7B/2) + C 40.4 40.4 40.4 22.9 41.4 8.9 12.4 5.4
EPI-Teste Positive Keine Positive
SCORAD ohne Subjektive Symptome   33.4 33.4 40.4 22.9 33.4 8.9 12.4 5.4
02.07.200207.02.2002 31.05.2002 07.06.2002 14.06.2002
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